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Abstract 
CTLA-4, a receptor for the B7 family of costimulatory molecules, is one of the main 
regulators of T-cell activation. The ligation of this glycoprotein with its ligands CD80 or 
CD86, produces a negative signal that down regulates IL-2 production, and causes cell 
cycle arrest. The main in vivo evidence that further substantiates the negative role of 
CTLA-4, is that mice deficient for this molecule, develop a lethal lymphoproliferative 
disorder that leads to death between 3 or 4 weeks after birth. The characteristics of this 
phenotype produce a very important limitation to study adult-stage immunity in the ab-
sence of CTLA-4. 
To overcome this problem, we generated a mouse model in which conditional Ctla-4 
inactivation can be performed using the Cre-loxP system. We are interested in studying 
the peripheral immune system of animals in which the inactivation of CTLA-4 can be 
temporally controlled, in order to gain access of adult-stage lymphoid tissue in the ab-
sence of this costimulatory molecule. 
In this thesis we report the generation and phenotypical characterization of mice bearing 
a targeted Ctla-4 allele. Homozygous individuals develop lymphoadenopathy with no 
signs of tissue damage. T cells from these mice over express CTLA-4 upon polyclonal 
activation and show qualitative differences in the expression of the transcripts corre-
sponding to the main CTLA-4 splice variants. 
Further modifications to the targeted CTLA-4 allele, by Cre-mediated recombination in 
the germ cells, yielded mice having an allele that lacks the coding sequences for two of 
the most important domains of this molecule. Mice with this genotype, develop a fatal 
autoimmune disorder very similar to that present in previously generated CTLA-4 
knock out models. The nature of the sequence deletion generated in these mice makes 
them an interesting model for further experimental work. 
We discussed the implications of these data with respect to the current literature in the 
field. 
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	  Chapter 1. Introduction 
1.1 T cell activation: the two signal model. 
1.1.1 Antigen-MHC interaction is insufficient for T cell 
activation. 
The production of a successful adaptive immune response requires the activation and 
clonal expansion of rare antigen specific lymphocytes, a decrease in the number of these 
cells and finally a mechanism to establish long-term memory once the antigen has been 
eliminated. Among those lymphocytes, T cells play a major role as effectors, coordina-
tors an regulators of such responses to specific antigens. T cell activation is a complex 
process that involve a variety of interactions between adhesion molecules and receptors 
on the cell surface of the T cells and the antigen presenting cells (APC). The activation 
of a T cell depends on the association of the T cell receptor with an antigenic peptide 
bound to the major hystocompatibility complex (MHC) on the surface of the APC 
(Zinkernagel., et al 1944). Although this interaction determines the generation of an 
antigen-specific T cell immune response, itself it is not sufficient to fully activate T 
cells, as initially demonstrated by the activation studies of cytotoxic T lymphocytes 
(CTL) to allogeneic transplant antigens (Laferty., et al 1975, reviewed in Laferty., et al 
1977). Laferty and co-workers showed, in a transplant model, that successful CTL re-
sponses could not be triggered by all the cells carrying alloantigens (abundant in the 
transplant), but only by haematopoietic cells having allogenic MHC antigen, and a sec-
ond stimulatory signal (co-stimulaton). Later, it was further postulated that in the ab-
sence of an antigen independent costimulatory signal, T cells become hyporesponsive or 
anergised rather than activated (Jenkins., et al 1987; Jenkins., et al 1988). 
The two signal model is schematically described in figure 1.1. 
Jenkins and Shwartz in the eighties suggested that the costimulatory signal was funda-
mentally independent to the signals provided by the TCR and this led to the search for 
cell surface receptors present on resting T cells, that had signaling properties distinct 
from the TCR. 
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Outcomes: 
Activation, clonal expansion 
IL-2 production and other effector 
functions 
Outcomes: 
Induced unresponsiveness 
(anergy) and apoptosis 
Outcomes: 
No observed effects 
Figure 1.1.- The "two signal" model of T cell activation. Antigen presenting cells can 
display antigen bound to the MHC and/or costimulatory ligands to provide two 
fundamentally independent signals to T cells. 
Given the nature of this model, three different outcomes can be expected: clonal 
expansion of T cells and effector functions will only develop upon ligation of both, 
Ag-MHC (signal 1) and costimulatory ligands and receptors (signal 2). In the absence 
of signal 2, T cells will be rendered unresponsive (anergic). Provision of only signal 
two, has produced no observed effects. We now today that this binary interactions are not 
the only mode of costimulation and that interactions "in trans" happen. 
Figure adapted from (Bretscher., et al 1970) and (June., et al 1994). 
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	  Chapter 1. Introduction 
1.1.2 The components of the second signal of T cell 
costimulation. 
The components of the second signal of T cell activation were identified in the late 
eighties using antibody reagents and various in vitro cell culture assays. One of the first 
costimulatory molecules to be identified was CD28. It was initially characterized and 
defined as a T cell costimulatory receptor in experiments where the activation of human 
T cells and T cell clones by antigen primed APC or in mixed lymphocyte reactions 
(MLR) were blocked using Fab fragments of antibodies reactive with the molecule. 
Here the activation of those T cells clones could not only be blocked by the CD28 anti-
bodies, but also the cells were rendered unresponsive to subsequent antigen challenges 
(Damle., et al 1988 and Harding., et al 1992). The now well characterized ligand for 
CD28 on the APC, CD80, was identified using blocking monoclonal antibodies against 
B7-1 (or CD80) on B cells to show the failure of these cells to adhere to chinese ham-
ster ovary cells transfected with CD28 (Linsley., et al 1990). 
In previous years, the search for activated cytotoxic T cell surface antigens through the 
screening of a subtracted complementary DNA (cDNA) library, resulted in the identifi-
cation of a structure homologue of CD28, the Cytotoxic T Lymphocyte antigen 4 
(CTLA-4) (Brunet., et al 1987). This molecule was soon associated with the T cell 
costimulatory pathway, as a fusion protein of the y immunoglobulin constant region and 
the extra-cellular domain of CTLA-4 (CTLA-4-Ig) was found to bind B7-1 on the sur-
face of transfected CHO cells (Linsley., et al 1991). The evidence that the immune re-
sponse - otherwise not compromised in CD80 knock out mice- could be suppressed by 
administering CTLA-4-Ig, together with the in vivo studies comparing the effects of the 
CTLA-4-Ig with the administration of a B7-1 (CD80) specific antibody led to the dis-
covery of an additional ligand for both CD28 and CTLA-4, namely B7-2 (CD86). 
The costimulatory ligands of the B7 family - CD80 and CD86, as defined under the 
cluster of differentiation nomenclature - are also referred as B7-1 and B7-2 throughout 
the literature. In this thesis, the term B7 will be used in reference to both molecules, 
otherwise their individual CD nomenclature will be used. 
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1.2 Costimulation receptors: their structure, interactions and 
expression. 
1.2.1 CD28 and CTLA-4. 
CD28 and CTLA-4 are structurally very similar yet they are not functionally redundant. 
CD28 provides positive costimulation and survival signals by promoting the production 
of IL-2, the expression of the IL-2 receptor and consequently T cell proliferation (Mar-
tin., et al 1986), together with the expression of the anti-apoptotic gene such as Bcl-xL 
(Boise., et al 1995) CTLA-4 ligation on T cells inhibits the up-regulation of activation 
markers like CD69 and CD25, decreases IL-2 accumulation and restricts cell cycle pro-
gression from G1 to S phase through inhibition of cell cycle proteins (Krumel., et al 
1996). The differential action of these two T cell receptors has been solidly demon-
strated by the study of the phenotyes of mice bearing targeted null mutations for both 
molecules. These evidence will be extensively discussed in subsequent sections. 
Cd28 locates adjacent Ctla-4 on chromosome 1 in mice and 2 in humans and they share 
similar gene structures. Evidence suggests that both genes probably evolved by duplica-
tion from a common ancestral sequence (Harper., et al 1991). The degree of sequence 
conservation of both proteins is high between human mouse and even in the rat. This is 
particularly clear when comparing the intracellular domain where the sequence is iden-
tical between human and mouse (Clark., et al 1992). They are both type-1 membrane 
proteins and members of the immunoglobulin superfamily (IgSF). They consist of a an 
extracellular IgV-like domains, a transmembrane domain and a highly conserved short 
intracellular tail without instrinsic enzymatic activity, which bears tyrosine-dependent 
signaling motifs substrate for phosphorylation. 
CTLA-4 and CD28 have a disulphide-linked homodimeric quaternary structure, com-
prising 44kDa and 33-37kDa monomers respectively. (Gros., et al 1990, Brunet., et al 
1987 and reviewed in Carretio., et al 2002). 
CTLA-4 climerizes through cystein (Cys 122) residues at towards the transmembrane 
domain. This mode of dimerization allows for a coligation with both B7 ligands 
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around an axis orthogonal to the membrane, thus making the interaction of CTLA-4 to 
B7 molecules bivalent and avidity-enhanced (Schwartz., et al 2001 and Stamper., et al 
2001) (see figure 1.2). 
Similar crystallographic data, where the interaction of CD28 and the B7 ligands is stud-
ied, are not available yet. Nevertheless amino acid sequence analysis show that despite 
the facts that is a high degree of sequence conservation between CD28 and CTLA-4, 
the residues responsible for dimerization in CTLA-4 are not conserved in CD28, sug-
gesting an independent mode of dimerization for CD28 monomers. 
Given the relatively high level of sequence conservation and the structural similarities 
between CD28 and CTLA-4, it has been assumed that CD28 homodimers are also biva-
lent on the cell surface (i.e. Greene., et al (1996). The comparison of the stoichiometry 
of binding of soluble B7-1 (sB7-1) molecules to immobilized CD28 and 
CTLA-4-Ig fusion proteins (CD28-Fc or CTLA-4-Fc), performed by surface plasmon 
resonance, showed that CTLA-4-Fc bound twice the amount of sB7-1 than that bound 
by CD28-Fc (Collins., et al 2002). Recent crystallographic data indicate that the ob-
served CD28 dimer has the overall shape and dimensions of that of CTLA-4. It is, how-
ever, of interest that their dimerization modes are fundamentally different. 
Whereas in CTLA-4 the residues that mediate contact between dimers are adjacent and 
include the stalk region, in CD28 crystals the contact is formed by the small 3-stranded 
A,G, F (3 sheet present in all IgV IgSF domains. 
An additional general difference in both structures is that the interface of contact be-
tween monomers of CTLA-4 allows the possible interaction of putative residues that 
mediate dimerization; the area containing a fraction of such conserved residues in the 
interface between CD28 monomers is buried. CD28-like homodimerization of CTLA-4 
is prevented by the substitution of His116 by Tyr115 and 11e114 by Gln113 and vise-
versa by the change of 11e117 by Pro119. The resemblance of the native CD28 dimeric 
structure to the crystals resolved was further confirmed by Cryo-electron microscopy 
and mutagenesis (Davis., et al 2005). 
The CTLA-4 homodimers are further stabilized by the interface between both mono-
mers through 19 hydrogen bonds and 48 contacts forming van der Walls interactions 
(Ostrov., et al 2000). In vivo dimerization also depends on the N-glycosylation of 
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two sites on the extracellular domains proximal to the membrane (N78, N110) (Darling-
ton., et al 2005 ). A very important structural hydrophobic motif found in the comple-
mentary determining region 3 of the IgV-like domain in both CD28 and CTLA-4 is the 
hexamer MYPPPY (in single letter aminoacid code) (Harper,. et al 1991). CD28 and 
CTLA-4 fusion proteins generated with variants of this motif (generated by site directed 
mutagenesis) have shown impaired binding to B7, thereby establishing this conserved 
motif as critical for ligand-binding (Linsley., et al 1995). 
1.2.2 The B7 ligands. 
CD80 and CD86 are both, transmembrane glycoproteins members of the immunoglobu-
lin super-family. Both B7 molecules have a chimeric structure as far as their extracellu-
lar domain is concerned, they comprise an IgV-like domain similar to those present in 
conventional recognition receptors like CD4 and a membrane proximal IgC1-like do-
main with a structure like antigen receptors and the MHC (Ikemizu., et al 2000). 
In crystal lattices and in solution, CD80 forms bivalent homodimers able to bind to 
CTLA-4 in a periodic and linear array which gives this interaction the characteristic 
mentioned above of enhanced avidity. In addition, there is no evidence for covalent di-
merization of CD80 (Stamper., et al 2001). 
In spite of the fact that crystallographic data shows a plausible dimeric structure for 
CD86, monomer asymmetry, the presence of hydrophilic residues in its putative dimeri-
zation interface and the evidence that neither non-glycosylated nor fully glycosylated 
soluble CD86 dimerizes in solution, favors the idea that dimerization under physiologi-
cal conditions is unlikely (reviewed in van der Merwe., et al 2003 ). Studies using 
soluble forms of CD86 show that glycosylation at the area of interface between mono-
mers may impede dimerization (Collins., et al 2002). Schwartz., et al previously pro-
posed the existance, in physiological conditions, of dimeric CD86 However they used 
dimeric CD86 proteins expressed by bacteria which will be non-gycosylated and per-
haps able to form dimers. This situation may have given a false impression of what may 
actually be occurring at the cell surface (Schwartz., et al 2001). 
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The monomeric state of CD86 on the surface of APC has also been confirmed by imag-
ing studies using photobleaching based fluorescence energy transfer (FRET) (Bhatia., et 
al 2005; reviewed in Bhatia., et al 2006). 
All these data imply that CD86 is monovalent and not able to form periodical arrays 
with CTLA-4 (reviewed in Davis., et al 2003). 
Figure 1.2 shows a scheme of these four costimulatory molecules and their interactions. 
The figure highlights the mode of interaction by which bivalent CTLA-4 homodimers 
form avidity enhanced interactions, particularly with CD80, in the form of stable peri-
odical arrays. 
Signaling through the B7 molecules has not been fully characterized yet but several re-
ports provide evidence to allocate signaling properties to the intracellular domains of 
these receptors. B7 receptors, expressed on T cells, may be involved in transmitting in-
hibitory signals by CD41- CD25÷ regulatory T cells (Treg) (Paust., et al 2004). CD80/ 
CD86 -/- double knock out (DKO) CD4+ CD25- T cells were resistant to suppression by 
concentrations of wild type Tregs able to suppress the activity of wild type CD41- CD25-
T cells. Interestingly suppression was only restored by the expression of full length B7 
molecules but not by expressing truncated B7 receptors lacking the intracellular do-
main. 
In support of the idea that B7 molecules can signal, more convincing experiments show 
the ability of B7 receptors to deliver signals to the expressing APC upon ligation with 
CTLA-4 on the surface of T cells. Engagement of B7 molecules can initiate the immu-
nosuppresive pathway of tryptophan catabolism through the production of IFNy and 
induction of the enzyme indoleamine 2,3-dioxigenase (IDO). Consequent production of 
tryptophan metabolites can suppress T cell proliferation. (Grohmann., et al 2002, Fallar-
ino., et al 2003 and Munn., 2004 reviewed in Greenwald., et al 2005). 
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enhanced in avidity. In contrast, bivalent dimers of CD80 interact with CTLA-4 with relatively high affinity 
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one extracellular IgV-like domain, a transmembrane domain and a cytoplasmic signalling domain. 
CTLA-4 has two putative phosphorylation sites in the intracellular domain. CD80 and CD86 have both two 
extracellular domains one (IgV and IgC-like) a transmembrane domain and a cytosolic signalling domain 
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As shown in figure 1.2, the intracellular domain of CD86 is longer than that of CD80 
and contains 3 putative phosphorylation sites for protein kinase C suggesting its poten-
tial signaling capabilities. (Azuma., et al 1993). 
The function of B7 molecules and their T cell ligands, are determined by the above-
mentioned structural characteristics. 
In the the following part we will discuss how these interactions have been defined, in 
particular by studies using surface plasmon resonance technology. 
1.2.3 Costimulation as defined by surface plasmon resonance 
studies and gene expression. 
i.- Affinity and kinetics of binding. 
The functional differences between CD28 and CTLA-4 have been well established, 
nevertheless, the reason why two different ligands, CD80 and CD86, are necessary has 
been not very clear. Preservation of both genes across mammalian species suggests that 
they have been subjected to independent selective pressures. 
Initial structural and binding studies provided limited molecular basis for the functional 
differences between these molecules. In fact the prevailing view was that CD80 and 
CD86 had similar structures and comparable rather high affinities of binding for CD28 
and CTLA-4 (Lindsey., et al 1994, reviewed in Carreflo., et al 2002 and Sharpe., et al 
2002). None of these studies gave a clear and accurate view of the interactions between 
costimulatory molecules, but more recently Surface plasmon resonance technology has 
shown, that the costimulatory receptors and ligands form complexes of diverse struc-
ture and binding properties, providing an explanation for the existence and functional 
differences between B7 ligands. 
The initial Plasmon resonance analyses used recombinant sCD80 produced in an 
eukaryiotic expression system (CHO cells) to ensure proper glycosylation of the re-
combinat products. They measured the affinities and kinetics of binding to immobilized 
recombinant CTLA-4 and CD28-Ig fusion proteins at physiological temperature and 
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reported binding affinities as dissociation constants (Kd) in micro molar concentrations 
units, an inverse magnitude of the strength of interaction. 
The measured binding affinities of CD80 with CD28 and CTLA-4 (Kd = 4µM and 
0.42µM respectively) resulted much lower that previously estimated using soluble 
CD80-Ig fusion proteins (Kd = 200 nM and 12 nM respectively) (Linsley., et al 1991). 
This lower affinity observed was the result of a fast kinetics of binding (van der Merwe., 
et al 1997). 
Complete analysis of the affinities and kinetics of binding between the four components 
of the costimulatory pathway produced the following key findings: CD86 binds 13-fold 
more weakly to CTLA-4 than CD80; relative to its CTLA-4 binding affinity CD86 
binds CD28 two to three fold more effectively than CD80 and finally, neither CD28 or 
CD86 can participate in avidity-enhanced interactions as the ones proposed for CTLA-
4. These indicate that relative to CD80, the binding of CD86 is biased against CTLA-4 
suggesting that there is a reduced likelihood that CD86-CD28 interactions will be at-
tenuated by simultaneous CTLA-4 ligation, thus favouring positive costimulation under 
conditions where only CD28, CD86 and CTLA-4 are expressed. The reverse applies for 
CD80, for instance its predominant inhibitory activity when ligated to CTLA-4 is less 
likely to be affected by the presence of CD28 (Collins., et al 2002, reviewed in van der 
Merwe., et al 2003). 
ii.- Gene expression of costimulatory receptors. 
CD28 is constitutively expressed at high levels by all mouse mature T cells and thymo-
cytes (Gross, J.A. et al 1992) whereas in humans, it is only expressed constitutively on 
CD4+ T cells and approximately 50% of CD8+ T cells (Damle., et al 1983). 
CD28 transcripts and protein expression increases upon TCR engagement but following 
ligation by CD80 is transiently down regulated at the mRNA level. This data are consis-
tent with the predominant inhibitory role of CD80 (Linlsey., et al 1993). In addition, 
CD28 is rapidly internalized by endocytosis and a proportion of the product targeted for 
degradation, the reminder is recycled to the cell surface. 
	  Chapter 1. Introduction 
The process of endocytosis may be mediated via phosphatidylinositol 3-kinase (PI3-K) 
which binds actively to the cytoplasmic tail of CD28 and was previously considered to 
be involved in the CD28 signaling cascades (Cefai., et al 1998). 
CTLA-4 is expressed on the T cell surface only following activation of CD4+ and CD8+ 
T cells in both mice (Brunet, J.F., et al 1987) and humans (Linsley., et al 1992; Lind-
sten., et al 1993). It's expression is tightly controlled and dependent on ligation of 
CD28; activated CD28 deficient mouse T cells express very low levels of CTLA-4 un-
less exogenous IL-2 is provided (Wallunas., et al 1994). In fact, the increase in the ex-
pression of CTLA-4 correlates with the CD28 expression levels when transcripts are 
analyzed (Freeman.,et al 1992; Lindsten., et al 1993). 
Upon activation, mouse and human CTLA-4 transcripts have been shown to peak be-
tween 24 and 48 hours post activation but are detectable as early as 1 hour (Linsley., et 
al 1992; Lindsten., et al 1993) and functionally effective at 12 hours (Krumel., et al 
1996). Regardless of the abundance of mRNA, CTLA-4 protein appearance at the cell 
surface is delayed and in most T cells only reaches levels 1/30 to 
1/50 of that of CD28 on the same cell (Linsley., et al 1992). Most CTLA-4 appears to 
be dynamically localized in post-Golgi vesicles polarized towards the synapse region 
(Alegre., et al 1996). CTLA-4 molecules are efficiently translocated to the cell surface 
following T cell activation and rapidly endocytosed through a clathrin, AP-1, AP-2-
mediated pathway dependent on the binding of AP complexes to the dephosphorylated 
intracellular domain. (Chuang., et al 1997). This post-translational mechanism of regu-
lation and the differences observed in human and mouse T cell subsets with respect to 
their CTLA- expression will be discussed in detail later in this chapter. 
The mechanisms underlying the transcriptional regulation of CTLA-4 expression are 
still been studied but it is known that the expression is initiated about 335 bp upstream 
from the start codon (Ling., et al 1999) and that it may be dependent on the transcrip-
tion factor N-FAT (nuclear factor of activated T cells), as inhibition of N-FAT activation 
with Cyclosporin A causes a marked decrease in CTLA-4 gene expression (Finn., et al 
1997). 
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Other sites for transcriptional regulatory elements (STAT, GATA1, NF-xl3 and the IL-4 
negative regulatory element) (Perkins., et al 1996) have been found in the 5' region of 
the gene. 
B7- expression on the surface of the APC is also modulated in accordance with the acti-
vation state of the cell. APC show a constitutive expression of CD86 that is up-
regulated rapidly upon activation (Hathcock., et al 1994). In contrast, surface levels of 
CD80 are virtually undetectable, before maturation and activation. This costimulatory 
ligand is induced to expression levels of approximately 10% of the levels of CD86 on 
the same cell (Inaba., et al 1994). 
The kinetics of expression of these molecules are as follows: CD86, which is detectable 
at low levels on the surface of APC, is rapidly up-regulated upon activation, its expres-
sion reaches a maximum at 48 hours and is sustained for several days. CD80, in con-
trast, is not detected on resting cells and it is slowly induced after activation. It reaches 
a peak at 72 hours lasting, as well for several days (Hathcock., et al 1994 and Len-
schow., et al 1994). 
Maturation and activation stimuli for APC include CD40 ligation, peptide-MHC II-TCR 
ligation in T-B interactions, B cell receptor cross linking, toll-like receptor binding, and 
growth factors such as granulocyte-macrophage colony stimulating factor (GM-CSF) 
(De Smedt., et al 1996; Ranheim., et al 1993; Lenschow., et al 1994; Hathcock., et al 
1994; Witmer-Pack., et al 1987). 
Some cytokines like IL-2 or IL-4 appear to enhance the induction (Valle., et al 1991; 
Stack., et al 1994) whereas IL-10 mediates the specific down-regulation of costimula-
tory molecules (CD86) suggesting a tolerogenic effect of such cytokine (Akbari., et al 
2001). 
The structural data of all the costimulatory molecules together with their patterns of 
gene expression have allowed the proposal of a functional hypothesis for this pathway 
of T cell activation. 
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iii.- The functional hypothesis. 
The intriguing question of why two similar ligands exist on the surface of the APC, 
which both bind to two functionally independent receptors on the surface of T cells, 
may now be explained if one considers the structure, dimerization patterns, binding 
properties and kinetics of expression of these four costimulatory molecules. 
As mentioned before, the oligomeric state and comparative affinities of binding of the 
B7 molecules to CD28 and CTLA-4 has provided evidence to propose a differential 
role for these two molecules. The observation that CD86 has a weaker interaction with 
CTLA-4 than CD80, that relative to its CTLA-4 binding affinity CD86 binds more ef-
fectively to CD28 and CD86 is constitutively expressed and up-regulated after APC ac-
tivation, supports the idea that this molecule favors positive costimulation and also indi-
cates that the most immediate interactions following peptide-MHC-TCR ligation may 
predominantly lead to T cell activation. 
The subsequent upregulation in the expression of CD86 may sustain positive costimula-
tion, but the induction of CD80 on the APC, although able to transduce a positive signal 
through CD28, may tip the balance of positive costimulation to inhibition of T cell re-
sponses as CD80 has a much higher affinity for CTLA-4; newly expressed or translo-
cated to the T cell surface after CD28 costimulation. An inhibitory interaction seems to 
be predominant at this stage as bivalent CTLA-4 homodimers can bind a higher density 
of CD86 molecules on the surface of the APC as well as forming very stable and affinity 
enhanced periodic interactions with CD80. CD28 monovalent dimers are, in contrast, 
unable to produce such enhanced interactions (reviewed in van der Merwe., et al 2003). 
Figure 1.3 summarizes these costimulatory interactions. Absolute affinities of binding 
are shown as equilibrium dissociation constants and the comparative differences in 
binding affinities that define this hypothesis is reported as Ka ratios of interaction. 
Important questions arise from this functional hypothesis of costimulatory interaction; it 
is known that the stability of binding of CTLA-4-CD80 complexes is 10,000 fold higher 
than that of CD28-CD86 (Collins., et al 2002), so why do such differences exist be-
tween very similar molecules?. A plausible explanation could be that, if weak 
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interactions between CD28 and CD86 are enough to activate T cells after peptide-MHC-
TCR ligation, long lasting inhibitory interactions may be necessary to control the re-
sponse. The higher stability of interaction observed between CD80 and CTLA-4 fulfills 
this characteristic, therefore it is likely that this molecules, once expressed in the cell 
surface, they would stay longer in the synapse providing active control of T cell re-
sponses (van der Merwe., et al 2003). 
In vivo studies are consistent with and support this functional hypothesis, for instance it 
has been reported that treatment of mice of the diabetes susceptible strain, NOD, with 
blocking anti CD86 mAb protects from diabetes. In contrast CD80 mAb exacerbates the 
disease in female mice and induces it in resistant males (Lenschow., et al 1995). Toler-
ance induction requires CD80 and CTLA-4 in a murine model of allo-transplantation, 
whereas CD86 is an activation requirement for allo-reactive T cells (Judge., et al 1999). 
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Figure 1.3.- Diagram of the quaternary structures of co-stimulatory and inhibitory 
complexes formed between CD28, CTLA-4 and B7. The equilibrium disociation 
constants (kd), determined in solution by surface plasmon resonance, and the kd 
ratio between B7 receptors are shown. Adapted from (van der Merwe, P.A et al 2003). 
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Recently, 1Vlanzotti and co-workers, have shown, using CD80 or CD86 CHO transfec-
tants, that CD80, despite being a more potent co-stimulator to human resting CD4+ 
CD25- T cells than CD86, as measured in terms of numbers of cells that undergo cycles 
of division, induce significantly slower kinetics of T cell proliferation. At initial stages 
no CTLA-4 expression was detected but later in the cultures, when CTLA-4 expression 
was identified, blocking with anti CTLA-4 mAb significantly increased the number of 
divisions of the CD80-stimulated T cells (Manzotti., et al 2006). 
The existence of functional ligands for CD28 and CTLA-4 other than CD80 and CD86 
is unlikely as CTLA-4, CD80 and CD86 triple null mutant mice have a normal pheno-
type instead of the lymphoproliferative phenotype observed in CTLA-4 deficient mice. 
This rules out the possibility of uncontrolled T cell activation that could possibly be 
mediated by the interaction of CD28 with another putative costimulatory ligand. (Man-
delbrot., et al 1999). The existence of other ligands for B7 on T cells other than CD28 
and CTLA-4 may, however, be possible (Mandelbrot., et al 2001). 
1.3. Other important costimulatory molecules. 
Various new members of the B7 family have been identified and a significant amount of 
work has accumulated in the last years allowing us to understand their functions. 
Two main new pathways can be delineated: one involving ICOS on the surface of T 
cells and its ligand ICOSL on the APC. The other; involving PD1 on T cells and two 
new ligands on the APC, PD-L1 and PD-L2. 
Additional B7 homologs (B7-H3 and B7-H4 together with a CD28 homologue, BTLA, 
expressed on T cells and B cells have also been identified and studied. Structural and 
functional studies on these molecules have been extensively reviewed (Greenwald., et al 
2005). Here their functional characteristics will briefly reviewed with emphasis on their 
potential to inhibit T cells responses, as it is important for the argument of this thesis to 
highlight any additional negative regulators that can act synergistically with or in the 
absence of CTLA-4. 
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1.3.1 ICOS. 
The inducible co-stimulator (ICOS) is a glycosylated disulfide-linked homodimeric 
transmembrane member of the IgSF encoded just adjacent to CTLA-4. Although it is 
similar with CD28, several structural differences result in their diverse functional effects 
(1-lutloff., et al 1999). At its cytoplasmic tail, one of the most important differences is 
the lack of the YMFM motif that for CD28 recruits Grb2 and is crucial for signals lead-
ing to IL-2 production (Okamoto., et al 2003) therefore the ligation of this receptor does 
not induce the production of this cytokine. ICOS is up-regulated on CD4+ and CD84- T 
cells only following activation and CD28 costimulation, although this is not dependent 
on costimulation as its blockade in CD28-'- mice inhibits one of ICOS primary func-
tions, the differentiation of T cells to Thl or Th2 cells and the production of the corre-
sponding cytokines (IL-4, IL-5 and IFN'y) (Kopf., et al 2000). ICOS is also present on 
effector and memory T cells (Coyle., et al 2000). 
ICOS ligand is expressed on various non-lymphoid cells such as kidney, liver and lung 
as well as on B cells, macrophages and dendritic cells (Yoshinaga., et al 1999; Nka-
zawa., et al 2004). 
Apart of the influence of ICOS ligation on Th differentiation, costimulation through this 
molecule provides critical T cell help to B cell activation and thus humoral responses. 
Perhaps the clearest evidence to support this view is the fact that ICOS deficient mice 
show reduced germinal centres and defects in their formation upon primary or secon-
dary immunizations together with impaired IgG class switching (McAdam., et al 200; 
Tafuri., et al 2001). 
Altogether, functional studies have shown that ICOS provides a key positive second and 
later signal that promotes T cell differentiation and effector functions such as T cell 
-mediated B cell help. No effects of ICOS are likely to affect T cell activation as ICOS 
does not induce IL-2. 
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1.3.2 The PD1-PD-L pathway. 
Programmed death-1 (PD-1) is another monomeric IgSF member. (Freeman, G.L., et al 
2000). Signaling through this molecule is mainly mediated through 2 tyrosines, one 
forming an immunoreceptor tyrosine based switch motif (ITSM) and the second one an 
immunoreceptor tyrosine-based inhibitory motif (ITIM) (Okazaky, T., et al 2001). 
PD-1 is expressed by double negative thymocytes, yo double negative thymocytes and 
it is induced on CD4+ and CD8+ T cells, B cells and monocytes in the periphery (Agata., 
et al 1996). The ligands, PD-L1 and 2 are expressed differentially; PD-L1 is expressed 
on resting T cells including Tregs, B cells, non lymphoid cells and dendritic cells and is 
up-regulated after activation. In contrast PD-L2 expression is only inducible on den-
dritic cells and macrophages (Liang., et al 2003). 
The main function of these pathway is the inhibition of T cells as illustrated by the pro-
pensity of PD-1 knock out mice to develop late onset autoimmunity. PD-1 deficient 
mice on the C57BL/6 background develop progressive arthritis and lupus-like glomeru-
lonephritis. PD-1 knock out mice on BALB/c background develop late cardiomyopathy 
(Nishimura., et al 1999; Nishimura., et al 2001). 
As opposed to CTLA-4, the broad pattern of expression of PD-1 and the ligands, to-
gether with its participation in controlling tissue-restricted autoimmunity point to a role 
in controlling inflammatory responses in the periphery. This may be mediated mainly 
through interaction between PD-1 and PD-L1 as PD-L2 is lymphoid-restricted, suggest-
ing an overlapping function with other B7 costimulatory molecules. 
1.3.3 B7••H3 and B7-H4. 
B7-H3 is expressed by lymphoid and non-lymphoid tissue and in the mouse B7-H3 
gives rise to two different splice variants (4Ig-B7-H3 and 2Ig Steinberger., et al 
2004; Ling., et al 2003). These costimulatory molecules are not constitutively expressed 
but thus induced under conditions of cytokine stimulation (IFNy, GM-CSF or LPS, Ste-
inberger., et al 2004). 
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A ligand for B7-H3 has not yet been identified. Although studies using B7-H3-/- APC in 
an mixed lymphocyte reaction (MLR) have shown an increase in alloreactive T cell pro-
liferation (Suh., et al 2003), other similar experiments have reported opposing evi-
dences (Wang., et al 2005). 
B7-H4 a gpi-linked molecule, is expressed broadly in both lymphoid and non lymphoid 
tissue including the lung, liver skeletal muscle and pancreas. On B cells, DC and T 
cells, it is not expressed at resting but it can be induced upon activation . As well, its 
receptor remains to be identified, but the function of this molecule has been postulated 
from experiments where transfectants or immobilized B7-H4-Ig have shown to deliver a 
negative signal that inhibits TCR-mediated proliferation and IL-2 production (Sica., et 
al 2003). 
1.3.4 BTLA. 
A member of the CD28 family this last costimulatory receptor has shown functions 
similar to PD-1 and CTLA-4. BTLA is a monomeric protein selectively expressed only 
in lymphocytes (B and T) and, for T cells, only in Thl cells . It is induced upon activa-
tion, but in contrast to ICOS, BTLA remains expressed in Thl but not in Th2 subsets 
(Watanabe., et al 2003). The negative regulatory role of this molecule has been proven 
using mice with targeted null mutations. These animals are similar to PD-1 knock outs 
as they develop increased antibody responses and susceptibility to autoimmunity. Both 
KO models develop more subtle phenotypes than CTLA-4 deficient mice (Watanabe., et 
al 2003). 
	 20 
	  Chapter 1. Introduction 
1.4 Negative regulation by CTLA-4. 
The structural similarities of CD28 with CTLA-4 and the fact that both receptors share 
ligands had suggested that both molecules could deliver positive stimulation upon liga-
tion. The phenotype of the CD28 deficient mice, however, did not support the idea that 
these two molecules have similar functions. 
T cells From CD28'- mice show significantly lower proliferative responses than wt 
mice, and exogenous stimulation with lectins (Concanavalin A) did not induce IL-2 
production and or expression of the IL-2 receptor a chain. In addition, basal IgG con-
centrations, and helper T cell responses were dramatically reduced in CD28 deficient 
mice, as compared with wild type littermates. Interestingly no effects were found in the 
induction of cytotoxic T cell responses suggesting that CD28 is not required for all T 
cells responses (Shahinian., et al 1993). This evidence contradicts the idea that CTLA-4 
could have a positive costimulatory activity as the previously mentioned defects that are 
present in CD28-/- T cells would have otherwise been compensated through CTLA-4. 
Another strategy that further confirmed the negative costimulatory potential of CTLA-4 
used monoclonal antibodies and antibody Fab fragments in vitro. Although initial stud-
ies that used anti CD28 and costimulatory anti CTLA-4 antibodies proposed a synergy 
between these receptors in promoting proliferation and IL-2 production, CTLA-4 liga-
tion alone did not replicate the effect on proliferation and cytokine production observed 
after TCR stimulation and anti CD28 treatment (Linsley., et al 1992). Subsequently, the 
use of Fab fragments of these antibodies was shown to have an enhancing effect on T 
cell responses and, in accordance with this, crosslinking CTLA-4 after in vitro CD3 and 
CD28 stimulation, reduced such proliferative responses (Wu., et al 1997 and Walunas., 
et al 1994). Altogether this proved that the initial synergy observed was the result of a 
block in the inhibitory signals provided to the T cells through CTLA-4 and B7. 
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The evidence that clearly defined a negative role for CTLA-4 came from the generation 
of mice bearing a targeted deletion of this gene. To date, three independent CTLA-4 
knock-out mice models have been published providing much evidence on the function 
of this molecule (Waterhouse., et al 1995; Tivol., et al 1995 and Chambers., et al 1997). 
CTLA-4 -/- mice develop a lethal lymphoproliferative disorder characterized by the ac-
cumulation and a massive infiltration of T lymphocytes in spleen, lymph nodes, heart, 
pancreas and lung. This lymphocytic infiltration or hyperproliferation leads to lym-
phoadenopathy, splenomegaly and mutliorgan damage, particularly myocarditis and 
pancreatitis that is fatal within 3 to 4 weeks of birth (Waterhouse., et al 1995 and 
Tivol., et al 1995). 
Mice lacking CTLA-4 are born healthy but 5 to 6 days after birth a large proportion of T 
cells become activated. The phenotype of these T cells is CD44hI, Melt° and CD45RB-
which suggest they have been activated in vivo. In addition a large proportion of cells 
blast transform and express CD69, an early activation marker and CD25, all indications 
of recent activation. Ex vivo proliferation in response to lectins, anti CD3 stimulation or 
anti-TCRap stimulation are increased in CTLA-4 -'- T cells when compared with cells 
from wt and heterozygous littermates. In fact CTLA-4 null T cells proliferate spontane-
ously in culture, although at "low levels". IFNy and IL-4 production by T cells from 
homozygous mutant animals is also enhanced (Waterhouse., et al 1995). 
One of the hypotheses to explain this phenotype relied on the assumption that altera-
tions in the process of negative selection in the thymus, could allow a large proportion 
of auto-antigen specific T cells into the periphery. To address this, Waterhouse., et al 
analyzed negative selection in CTLA-4 deficient mice using a TCR transgenic line spe-
cific for the male H-Y antigen. In the thymus of male animals, a homogeneous popula-
tion of T cells undergo synchronous negative selection, when transgenics were crossed 
with CTLA-4 deficient mice. T cells in the offspring of this cross had a resting pheno-
type indicating that the dysregulation was not due to alterations in 
negative selection (Waterhouse., et al 1997). CTLA-4 may, however, fine tune negative 
selection (Takahashi., et al 2005). 
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In one of the previous CTLA-4 knock out models generated (Tivol, EA., et al 1995) a 
gross dysbalance in the CD4/CD8 thymic profile of mutant mice was observed when 
compared with wt littermates. This suggested abnormalities during T cell development. 
A third CTLA-4 knock out model where thymocytes were analyzed during their entire 
ontogeny indicated that the altered CD4/CD8 profile previously observed was due to an 
imprecision in the dissection techniques for thymi collection and an that enlarged para-
thymic lymph node had been harvested together with the thymus (Chambers., et al 
1997). 
Further research has shown that the severe proliferation of peripheral T ymphocytes in 
CTLA-4 knock out mice is mediated by CD28-dependent activation of CD4+ T cells, as 
antibody depletion of CD4+ cells rescues the phenotype. Similar evidence was not found 
for CD8+ cells although the predominant role of CD4+ T cells in producing the pheno-
type observed is not reflected in an altered CD4/CD8 ratio in the periphery. (Chambers., 
et al 1997, Mandelbrot., et al 1999). 
To further support the dependence of the lymphoproliferative response, associated with 
the CTLA-4 deficiency with costimulation through both CD80 and CD86, Mandelbrot., 
et al crossed CTLA-4 mice with animals deficient for CD80, for CD86 and for both 
CD80 and CD86. The results obtained showed that either CTLA-4/CD80-i- or CTLA-4/ 
CD86-'- mice developed a severe lymhoproliferative disorder, but in contrast, CTLA-4/ 
CD80/CD86-/- mice appeared normal (Mandelbrot., et al 1999). Moreover the inhibi-
tory effects of CTLA-4 appear to be required to control positive costimulation via CD28 
as CTLA-4 -/- CD28 double knock out mice do not develop a lymphoproliferation 
(Mandelbrot., et al 2001). 
Treatment of CTLA-4 deficient mice with CTLA-4 Ig, which binds to B7 molecules 
preventing costimulation, has proven to protect these animals from lymphoproliferation, 
rulling out a defect in the TCR signaling machinery in CTLA-4-/- mice (Tivol., et al 
1997). 
Putting all these data together, there is unequivocal evidence to point out the require-
ment of CD28 and both B7 ligands to provide essential costimulation which under con-
ditions of CTLA-4 absence triggers in the development of the autoimmunity. 
	 23 
	  Chapter 1. Introduction 
A final rather puzzling observation is that the autoimmunity observed in CTLA-4 defi-
cient mice is not cell autonomous. Reconstituted RAG 1-/- mice with equal numbers of 
wild type and CTLA-4-'- T cells do not develop autoimmunity and remain heathy. This 
is not only explained by an inhibition provided by wild type T cells as in these mice the 
CTLA-44- T cells undergo normal activation and expansion. 
This indicates that although the inhibition exerted through CTLA-4 is T cell autono-
mous, suppressive cytokines or negative stimuli produced by other cells or by CTLA-4 
expressing cells (perhaps Tregs) can protect CTLA-4-'- animals from autoimmunity (Ti-
vol., et al 2002). 
All the data described above point out that CTLA-4 is a major T cell costimulatory 
molecule involved in controlling T cell immunity. Despite the fact that most of the data 
point in such direction and only few reports have generated controversial evidence to 
consider the opposite, the precise mechanisms of action of CTLA-4 are still not fully 
understood. 
1.5 Molecular genetics of Ctla-4. 
1.5.1 CTLA-4 genomic organization and splicing. 
Ctla-4 is located on chromosome 1 in mice and on 2 in humans. Mouse CTLA-4 maps 
to cytoband C at 30.1 cM (location between 61212315-61219120 bp on the sense 
strand). In humans this corresponds to the syntenic genomic region of chromosome 2 
coded as 2q33. 
Encoded adjacent to mouse Ctla-4 is Cd28 (band C10-C3, location between 61049756-
61076649 bp + strand) and Icos (30.2 cM at 61281213-61302409 bp on the sense stran) 
(Mouse genome informatics, Jackson Laboratories http://www.informatics.jax.org/). 
Ctla-4 consists of 4 exons: exon 1 encodes the leader peptide, exon 2 the extracellular 
ligand binding domain, exon 3 the transmembrane domain and exon four the cytoplas-
mic tail (Dariavach., et al 1988 and Ling., et al 1999). 
	 24 
	  Chapter 1. Introduction 
Upon transcription, the resulting mRNA can undergo splicing, various splice variants 
are expressed and they differ between man and mouse. For human Ctla-4 is possible to 
detect a full-length mRNA transcribed from all exons, a transcript coding for a soluble 
form of CTLA-4 (sCTLA-4) that does not contain exon 3 and a transcript containing 
only exons 1 and 4. In mice, the expression of a fourth splice variant has been detected 
and its mRNA encodes for exons 1, 3 and 4. This last variant is called ligand-
independent CTLA-4 (LiCTLA-4) as it lacks the B7 binding domain (Ling, V., et al 
1999; Ueda., et al 2003; Magistrelli., et al 1999 and Oaks., et al 2000) (see figure 1.4). 
Li CTLA-4 is a functional CTLA-4 isoform strongly linked to type-1 diabetes in non-
obese-diabetic mice. It is expressed on primary mouse T cells and it has shown higher 
expression in memory and regulatory T cells from congenic diabetes resistant NOD 
mice as compared with diabetes susceptible NOD animals. Biochemical studies have 
demonstrated that LiCTLA-4 dephosphorylates TCR-zeta chain thereby inhibiting T 
cells responses and regulating autoimmunity (Vijayakrishnan., et al 2004). 
1.5.2 Ctla-4 is polymorphic and its locus associates with autoimmunity. 
Given the importance of CTLA-4 as a negative costimulator, its role in determining pe-
ripheral tolerance and its specific pattern of expression in functionally different T cells 
subsets, transcriptional or translational changes in expression can have important conse-
quences for immune homeostasis. For this reason the investigation of polymorphisms 
associated with autoimmune diseases has had CTLA-4 as obvious target. 
The first CTLA-4 polymorphism detected was a microsatellite marker corresponding to 
a (AT)n repeat in the 3' untranslated region (UTR) downstream exon 4 producing sig-
nificant odds ratio for development of Graves' disease (Yanagawa., et al 1995). This 
marker is not conserved in mice (Ling., et al 1996) and, in fact, locates in the area with 
the smallest sequence similarity between mice and human, suggesting it is not important 
for protein function or expression and that genetic susceptibility to Graves' may there-
fore be caused by an alternative mechanism. 
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Figure 1.4.- Ctla-4 and its splice variants. Ctla-4 has four exons encoding 
different polypetide chains (top). Four different splice variants have been identified 
at the level of mRNA. Humans express full length Ctla-4, exons 14 Ctla-4 and soluble 
Ctla-4 (exons 1,2,4). In mice an alternative variant (1iCTLA-4) is expressed lacking 
exon 2. Taken from (Teft., et al 2005) 
	 26 
	  Chapter 1. Introduction 
This sequence alteration could indeed become a good etiological candidate as AT rich 
sequences in 3' UTR may generate mRNA instability (Conne., et al 2000). 
Genome-wide searches identified in type-1 diabetes and less clearly in Graves' linkage 
with regions of the chromosome 2 (2q31-q35), and within the regions locus IDDM7 
(the CTLA-4 locus) was included (Copeman., et al 1995). 
Later the first single nucleotide polymorphism (SNP) in Ctla-4, an A-G change at posi-
tion 49 in exon 1, was reported to be associated with the two diseases already men-
tioned (Nistico., et al 1996). 
This substitution (Thr to Ala in the protein) would not affect the function of the leader 
peptide but may alter intracellular trafficking of CTLA-4 by causing differences in gly-
cosylation (Bradshow., et al 1997). This SNP was further associated with numerous 
autoimmune diseases. 
Two independent SNPs have also been identified within CTLA-4; C-T at position + 
1822 in intron 1 and C-T at - 318 in the promoter region. The first of these has been as-
sociated with type 1 diabetes and Graves' disease (Marron., et al 2000: Vaidya., B et al 
2003), the second has not shown disease association. Subsequent mapping of a greater 
area of the genome, that includes CD28, CTLA-4 and ICOS, together with regression 
analysis on Graves' cases, identified a significant number of polymorphisms (108) of 
which 4 were highly disease associated. These variations, CT 60, J031, J030 and J027-
1, span a 6.1Kb region 3' of CTLA-4, a common autoimmune disease locus (Ueda, H., 
et al 2003 reviewed in Gough., et al 2005), see figure 1.5. 
Establishing how the CTLA-4 polymorphisms trigger or contribute to pathophisiology 
of autoimmunity is still not clear, researchers have observed differences in T-cell acti-
vation and proliferation, in vitro, between patients possessing susceptibility alleles as 
compared to controls. Hypotheses to explain such observations have also been proposed 
including alterations in the levels or patterns of CTLA-4 expression or CTLA-4 traffick-
ing, but no clear links with disease causes or progression have been determined (re-
viewed in Gough., et al 2005). A clearer picture in this respect comes from studies 
where the abundance of mRNA of full length CTLA-4 transcripts and the soluble iso-
form (sCTLA-4 ) were compared between homozygous disease protective haplotypes 
and heterozygous individuals. 
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SNP 	202560bp 202927bp 204700bp 209108bp 213120bp 213595bp 215189bp 
CT44 CT42 CT55 	(CT60) (J031) (J030) (J027-1) 
(-319C-T) (+49G-A) (+1822C-T) 
(AT)n 	 208256-208295 
Figure 1.5.- Localization of 7 single nucleotide polymorphisms (SNP) and 
the (AT)n repeat sequence with in the 2q33 human CTLA-4 locus. 
Taken from Gough., et al 2005. 
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No differences were observed in the mRNA levels of F1CTLA-4 but higher levels of 
sCTLA-4 were observed in the disease protective haplotype as compared with the sus-
ceptible one. Subsequent analysis by quantitative RT-PCR showed that the sCTLA-4/ 
F1CTLA-4 mRNA ratio was 50 % lower in homozygous susceptible individuals com-
pared with homozygous protected subjects. These data show that the 6.1Kb 3' region of 
CTLA-4 determines the efficacy of splicing leading to sCTLA-4 production (Magis-
trelli., et al 1999). Higher sCTLA-4 serum levels have additionally been found in pa-
tients with autoimmune thyroid disease when compared to healthy controls (Oaks., et al 
2000). 
Lastly, mouse orthologues to the 2q33 susceptibility region have been identified, these 
regions (Idd5.1 and 5.2) determining susceptibility to diabetes in NOD mice. Region 
Idd5.1 includes kos and Ctla-4 but not Cd28 and approximately 62 SNPs have been 
identified, only 2 being in coding regions. One of those SNP maps to exon 2 of CTLA-4 
and has an A at position 77 in the diabetes resistant strains C57BL/10 and C57BL/6, and 
a G in the diabetes-prone strain NOD. This sequence substitution has been postulated to 
be a modulator of the splicing of CTLA-4 reducing the abundance of its ligand-
independent isoform (LiCTLA-4) highly expressed in T cells from diabetes resistant 
strains by favouring the inclusion of exon 2 in the final transcript (Ueda., et al 2003; 
Vijayakrishnan., et al 2004) 
1.6 Mechanisms of CTLA-4 costimulation. 
1.6.1 Competition with CD28 for ligands. 
As mentioned in section 1.2.3, the greater affinities and avidities of binding of CTLA-4 
to B7 ligands is consistent with the possibility that upon T cell activation once CTLA-4 
is translocated to the surface it may sequester the available ligands limiting essential 
CD28 signals. 
In a study where mutant forms of CTLA-4, either with truncations, modifications or 
absence of the intracellular domain were produced and expressed as transgenes in 
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mice, the authors show that these CTLA-4 mutants can still exert a negative function. 
(Masteller., et al 2000). This could also be the mechanism of action of sCTLA-4, as 
once secreted it could block binding of CD28 to B7. However the evidence that the 
soluble CTLA-4 fusion protein CTLA-4 Ig can trigger the IDO pathway (Grohmann., et 
al 2002) and that some agonistic CTLA-4 antibodies are also inhibitory (Fallarino., et 
al 1998; Krummel., et al 1995), complicates this scenario as it is then difficult to ascer-
tain when each individual mechanism is likely to come into action. 
1.6.2 CTLA-4 negative signaling. 
Antibody crosslinking of both CTLA-4 and TCR, under CD28 costimulation, is suffi-
cient to induce the canonical CTLA-4 effector mechanisms, cell cycle arrest and inhibi-
tion of IL-2 production (Baroja., et al 2000). CTLA-4 may interfere with TCR proximal 
events by recruiting phosphatases (i.e. PP2A) to the TCR/CD28 complexes and there-
fore inhibiting early phosphorylation (Lee., et al 1998). A second mechanism that has 
been postulated, involves as well, interference with TCR signaling but now by exclu-
sion from lipid rafts of the TCR chain limiting complete TCR signaling (Darlington., 
et al 2002). 
Finally analysis of the expression of lipid rafts have suggested CTLA-4 as an inhibitor 
of raft formation in the cell surface, therefore again limiting TCR organization at the 
immune synapse (Martin., et al 2001). 
Signaling through CTLA-4 may not require ligand binding, at least in mice and evi-
dence for that comes from the observations that LiCTLA-4 is an active isoform able to 
induce the dephosphorilation of TCR chain (Vijayakrishnan., et al 2004). 
1.6.3 CTLA-4 and CD4+ CD25+ regulatory T cells. 
CD4+ CD25÷ Regulatory T cells include a subset of naturally occurring T cells that ex- 
press high levels of the IL-2 receptor a chain (CD25). These cells derive from the thy-
mus, suppress T cell proliferation and cytokine production and they posses constitutive 
	 30 
	  Chapter I. Introduction 
expression of CTLA-4, all these observations have suggested that CTLA- may have an 
individual functional role through T regs (Takahashi., et al 2000: Read., et al 2000). 
The mechanism of action of CTLA-4 in T regs is still quite controversial and research-
ers have used monoclonal blocking antibodie in an approach to understand its function. 
Several groups have shown that Treg suppression can be inhibited by blocking CTLA-4, 
indicating an important role of this molecule for Treg activity (Takahashi., et al 2000, 
Tang., et al 2004). In contrast opposing evidence has also been published, indicating the 
limitations posed by this strategy (Thornton., et al 2004). Blocking antibodies, although 
one of the only strategies available to analyze the function of specific markers on spe-
cific cells, are limited in functional studies for reasons such as inaccessibility to the T 
cell immune synapse in the culture setup due to size, the predominant location of 
CTLA-4 in cytosolic vesicles and finally the fact that antibodies can also block CTLA-4 
on the surface of activated effector T cells making the analysis of experimental data 
complicated. All these limitations complicate the analysis of CTLA-4 on this subset of 
T cells as the lack of inhibition can not always refute a possible functional role of 
CTLA-4 in these T cells. 
In Tregs CTLA-4 may have actually a role to enhance function (Takahashi, T., et al 
2004). In disagreement with this view is the observation that CTLA-4 knock out mice 
have T cells that express the canonical T reg transcription factor Foxp3 and are able to 
suppress (Tang., et al 2004). This last observation does not rule out a possible functional 
role for CTLA-4, instead suggesting that it may not be essential. 
The observation that the enzyme IDO (see above) can trigger the tryptophan catabolism 
pathway in APC to indirectly inhibit T cell responses, has now been also consider as a 
potential mechanism of action for T regs (Mellor., et al 2004). High expression levels of 
CTLA-4 on the surface of Tregs can produce a signal to dendritic cells to produce IDO 
and subsequently inhibit 3rd party T cells responses (reviewed in Sansom., et al 2006). 
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In conclusion it is attractive to consider that CTLA-4 might play a role in T cell regula-
tion by Tregs. The reasons to consider that are that it is express constitutively, that the 
phenotype observed in CTLA-4-'- is not cell autonomous and secondary suppressive 
signals (cytokines) provided by Tregs may coexist, and finally, that the phenotype seen 
in CTLA-44- mice is similar to the phenotype observed in Foxp3 deficient mice which 
lack T regs (Khattri., et al 2003). Important limitations hamper our understanding of 
the function of CTLA-4 in Treg biology and although much has been done, novel 
strategies are required to overcome such limitation. 
1.7 The role of CTLA-4 in the induction of peripheral 
tolerance. 
The disease phenotype present in CTLA-4 deficiencient mice has provided an invalu-
able system to test the role of this molecule as a negative costimulator. It has been pos-
tulated that the hyper activation of T cells observed in these mice is the result of reactiv-
ity to self antigens present in the periphery which otherwise would be under control of 
CTLA-4 inhibition. 
In order to study the the role of CTLA-4 in peripheral tolerance, approaches such as the 
use of blocking mAbs have also been useful, yet they have also produced conflicting 
conclusions as to the role of negative regulatory properties of this protein. 
Studies using blocking CTLA-4 mAb in the response to a superantigen demonstrated 
that this receptor is essential for tolerance induction in both CD4+ and CD8 cells, 
antibody-treated individuals showing increased numbers of superantigen-specific T cells 
and a 1ac3232k of tolerance induction. (Walunas., et al 1998). Others have demon-
strated that the use of blocking CTLA-4 mAb during and after a tolerogenic stimulus, 
using antigen-coupled splenocytes as APC as a system for tolerance induction to ex-
perimental autoimmune encephalomyelitis EAE, showed a potent activity of CTLA-4 
during tolerogenesis, indicating an important participation of this receptor in maintain-
ing a tolerant state (Eagar,. et al 2002). 
There is evidence to suggest CTLA-4 as one of the key molecules mediating allograft 
tolerance, this has been performed by analyzing ligation, by membrane bound 
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anti-CTLA-4 antibodies (Hwang., et al 2002). However, several other groups have pro-
duced opposing evidence particularly at the level of CD8 T cell responses. 
In a model of inducible anergy, Frauwirth, et al have shown, using CTLA-4/B7 block-
ing antibodies, that primary CTLA-4+4 T cells as well as CTLA4-/- T cells are equally 
anergized when injected with soluble antigenic peptide (Frauwirth., et al 2000 and 
Frauwirth., et al 2001). This evidence has also been produced in a system of tumour an-
tigen specific tolerance induction (Sotomayor., et al 1999). 
An interesting approach to understand the function of CTLA-4 in establishing periph-
eral tolerance, comes from experiments where CTLA-4 deficient mouse cells are trans-
ferred into RAG-2 deficient mice. Under these circumstances researchers are able to 
transfer the lymphoproliferative disorder seen in CTLA-4-/- mice and, in addition, it is 
possible to revert the phenotype when wild type T cells are concomitantly transferred. 
This shows that the role of CTLA-4 in the establishment of peripheral tolerance is more 
complex than the simple transmission of inhibitory signals to self reactive T cells, and 
may involve the presence of other cell populations within a regulatory network (Tivol., 
et al 2002). 
The study of tolerance induction requires the employment of in vivo models as the mul-
tifactorial cellular interactions that determine the tolerance state cannot be reproduced in 
vitro. With this in mind and aiming to further dissect the role of CTLA-4 in tolerance 
induction to a tissue restricted self antigen and also to compare this in a scenario where 
the self antigen is present systemically, Eggena. et al develop a system using Rag defi-
cient TCR transgenics. In their experiments T cell from D011.10/Rag-'- and in a CTLA-
4-/- or WT background were transfer into transgenic recipients (also on the Rag'- back-
ground) able to express ovalbumin specifically in f3-cells in pancreatic islets. Upon 
transfer of D011.10/Rag-i-/CTLA-44- T cells, recipient mice developed severe insulinitis 
and diabetes. This pathology was mediated by CTLA-4-/- CD4+ cells spontaneously or in 
an induced fashion through D011.10/Rag-/-/WT T cells only if animals were challenged 
with exogenous OVA plus adjuvant (Eggena., et al 2004). These data indicate that in 
the presence of CTLA-4, self antigen is not able to activate autoreactive 
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CD4+ T cells, whereas in its absence self antigen is sufficient to trigger autoimmunity, 
This is consistent with the idea that CTLA-4 increases the activation threshold of T 
cells. A variation of the system in which OVA is not expressed in a tissue restricted fash-
ion but as a soluble protein and therefore systemically, was used to compare the role of 
CTLA-4 deficient and wt T cells to break tolerance. CTLA-4 appeared not to have the 
same role in determining tolerance to an antigen with systemic expression (Lohr., et al 
2004) and other mechanisms of regulation may exist to achieve tolerance for instance 
through regulatory T cells. 
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1.8 Targeted mutagenesis in mice. 
1.8.1 The history of gene targeting. 
Mouse Genetics and years of intensive breeding have generated a large number of 
mouse strains, many of which serve as models to understand genotype-phenotype inter-
actions. More recently, gene targeting has made it possible to introduce precise muta-
tions in the mouse genome, facilitating the reproduction of both genocopies and pheno-
copies of such mutations with either basic biological relevance or identified in diseases, 
sometimes also in human disorders. 
The technology of gene targeting started with the isolation and culturing of pluripotent 
ES cells from the inner cell mass of the mouse blastocyst, (Evans., et al 1981 and Mar-
tin., et al 1981). A crucial observation that made possible the implementation of this 
technique was that these ES cells, retained their capacity to colonize the germline of 
chimeric mice created by injection of the cells into blastocysts following prolonged cul-
ture ex vivo (Bradley., et al 1984). Subsequently, the demonstration that a fragment of 
genomic DNA introduced into a mammalian cell can undergo random integration or re-
combination with the endogenous sequence with which it shares a degree of homology 
provided a mean to produce specific genetic alterations in the mouse genome. This later 
process is known as gene targeting by homologous recombination and involves the oc-
currence of pairing and cross-over events between the homologous sequence of the ex-
ogenous fragment of DNA and the chromosomal target site, whereupon only the ho-
mologous region of the exogenous DNA recombines with the genome. 
The first evidence of the occurrence of gene targeting in mammalian cells came from 
the studies of a fibroblast cell line harboring a truncated - therefore dysfunctional- copy 
of the thymidine kinase (TK) gene. The activity of this gene was restored when the 
missing sequence, sharing an area of homology with the chromosomal TK gene, was 
introduced as a exogenous fragment of DNA (Lin., et al 1985). 
Homologous recombination was also demonstrated at the endogenous (3-globin locus 
(Smithies., et al 1985). The previous observation and the ability to culture and inject 
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ES cells into blastocysts led (Thomas and Capecchi. 1987) and (Doetschman,, et al 
1987) to perform the first experiments of gene targeting by homologous recombination 
in ES. In the first case the sequence of the selectable neomycin phosphotransferase gene 
(neo) was inserted into an exon of a cloned fragment of the hypoxanthine phosphoribo-
syl transferase (HPRT) gene and transfected into murine ES cells. After recovery of 
G418 resistant colonies of ES cells, approximately 1 in every 103 cells showed an 
Hprt phenotype, as analyzed by resistance to the base analog 6-thioguanine (6-TG). In 
the later instance, it was demonstrated that homologous recombination could be used to 
correct a mutant from of HPRT in an ES cell line. 
Two years later Koller's group, generated chimeric mice from the ES cells bearing a 
corrected HPRT gene, subsequently demonstrating the germline transmission of such 
genetic modification (Koller., et al 1989). 
1.8.2 The methodology of gene targeting. 
The principal applications of gene targeting have been the generation of animals har-
bouring null mutations in a desired locus (knock outs), the introduction of point muta-
tions into specific genomic loci or the site-specific insertion of exogenous coding se-
quences in what is known as "Knock in" strategies. 
Overall the strategy involves the construction of a targeting vector, comprising a modi-
fied mouse genomic sequence that is designed to either replace or insert into an specific 
homologous sequence in ES cells, by homologous recombination. Once an event of in-
sertion or replacement is identified, a preparation of so called "targeted" ES cells is in-
jected to pre-implantation blastocysts, followed by the generation of chimeric animals 
from those embryos. The final step involves the transmission of the targeted mutation 
through the germline by crossing the chimeric mice. 
1.8.3 The targeting vectors. 
Targeting vectors generally include a region homologous with the desired chromosomal 
recombination site, a selectable marker gene able to drive position dependent expression 
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of antibiotic resistant and a plasmid backbone. Two different vector designs can be em-
ployed to achieve the desired mutation; replacement and insertion vectors each yielding 
different types of recombination products (figure 1.6). 
Replacements vectors are typically used to generate null mutations and require lineari-
zation within the plasmid backbone prior cellular transfection, whereupon recombina-
tion replaces the targeted chromosomal DNA sequence with that of the targeting vector 
(Figure 1.6 A). Insertion vectors are linearized within the region of homology, so the 
plasmid undergoes a single reciprocal recombination event resulting in the integration 
of the entire plasmid into the chromosomal locus (Figure 1.6 B). 
Insertion vectors can be used in experiments aiming to disrupt alleles, however, re-
placement vectors are more commonly used as the screening for positive homologous 
recombination events is less complex (Hasty., et al., 1991). 
In order to translate targeted mutations to whole animals, pluripotent ES cells are elec-
troporated with a preparation targeting vector and cultured under selection conditions. 
ES cells that integrated the construct will develop antibiotic resistance (due to the se-
lection maker) and therefore survive to clonally expand. 
During the culture of ES cell, normally performed for short periods of time to keep low 
passaged cells, the differentiation ability of the cells is impeded using leukemia inhibit-
ing factor. 
At this stage ES clones can be independently isolated for screening, as two different 
phenomena could have occurred. On the one hand, the targeting vector could have re-
combined within its region of homology on the target locus (either replacing the wild 
type gene or as an insertion) and on the other, the vector could have also integrated 
somewhere else in the genome. The first case is known as a homologous recombina. 
tionevent and the later a random integration. 
It is important to mention that those events are not mutually exclusive as copies of the 
construct can randomly integrate at the same time as the locus of interest has been tar-
geted. Initial experiments demonstrated a very low frequency of gene targeting by ho-
mologous recombination in mammalian cells relative to the levels observed in yeast. 
This is probably due to the proficient competing pathway of random integration of ex-
ogenous DNA versus a homologous recombination event (Hasty,. et al, in Joyner, A 
2000). 
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Figure 1.6.- Scheme of replacement and insertion vectors and their products of recombina-
tion. (A) shows a typical replacement vector, normally linearized within the plasmid se-
quence, that integrates into the target locus by two reciprocal events of crossover replacing 
the region of homology (thick line). Insertion vectors (B) are linearized within the region 
of homology and after recombination, by a single event of crossover, all vector components 
are integrated duplicating the homologous sequences (vector and locus differentiated by 
lines of different thickness). Figure adapted from (Joyner, A.L. 2000). 
	 38 
	  Chapter 1. Introduction 
Observations of the critical characteristics of targeting vectors together with advances in 
their construction, have been made possible to enrich for and improve the ratio of gene 
targeting events. Among these characteristics the most important ones are: 
i. The length of the homologous region of the targeting vector. 
The homologous region of the vector with its target locus is the most important factor 
affecting the frequency of gene targeting. Targeting experiments done at the Hprt locus 
have shown that the efficiency of homologous recombination was strongly dependent 
and proportional to the length of homology of both insertion and replacement vectors 
(Thomas., et al 1987). Generally, regions of homology of 5Kb to 10Kb are used in gene 
targeting experiments (Hasty., et al 1991). However, with an increase in size of the tar-
geting construct, difficulty arises due several reasons: the cloning and handling of big 
constructs is sometimes inconvenient because the plasmid yield is inversely propor-
tional to its size when amplified by bacteria during transformations. Very large homol-
ogy may also limit the availability of unique restriction sites for both linearization and 
Southern blot analysis of recovered neo resistant clones, in addition, very large restric-
tion fragments are difficult to resolve by normal electrophoresis. 
Finally PCR screening strategies can become complicated with large homology, as the 
amplification of very long products is not always reliable. 
In order to tackle this last limitation imposed by the size of the area of homology, the 
selectable marker cassette can be placed towards one side of the construct, albeit creat-
ing a short and a long arm of homology, facilitating the screening of targeted ES cell 
clones by a diagnostic PCR. 
Despite the requirement of large regions of homology for successful targeting con-
structs, it has been experimentally established that a minimum arm of homology of 
0.5kb can render homologous recombination events at frequencies high enough to se-
lect a clone within hundreds screened (Thomas., et al 1992). 
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ii. Degree of Polymorphism and isogeneity of the homologous sequence. 
The 129 mouse strain initially proved the most permissive in the yielding of embryonic 
stem cell lines in contrast to other strains. 
129 mice have a relatively high prevalence of rare germ cell tumours in the testes (Ste-
vens. 1983). These tumours progress to form teratocarcinomas in embryos and this 
characteristic helped the derivation of ES cells directly from embryos. 
The ES cells isolated by Martin. et al in 1981 were derived from the ICM of blastocysts 
that were cultured in medium conditioned by an established teratocarcinoma cell line. 
Thus the advantage given by that tissue culture methodology determined that most ES 
cell lines generated to date and used for gene targeting experiments are of 129 origin. 
However, efforts have yielded ES cell lines in several "nonpermissive" strains, for ex-
ample, the C57B1/6J (Doetschman., et al., 1985), CBA/Ca inbred strains and PO and 
MF-1 random-bred strains (Brook., et al 1997). 
An important disadvantage of using this strain for gene targeting experiments is that the 
degree of polymorphisms among the 129 mouse substrains, at a given genomic target 
site, varies widely from locus to locus. Analysis of simple sequence length polymor-
phisms (SSLP) at randomly chosen DNA loci, revealed that a high degree of genetic 
variation exists within the 129 mouse substrains and ES cells. Overall, 65% of the SSLP 
markers differed between the 129 substrains examined and in addition, the 129/SvJ sub-
strain was demonstrated to be accidently contaminated with genomic segments of non-
129 origin (Simpson., et al 1997). 
These evidence, together with the previous empiric observation that variable frequen-
cies of recombination can be expected when 129 DNA and ES cells form different 
strains are use, strongly encourages the researcher to perform a careful selection of the 
source of DNA used to construct the targeting vector as well as the substrain of mouse 
ES cells used to produce chimeric mice (Deng., et al 1992). In ideal circumstances, 
gene targeting plasmids are best constructed from a genomic library of the strain of the 
ES cells chosen for transfection, although this is not always practical. 
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iii. Positive selection. 
Following transfection, the targeting vector can either integrate into its target locus or 
into a random chromosomal location. The ratio of these events depend upon several fac-
tors, such as the location of the target locus in the genome and in most cases, random 
insertions can happen with a higher frequency than homologous recombination events. 
In fact, both phenomena are considered to be competing events and this competition 
determines the frequency of homologous recombination of the targeting vector. 
Cloning, within the region of homology of the vector, a drug resistance gene (i.e. the 
neomycin analog G418, spectinomycin, puromycin) is essential to enrich for ES cell 
clones that have a stable insertion of the vector. Therefore after transfection, the sample 
of ES cells is cultured in the presence of the corresponding antibiotic and drug-resistant 
colonies selected. Drug resistance can be triggered in ES cells either because the con-
struct underwent homologous recombination, or if random insertions of at least the se-
quence of the resistance gene have occurred. 
As an advantage, positive selection cassettes can have a dual function, once they pri-
marily serve as a mechanism to enrich for the insertion of the targeting vector, they are 
also actively used as tools to disrupt coding sequences when knock out models are gen-
erated. It is important to note that the insertion into the genome, of resistance cassettes 
driven by strong and very active promoters, can also be disadvantageous. This has been 
demonstrated in gene targeting experiments aiming to introduce and retain a neomycin 
resistance cassette in various loci. An example of this was reported in mice bearing an 
insertions of a pGK neo cassette in the granzyme B locus. This mutation significantly 
reduced the expression of downstream sequences encoding other granzymes, even when 
the insertion site lies as far as 100 Kb away form the affected gene (Pham., et al 1996). 
The exact mechanisms underlying this phenomena are not well known yet, however, 
the insertion of selection cassettes in the fl-globin gene locus control region (LCR), 
have demonstrated that pGK-neo cassettes can disrupt the normal interaction between 
the LCR and downstream gene promoters or regulatory elements either by potentiation 
or competition. Subsequent deletion of the cassette restores gene expression suggesting 
the specificity of the effect (Hugh., et al 1996). 
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These effects could be influenced by the position where the selection marker is inserted, 
in another report, the same group demonstrated that targeting at a different location in 
the (3-globin locus does not produced alterations in neighbour genes (Kaufman., et al 
2001). These effects, often called hypomorphic or neighbourhood effects, are to be con-
sidered as part of the strategy to generate knock out models; altered phenotypes can 
sometimes be the outcome of targeted mutations that keep the selection markers, and 
this may mask or complicate the phenotypic characterization of the model. 
Several strategies are available to overcome this problems, for instance, the use of selec-
tion cassettes flanked by site-specific recominase sites (LoxP or FRT) allow to selec-
tively excise such cassettes either in the ES cells (i.e. by transient transfection of Cre) or 
in mice by crosses with transgenics that express the appropriate recombinases. 
iv. Negative selection. 
Random integration of the gene targeting vector typically involves the insertion of both 
genomic and bacterial plasmid sequences into the genome, a situation that can lead to 
disruption of aditional coding sequences in the genome. This problem can be resolved 
by using negative selection. This involves the incorporation of a cassette within the 
plasmid sequence, such that the cassette is lost upon homologous recombination but re-
tained when the vector inserts into a random location. Drug selection against this cas-
sette then enriches for targeted clones. For example inclusion of the Herpes simplex 
thymidine kinase (fISVtk) gene in the plasmid backbone of the targeting construct and 
application of the selection drug ganciclovir, negatively selects against clones that have 
retained this cassette. Negative selection has been reported to enrich for gene targeting 
events by up to 20-fold (Hasty., et al, in Joyner, A. 2000) 
1.8.4 Screening for homologous recombination. 
In this section we will describe the recombinant alleles produced by replacement vec-
tors, the undesirable targeted products that can occur as well as the main strategies used 
to screen and confirm events of homologous recombination among drug-resistant ES 
cell clones. The desired genetic exchange when a replacement vector is used in a gene 
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targeting experiment is one in which the full sequence of homology and other elements 
of the vector replace the homologous region in the genome. However, undesirable tar-
geted mutations can happen. Some of those incorrect targeted insertions are formed 
when vector ends join together or the construct re-circularizes following insertion into 
the region of homology by two events of cross over. The final recombination product of 
this phenomena is the insertion of all the elements of the targeting vector including the 
plasmid, in a single or multiple fashion. Figure 1.7 shows these as compared with an 
event of gene targeting or simple gene replacement. 
An initial screening to select ES cell clones for homologous recombination utilizes the 
technique of Polymerase chain reaction. This strategy is logistically very useful as it 
provides the possibility to narrow down the amount of positive selection-resistant ES 
cell clones selected after electroporation, before confirmation of targeting is performed 
by Southern blot. PCR screens rely on the use of primers that will amplify a specific 
junction fragment produced following a cross-over event of an arm of the targeting vec-
tor. For example, one primer locates within the positive selection cassette and the other 
within the genomic target locus but outside the homologous sequence of the vector. This 
type of PCR will only produce a product if the targeting vector (or at least the corre-
sponding arm of homology) has undergone homologous recombination. 
This type of PCR may not be able to amplify following the insertion of a concatamer as 
the presence of the plasmid backbone or other duplicated sequences may increase the 
distance between primers (see figure 1.7B). Another type of insertions that result in in-
appropriate targeting and that may or may not be detected by PCR are the insertions fol-
lowing only one event of crossover. In this case, only the region of homology integrates 
into the locus but the endogenous sequence is not replaced and is actually duplicated. 
As we can see in figure 1.7 an event of simple gene replacement requires that the vector 
recombines following two reciprocal events of crossover, one on each arm of homology. 
If the integration happens through crossover on only one arm of homology, the con-
struct integrates in either a 5' or a 3' duplicate increasing the size of the locus. 
The insertion of all the elements of the targeting vector after concatamer formation or 
re-circularization, as well as insertions in 5' or 3' duplicate can be readily discriminated 
by Southern blot analysis. This type of screening technique relies in the generation of 
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altered restriction fragments within the locus if an event of simple gene replacement has 
occurred. This is detected with a set of external probes (one at either end of the se-
quence targeted) homologous to the sequence of the target gene, but outside the area of 
homology of the construct. 
These probes are insensitive to events of random integration that can happen with sig-
nificant frequencies. To discriminate ES cell clones with such integrations, a probe in-
ternal to the construct (i.e homologous to the positive selection marker) can be used 
which will illuminate restriction fragments of the expected size corresponding to tar-
geted alleles together with, extra fragments if random integrations are present simulta-
neously. 
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Figure 1.7.- Integration of a replacement vector. In (A) the figure illustrates a 
simple gene replacement of the targeting vector and the homologous sequence. 
Crosses represent points of crossover, thick line the homologous sequence of 
the vector and dashed lines its counterpart in chromosomal DNA. Screening PCR 
primers are represented as horizontal arrows. (B) represents targeted mutations 
where either by re-ligation of one copy of the vector or more, the mutation 
results in the insertion of all the elements of the targeting vector. Figure 
adapted from (Joyner. 1999). 
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1.8.5 Chimera production and germline transmission of the targeted 
mutation 
Mutations created by gene targeting in ES cells can be transmitted through the germline 
of the mouse by chimera production. The most common method in use today to pro-
duce such chimeric mice, involves the microinjection of ES cells of a particular mouse 
strain, into the blastocoele cavity of pre-implantation blastocysts belonging from a dif-
ferent strain (Moustafa., et al 1972). 
Following the microinjection the chimeric embryos are grown in culture and then im-
planted into a pseudo-pregnant foster mother to continue the development until birth. 
The objective of using blastocysts of a different mouse strain is to facilitate the assess-
ment of the potential transmission of the targeted mutation to the germline of the mouse. 
For example; when ES cells corresponding to the 129 strain, which carry a dominant 
agouti-coat colour, are injected into blastocysts of the C57BL6/J background (of black 
coat colour), the contribution of the ES cells to the embryo can be assessed by simply 
analyzing the level of agouti colour in the fur of the chimeric offspring. This gives an 
indication of the potential that those ES cells have had to colonize the germline of this 
chimera and therefore to transmit the mutation. The degree of coat-colour chimerism in 
these mice can only give an indication of the potential germline transmission of the mu-
tation, contributed by the population of the targeted 129 ES cells in the embryo. To test 
that, chimeric mice are backcrossed to C57BL6/J mice and then the appearance of a 
complete agouti coat-colour in the offspring confirms germline transmission. 
It is important to consider that fifty percent of these mice are statistically predicted to be 
heterozygous for the recombinant mutated allele, which can be tested for by Southern 
blot screening of tail DNA. 
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1.9 Site Specific Recombination. 
There are several prokaryotic organisms as well as yeast species that encode site-
specific recombinases able to catalyze the cleavage of DNA at a single site and its liga-
tion to another single independent target site. Among those enzymes two important 
ones are Cre and Flp. 
1.9.1 The Cre-loxP system. 
The Cre recombinase is a 38 kDa monomeric product of the cre gene of bacteriophage 
P1 (Sternberg., et al 1986). It is a member of the k integrase superfamily of site specific 
recombinases (Argos., et al. 1986). The normal function of this gene is the maintenance 
of the P1 genome in monomeric circular form in a bacterial host. The Cre recombinase 
recognises a 34 bp sequence (see figure 1.8 A) and referred to as loxP (locus of cross-
over (x) in P1), which consists of two 13 bp inverted repeat sequences flanking an 8 bp 
non-palindromic core sequence. The 13 bp sequences act as binding sites for recombi- 
nase monomers and the 8 bp core confers directionality to the loxP site and hence, direc-
tionality on the recombination reaction. It is at this A:T-rich asymmetric core sequence 
that strand cleavage and reciprocal ligation happen. Upon binding of the recombinase 
monomers to each palindromic half of the loxP site, two such 13 bp target sites come 
together to form a synaptic complex, figure 1.8 C. A Holliday intermediate is formed 
initially by the cleavage, exchange and ligation of one DNA strand. This sequence is 
repeated for the second strand of DNA to resolve the Holliday junction into two recom-
binant DNA strands. 
The Cre recombinase can interact with its respective target sites to give a variety of out-
comes, depending on the positioning of the sites. Recombination between two unidirec- 
tional target sites in a head-to-tail orientation excises the intervening DNA as a circular 
molecule. 
	 47 
TATTGAAGCATAT 	TACG  ATATGCTTCAAT A 
ATAACTTCGTATA 
TATTGAAGCATAT 
ATAACTTCGTATA 
loxP 
core 
ATGC TATACGAAGTTAT 
lACG ATATGCTTCAATA 
(—D 
ATGC TA1.1"A-A-riT TAT 
AT 
C 
lox? 
loxP 
ATAACTTCGTATA ATGTATGC 
TATTGAAGCATAT 
TATACGAAGTTAT 
ATATGCTTCAATA TACATACG 
ATAACTTCGTATA 
TATTGAAGCATAT 
TATACGAAGTTAT 
ATATGCTTCAATA 
ATGC 
pfTACG 
	  Chapter 1. Introduction 
core 
5' ATAACTTCGTATA ATGTATGC TATACGAAGTTAT 3' 
3' TATTGAAGCATAT TACATACG ATATGCTTCAATA 5' 
13 by 	 13 by 
■ Minimal FRT 	  
(Dispensible element) 
5' GAAGTTCCTATTCC GAAGTTCCTATTC TCTAGAAA GTATAGGAACTTC 3' 
3' CTTCAAGGATAAGG CTTCAAGGATAAG AGATCTTT CATATCCTTGAAG 5' 
13 by 	 13 by 	 core 	 13 by 
core 
A.  
B.  
Cre recombinase 
monomers 
core 
core 
Figure 1.8.- A The loxP site sequence, Cre target site. B. The FRT site, Flp recombinase target 
site and the dispensable element. C. Recombination between 2 unidirectional loxP sites medi-
ated by Cre recombinase. Adapted from (Joyner. 2000). 
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Alternatively, recombination between target sites in an inverted head-to-head orientation 
inverts the direction of the intervening DNA sequence. Moreover, these reactions are 
reversible depending on the availability of the recombinase. The demonstration that ef-
ficient recombination can occur between altered Cre recombinase sites has led to the 
development of mutated sequences that change the equilibrium of the reaction towards 
generation of recombination products, for example, the loxP 511 and loxP 514 se-
quences (Hoess et al. 1986). Such mutant loxP sites can recombine with wild-type se-
quences, but recombination between mutant substrates is extremely inefficient. Single 
base-pair mutations at either end of the 8 bp spacer of wild-type loxP cassettes were 
demonstrated to have little effect on recombination between the mutant and wild-type 
loxP sequences but the efficiency of recombination was much lower between two mu-
tant sequences (Lee., et al 1998). Double substitution mutations within the spacer region 
were also tolerated, but led to drastically reduced levels of recombination. 
1.9.2 The FLP — FRT system. 
The Flp recombinase is a 43 kDa protein encoded by the 21,t circular plasmid of the 
budding yeast Saccharomyces cerevisiae (Gerbaud, C., et al 1979; Broach., et al 1980). 
The target site of the Flp recombinase, designated FRT (Flp recognition target se-
quence), comprises structural elements similar to the loxP sequence (Figure 1.8). The 
dispensable element is present in the 2v, plasmid, but is not essential for Flp mediated 
recombination (Sadowski. 1995). 
1.9.3 Site specific recombinases in gene targeting. 
Recombinase systems have been used in gene targeting for the design of targeting con-
structs, the efficient removal of the selectable markers from targeted alleles and for con-
ditional gene targeting. Furthermore, conventional gene knockout experiments that gen-
erate null alleles, by insertion of the positive selection marker into a coding sequence of 
the gene, may, in several instances, generate abnormal but functional targeted products, 
due to alterations in the alternative splicing or the induction of hypomorphic 
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alleles effects. These effects are caused by the elements of targeting constructs, such as 
strong viral promoter-driven antibiotic resistance cassettes, which can alter the expres-
sion of proximal and sometimes distant genes- (Nagy., et al 1998; Meyers., et al 1998) . 
This problem may be overcome with the inclusion of recombinase sites in the gene tar-
geting vector, flanking the selection marker, so that it can be removed subsequent to a 
homologous targeting event. In addition, by flanking the region to be deleted within the 
targeting vector with recombinase sites, it is possible to use recombinase systems to by-
pass the embryonic lethality of some conventional null mutations and provides a route 
to conditionally modify genes in vivo. 
A potential disadvantage of using such recombinase target sites within sequences of the 
targeting vector is that the recombinase leaves behind the heterologous sequence of the 
target site, for example, the 34 bp loxP sequence recognised by the Cre recombinase. 
However, the sequence appears sufficiently small so as to be neutral towards gene ex-
pression when positioned in non—coding genomic DNA. Depending on the gene target-
ing strategy, retaining such recombinase sites is useful if further deletions are required. 
At present recombinase systems like Cre-loxP and Flp-FRT are commonly used as ge-
netic engineering tools to manipulate endogenous sequences and transgenes in vivo. Cre 
has demonstrated a higher efficiency of recombination than Flp. This may be due to 
discrepancies in optimal working temperatures as Cre recombinase works at 37°C, but 
Flp recombinase has an optimum temperature of 30°C. In consequence, Flp currently 
seems to be the recombinase of choice to perform in vitro eviction of FRT—flanked 
marker sequences (Dymecki. 1996) while Cre recombinase is commonly utilized for in 
vivo gene manipulation in mice (Orban., et al 1992). Both Cre and Flp can mediate re-
combination between target sites over very large genomic distances, although variable 
recombination frequencies have been observed depending on different factors. 
Vooijs. et al have shown that for various alleles (R26R and Brca2), the distance between 
loxP sites has an impact on the recombination frequencies using a system where the ac-
tivity of a mutant form of Cre was temporally regulated by an estrogen derivate 4-
hydroxy Tamoxifen (Vooijs., et al 2001). 
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Cre transgenic mice are valuable tools to perform in vivo modifications to targeted al-
leles such as the elimination of positive selection cassettes or the generation of interme-
diate alleles required for conditional gene targeting strategies. Among these transgenics 
the so called "germ line deleters" are particularly useful as their expression of Cre in 
embryological tissues facilitates the generation of the genotypes needed, simply by per-
forming a cross with animals bearing the loxP sites flanking the DNA sequences of in-
terest, an example of these transgenic mice is the EIIa-Cre. In this line, Cre expression 
is driven by the Ella adenoviral promoter, which targets Cre expression to the early 
mouse embryo (Lakso., et al 1996). Another very potent and reliable Cre deleter line, in 
this case with expression driven by the early acting PGK-1 promoter, possesses Cre ex-
pression under dominant maternal control, meaning that when females are crossed with 
males that carry a gene flanked by loxP sites ("foxed"), deletion is observed even in the 
offspring negative in genotype for Cre (Lallemand., et al 2004). 
Finally another strategy to deliver Cre and to induce recombination on loxP site-bearing 
sequences, comprises the transient delivery of Cre through viral transduction using Ad-
enoviral strains encoding Cre. These tools are valuable to turn on or off "foxed" genes 
by transient expression of Cre and subsequent temporal recombination in genetically 
modified cell lines. They have also proven efficient for deletion in embryos kept in cul-
ture before implantation. On of such strains that has shown successful viral transduction 
in cells and embryos is AxCanCre (Kanegae., et al 1995). 
Several other specific Cre transgenics have been generated by pronuclear injection and 
knock-in strategies. These reagents are thoroughly described in this online database; 
http ://www.mshri . on .ca/nagy/Cre-pub html. 
1.10 Conditional gene targeting. 
The generation of null mutants can result in severe early phenotypes or even lethality at 
the developmental stages, therefore several strategies aimed at gaining spatial and tem-
poral control of the process of gene ablation have been developed. 
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One of the most widely used strategy uses the Cre-lox system, where Cre is controlled 
in its temporal and spacial expression. 
Cre—loxP conditional gene targeting requires the generation of a mouse harbouring a 
loxP—flanked segment of the gene to be altered and a second mouse strain expressing 
the Cre recombinase from a transgene which is under the control of a particular pro-
moter with a desired tissue expression profile, and/or with the ability to deliver an active 
form of Cre, only in the presence of an inducing agent or drug. 
Crossing the two strains produces double transgenic offspring with a Cre—loxP induced 
temporally and/or spatially restricted genetic modification, thus generating a conditional 
mutant. 
The spatial control of the targeted mutation affords the study of gene function in specific 
tissues or cell lineages to permit the dissection of particular components of a disease 
phenotype. Tissue-specific gene ablation was first demonstrated by (Gu., et al 1994) 
who generated a mouse harbouring a floxed promoter and first exon of the DNA po-
lymerase (3 gene (pol (3). This gene-targeted mouse was mated with a Cre transgenic 
mouse that expressed Cre recombinase in T cells only. The consequence was DNA pol (3 
gene ablation in about 40% of T cells but not any other tissues in offspring mice. 
Temporal control of the mutation provides a means of inducing a mutant genotype at a 
particular stage of development. Such control is able to negate adaptive or gene redun-
dancy mechanisms which have been observed in conventional knockout models, often 
obscuring precise genotype—phenotype relationships (Suemori., et al 2000). 
This enables the differentiation between the phenotype of chronic versus acute ablation 
of a protein. Spatial and temporal control of Cre-mediated recombination has been per-
formed through several strategies. Adenoviral expression of Cre have been used to by 
several groups (Akagi., et al 1997 and Shibata., et al 1997). However the immune re-
sponse of animals infected has made difficult the analysis and has affected the health 
status of animals studied. Another method used to gain temporal control of Cre in vivo, 
has utilized elements of the Tetracycline operon, but these has not always provided 
tight and reliable control of Cre expression and such leakiness complicates the analysis 
(Utomo., et al 1999). Finally interferon inducible Cre expression systems have also 
been employed to control Cre recombination in vivo (Khun., et al 1995). 
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An alternative approach takes advantage of recombinases fused with either one or two 
domains of a mutated estrogen receptor. These fusion protein becomes active only in 
the presence of the synthetic estrogen agonist Tamoxifen (as well as 4-hydroxy ta-
moxifen) instead of its natural ligand 1713-estradiol (Feil., et al 1996). This system has 
proven to deliver a very tight control of the expression of Cre, and several transgenics 
have been generated where the system is driven by tissue specific promoters (Brocard., 
et al 1997; Schwenk., et al 1998: Vasioukhin., et al 1999). However one of the main 
problems observed still with these animal models is that random insertions of the trans-
gene, generate a mosaic expression limiting the control of Cre expression (Garrick., et 
al 1998). This obstacle can be overcome with the generation of tissue-specific, inducible 
Cre expressing mice through knock in strategies, where single copy transgenes can be 
introduced into stable loci that are ubiquitously express throughout the mouse develop-
ment and adult stages (Vooijs., et al 2001). Figure 1.9 sows how the estrogen-dependent 
Cre inducible system works. 
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Figure 1.9.- Spatio-temporal control of gene inactivation through Cre-mediated 
recombination in cells and mice. In (A) the figure illustrates the two genetically 
modified animals required for the system. First; a transgenic mouse having tissue 
restricted expression of the fusion protein Cre recombinase is crossed with an animal 
bearing a foxed gene of interest. B shows that at the level of the cells in the 
specific tissue where Cre is expressed, only the presence of Tamoxifen or 4-hidroxy 
tamoxifen, can induce the dissociation of the heat shock protein (HSP90) that keeps 
Cre inactive in the cytoplasm. After such dissociation, Cre can use the 
nucleo-localization sequences of the mutated estrogen domains to translocate to the 
nucleus and excise the gene of interest. In other tissues (C), Cre is not expressed and 
no effect is observed. 
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1.11 Conclusions and aims 
It has been approximately 20 years since CTLA-4 was first identified and a vast amount 
of data is already available which allow us to understand its predominant role as a nega-
tive costimulatory molecule. From genetic mapping to structural characterization and 
biologically functional experiments, the methodologies used are diverse and very pow-
erful but all have important limitations when studying the mechanisms of action of a 
molecule like CTLA-4. 
Perhaps the clearest image obtained about the function of CTLA-4 as a negative co-
stimulatory molecule, has been elucidated by analyzing the immunity of CTLA-4-/- 
mice. However the lethality of this phenotype limits the study of the mechanisms of 
action of this molecule at the adult-stage peripheral T cell regulation. This problem 
could be overcome by using conditional gene targeting. 
Gaining temporal control of CTLA-4 deficiency will not only allow us to study the im- 
mune system in the absence of this gene at different stages of life, but also will be use-
ful to extend the knowledge already obtained from other mouse models, for instance , 
the above-mentioned autoantigen systemic and tissue restricted transgenic system 
Another advantage would be the ability to obtain T cell subsets (i.e. CD4+ CD25+ regu-
latory T cells) in which a Ctla-4 deletion can be induced at later stages, to use them in in 
vitro assays. 
In the process of making such model for conditional inactivation, animals bearing a 
targeted CTLA-4 allele can also be employed to address questions on the genetic regu-
lation of this gene. Sequence modifications required for targeting can produce hypo-
morphic alleles that may alter the expression of the gene of interest or neighboring 
genes, a situation that for CTLA-4 is of interest for two reasons: First, Ctla-4 is adjacent 
to two of the most important T cell costimulatory molecules; ICOS and CD28. Second, 
due to what is already known on its polymorphic variants and their association with 
autoimmunity, targeting Ctla-4 with out inactivation may result in an interesting pheno-
type. 
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In this project we will apply conditional gene targeting with the aim of selectively inac-
tivating CTLA-4 expression in a temporal and spacial fashion in animals. Our essential 
aim is to analyze the peripheral immune system of animals in which conditional inacti-
vation has been achieved particularly in adult stage. 
1.12 General Aims. 
• Generate a mouse in which conditional Ctla-4 inactivation can be achieved using the 
Cre-/oxP system. 
• Perform a phenotypic analysis of mice homozygous for a targeted Ctla-4 allele, as 
well as mice with a Ctla-4 allele in which exons 2 and 3 have been deleted by Cre-
mediated recombination. 
• To study the peripheral immune system of animals in which a conditional CTLA-4 
inactivation has been achieved, particularly later in the development or in adult stage. 
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Chapter 2. Materials and Methods 
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2.1 Materials. 
2.1.1 Buffers, solutions and media. 
i. Molecular Biology. 
• Ampicilin: (Amp; A9518 Sigma) was prepared as a 50mg/m1 stock solution and added 
to LB media to a final concentration of 50pg/m1 when media was at 50 °C. Amp ali-
quots were stored at -20 °C 
• Luria Bertani medium (LB): 1% (w/v) Bacto-tryptone (0123-17-3, Difco), 0.5% (w/ 
v) yeast extract (0127-17-9; Difco), 0.25 mM NaC1 (S9625, Sigma). 1.5% w/v agar 
for plates (0145-17-0, Difco). 
• Loading Buffer (6x): 0.25% bromophenol blue (B5525, Sigma), 50% (v/v) Glycerol 
(101186, BDH). 
• Tris-EDTA (TE) buffer: 10mM Tris-HC1 pH 8.0 (T3252, Sigma), EDTA pH 8.0 
(E5134, Sigma). 
• 10X Tris-borate buffer (TBE) buffer: 0.89M Tris-borate (T1503, Sigma), 20mM 
EDTA pH 8.0. 
• 10X Tris-acetate-EDTA (TAE) buffer: 400mM Tris-acetate, 10mM EDTA, pH 7.0 
• Hybridization buffer: Ultrahybe bufferTM (8669, Ambion). 
• 20X Salt Sodium Citrate (SSC): 5M NaCI, 0.3M Tri-sodium citrate (C7254, Sigma) 
• 10X TNE: 50mM Tris pH 8.0, 150mM NaCl, 100mM EDTA. 
• Depurination solution lx: 250mM HC1 (H1758, Sigma). 
• Denaturing solution 1X:1.5M NaCI, 0.5M NaOH (480878, Sigma). 
• Neutralising solution 1X: 1M Tris-HC1, pH 8.0, 1.5M NaCI. 
• GNTK buffer, (50 mM KC1 (P9333, Sigma), 1.5 mM MgC12, 10 mM Tris-HCI, pH 
8.5, 0.01% gelatin (G2500, Sigma), 0.45% Nonidet P-40 (21-3277, Sigma), 0.45% 
Tween-20 (P1379, Sigma). 
• Dyethil pyro-carbonate treated H2O (9916, Ambion). 
• Ethidium Bromide: 10mg/m1 stock (E2515, Sigma). 
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• Radioisotopes: [a-321] dCTP„ 3000 Ci/mmol 250pCi (A0005, GE Healthcare for-
merly Amersham Biosciences). 
• DNA Molecular weight markers: 1Kb plusTM DNA ladder 100bp-12Kb range 
(SM1331 250, Invitrogen). 
• Deoxinucleotide triphosphates (dNTP): Set of 4, 100mM each (U1330, Promega). 
Autoclaving of solutions was performed at 121°C, 151b/in2 for 20 min or by filtration 
through a 0.2tim Millipore membrane. 
ii. Techniques for protein analysis. 
• Tris glycine running buffer: 0.025M Tris pH 8.3, 0.192M glycine (G7126, Sigma), 
0.1% SDS (L4390, Sigma). 
• 2X Sample buffer: 0.125M tris-HC1 pH 6.8, 4% SDS, 20% glycerol, 0.1% bromo-
phenol blue, 10% 2-mercaptoethanol (M7522, Sigma). 
• Towbin transfer buffer: 0.025M Tris pH 8.3, 0.192M glycine, 20% methanol (10158, 
BDH). 
• Coomassie blue staining solution: 10% glacial acetic acid, 10% methanol 0.01% 
Coomasie Brilliant Blue R (B0149, Sigma). 
• Coomassie destain solution 10% glacial acetic acid, 10% methanol. 
• 1X Phosphate buffered saline (PBS): 10 Dulbecco's A phosphate buffered saline tab-
lets (BR14a; Oxoid) were dissolved in 1 litre of distilled water to give a final concen-
tration of: 8g/L NaC1, 0.2g/L KC1, 1.15g/L Disodium hydrogen phosphate and 
0.1g/L Potassium hydrogen phosphate. 
• Blocking/antibody buffer: 1X PBS, 5% skimmed milk (domestic). 
• Membrane washing buffer: lx PBS, 0.1% Tween-20. 
• 40% Bis/Acrylamide solution (A3574, Sigma). 
• BenchmarkTM pre-stained molecular weigh markers 6.0 kDa to 181.1kDa (10748-010, 
Invitrogen). 
• RestoreTM Western blot stripping solution (21059, Pierce). 
• Protease inhibitors Complete mini EDTA free (1836170, Roche). 
• PhosphosafeTM Cell lysis buffer (71296-3, Novagen). 
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iii. Tissue culture techniques. 
• Cell culture medium: RPMI-1640 (31870-108, Gibco BRL-Invitrogen), 0.58g/L L-
glutamine (25033-010, Gibco BRL-Invitrogen), 0.2U/ml Penicillin-streptomycin 
(15070-022, Gibco BRL-Invitrogen), 10% to 15% heat inactivated foetal calf serum 
(FCS) (253500; Harlan) and 2.5x10-5M 2-mercapto ethanol. 
• Tritiated thymidine: 5% v/v stock solution ([31-1]-thymidine; 2407005, ICN Biochemi-
cals). 
• Sodium and potassium free Dulbecco's tissue culture PBS (P5368, Sigma). 
• Trypan blue: 0.4% working solution in PBS (T6146, Sigma). 
• Erythrocyte lysis buffer: 8.34g Ammonium chloride (A-9434, Sigma), 0.037g 
EDTA, lg Sodium bicarbonate (S6014, Sigma). Sterilized by autoclaving. 
iv. Flow cytometry. 
• Staining buffer: Ice cold PBS, 10% Bovine serum albumin (BSA)(A2153, Sigma), 
10% normal mouse serum (M5905, Sigma). 
• Washing buffer: Ice cold PBS, 10%BSA. 
v. Tamoxifen Treatment. 
• Preparation for injections: Tamoxifen; (T5648-1G, Sigma). Stock 100µg/µL Ta-
moxifen in 100% ethanol and emulsified in 2m1 sunflower oil (domestic) to give an 
approximate final concentration of 50µg/ml. 
• Preparation for oral administration was prepared with the required amount directly in 
sunflower oil. 
2.1.2 Heat shock competent bacteria. 
The Escherichia coli strain used for all clone propagations was XL 10-Gold (Strata-
gene). Genotype: TetR, A(mcrA)183, AmcrCB-hdsSMR-mrr)173, endA 1, supE44, thi-
1, recAl, gryA96, relAl, lac, Htr, (F', proAB, lacqZ AM15tn10, (TetR), Amy, Cam)a. 
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2.1.3 Enzymes. 
• Restriction endonucleases (Promega and New England Biolabs). 
• T4 DNA ligase (M180, Promega). 
• Taq polymerase (M2035, Promega). 
• Calf intestinal alkaline phosphatase (M1821, Promega). 
• DNA polymerase I (Klenow fragment) (Y01396, Invitrogen). 
• Proteinase K (P2308, Sigma), DNA free recombinant Proteinase K (3115836, Roche). 
2.1.4 Kits for Molecular Biology. 
• GeneClean by NaI-glass beads method: Easypure, (390001, Biozym Inc) 
• Plasmid DNA isolations: Maxirep Kit endotoxin free (C-12362, Qiagen) and Miniprep 
Kit (C-27106, Qiagen). 
• DNA labeling by random priming: RadPrime DNA labelling kit (18428-011, 
Invitrogen) 
• Probe cleaning: Sephadex SH-200 HR MicroSpin columns 
(27-5120-01, GE Healthcare). 
• Absolute RNATM mini-prep kit (400800, Stratagene). 
• High capacity cDNA archive kit (ABI, 432217). 
• Expand LongTM PCR kit (1681834, Roche) 
2.1.5 Plasmid vectors. 
i. pBluescript II KS+ 
This vector, from Stratagene, is a colony producing phagemid, derived from the pBS 
phagemid. It contains a synthetic polylinker, a fragment of the LacZ gene to facilitate 
blue/white colony screening and an ampicilin resistance gene. 
All the constructs produced, including pGKneo which contains the sequence of the 
neomycin resistance gene flanked by loxP sites, had pBluescript as backcbone. pGKneo 
was kindly provided by Dr Yuri Mishima at NIH USA. 
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2.1.6 Oligonucleotides. 
Primer name 5'-3' Sequence 
LoxF GTATACACCACTCTACCACAGTGA 
LoxR GGCAAATAATTCTTCCTTTCATTTATT 
E4F CTTGGGCATTTTGGTTGTTC 
E4R ACGCGTCGACTCCTTCTTC1 1 CATAAACGGC 
E3EcoR1F CACCATGTCTGTGTAAGGCT 
EA-EcoR 1 R TCCCTCCCCAGCAAAAATAA 
BpAF CCCTGGAAGGTGCCACTCCC 
Neo2R CAGAAGACAGGAGTTGGATTCCCAGC 
Neo2F GAAGACAATAGCAGGCATGC 
El R AGCAAGCTGCTGTGGCTAGT 
E2F CAAAGGGTGAAGGGAGTGAT 
GR CAGAAGACAGGAGTTGGATTCCCAGC 
5' pF TGCTGAGGTATATGAACTACGT 
5 ' pR CTTTGATCCAAGGTACGTGTGCTA 
Neol TGCCGCGCTGTTCTCCTC 
Neo2 AAGCGGCCATTTTCCGCCAT 
PGKR GGTGGATGTGGAATGTGTGC 
E4NeoR AACTGAGCTAGTCAAATTCACC 
Exon1F CTTGTCTTGGACTCCGGAGG 
E4R ACGCGTCGACTCCTTCTTCTTCATAAACGGC 
HPRTF TCGTGATTAGCGATGATGAACC 
HPRTR CTGGCAACATCAACAGGACTCC 
Cre 1 CGCAGAACCTGAAGATGTTCGCGA 
Crc2 GGATCATCAGCTACACCAGAGACG 
Table 2.1.- Oligonucleotides used for PCR and sequencing were selected from the mouse ge-
nomic sequence (Ctla-4: NCBI accession #AF142145, Hprt:accession # NM013556) and syn-
thesized by Sigma Genosys. 
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2.1.6 Kits used for the techniques of protein analysis. 
• Protein concentration: BCATM protein assay kit based on the Biuret reaction (23227, 
Pierce). 
• Chemio-luminescence detection of proteins: Western Pico ECL kit (34080, Pierce). 
2.1.7 Antibodies used for tissue culture, Western blot and 
flow cytometry. 
i. Antibodies used for western blot. 
Reference 
& source 
Specificity Species 
isotype 
Format Clone Dilution 
Santa Cruz 
s-1628 
Mouse CD152 
C terminus 
Goat poly- 
clonal IgG 
Serum C19 1:200 
Sigma 
A5420-1ML 
Goat IgG Rabbit IgG Purified HRP 
conjugated 
-- 1:8000 
Chemicon 
MAB 1501R 
Pan actin Monoclonal Purified C4 1:1000 
GE 
Healthcare 
NA931 
Mouse IgG Sheep poly- 
clonal IgG 
Purified HRP 
conjugated 
-- 1:1000 
Table 2.2.- Primary and secondary antibodies used for Western blot. 
ii. Purified Antibodies used for tissue culture. 
Reference Specificity Species isotype Clone 
553238 Mouse CD3e hamster IgG2 500A2 
553294 Mouse CD28 hamster IgG2 37.51 
Table 2.3.- Mouse purified (azide free) monoclonal antibodies used for stimulation of T cells. 
All antibodies were purchased from BD and used at a final concentration of 1µg/ml. 
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iii .Anti mouse monoclonal and isotype antibodies control used for flow cytometry. 
Reference Specificity Fluorochrome Species isotype Clone 
553062 CD3e FITC hamster IgG1 145-2C11 
553050 CD4 (1:400) PE-Cy5 rat IgG2a RM4-5 
553031 CD8a (Ly-2) FITC rat IgG2a 53-6.7 
557399 CD19 R-PE rat IgG2a 1D3 
553866 CD25 R-PE rat IgG1 PC61 
553297 CD28 R-PE hamster IgG2 37.51 
553237 CD69 R-PE hamster IgG1 H1.2F3 
553720 CD152 (CTLA-4) R-PE hamster IgG1 UC10-4F10-11 
552146 CD278 ( ICOS ) R-PE rat IgG2b 7E.17G9 
551892 CD279 ( PD-1) R-PE hamster IgG2 J43 
Table 2.4.- Mouse monoclonal conjugated antibodies used for flow cytometry. All antibodies 
were purchased from Beckton Dickinson (BD) and used at a 1:100 dilution or otherwise stated. 
Reference Fluorochrome Species isotype Clone 
553953 FITC hamster IgG1 G235-2356 
553954 R-PE hamster IgG G235-2356 
557078 R-PE rat IgG1 A110-1 
550085 R-PE hamster IgG2 B81-3 
553929 FITC rat IgG2a R35-95 
553930 R-PE rat IgG2a R35-95 
553989 R-PE rat IgG2b A95-1 
Table 2.5.- Mouse anti TNP isotype control antibodies. All antibodies were purchased from BD 
and used at a 1:100 dilution. 
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2.2 Methods. 
2.2.1 Molecular Biology 
i. Agarose gel electrophoresis. 
DNA samples were mixed with loading buffer and subjected to electrophoresis through 
0.8% to 2% agarose gel (A5643, Sigma, LMP4327, Appligen Oncor) for low melting 
point) in TBE or TAE with ethidium bromide. Gels were visualized with a UV transilu-
minator (Herolab). Documentation was performed using a UV sensitive camera (Hero-
lab) and a thermal paper printer (Sony). 
DNA fragments sizes were estimated using the 1Kb plus DNA ladder 
(100,200,300,400,500,650,800,1000, 1650,2000bp with increments of 1Kb up to 12Kb). 
ii. Small and large scale plasmid DNA purification. 
The "maxi" and "mini" prep kits (Qiagen,) were used to isolate plasmid DNA from bac-
teria. For a "maxi-prep" 10 mL LB containing 100 vg/mL ampicillin were inoculated 
with a single bacterial colony and grown overnight at 37°C, shaking at 250 rpm. The 
overnight culture was used to inoculate 500 mL of LB broth containing ampicillin, and 
grown overnight. Bacteria were pelleted by centrifugation for 15 min at 6000 g, at 4°C. 
The pellet was resuspended in 10 mL of Buffer P1 containing 100 vg/mL RNase A. 10 
mL Buffer P2 was added to the bacterial suspension, mixed gently and incubated at 
room temperature for 5 min. 10 mL chilled Buffer P3 was added, mixed gently and 
stored on ice for a further 20 min. Precipitated protein and chromosomal DNA were re-
moved by centrifugation at 4°C for 30 min at 20 000 g. Another centrifugation step of 
20 000 g at 4°C for 15 min was applied to the supernatant to remove the remaining par-
ticulate material. 
A Qiagen-tip 500 resin column was equilibrated with 10 mL Buffer QBT, and allowed 
to empty by gravity flow. The supernatant containing the plasmid DNA was applied to 
the column and again allowed to enter by gravity flow. The column was washed twice 
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with 30 mL Buffer QC, and the DNA eluted with 15 mL Buffer QE Nucleic acids were 
precipitated with 0.7X volumes of isopropanol and pelleted by centrifugation at 10,000 
g for 30 min at 4°C. The DNA pellet was washed with 5mL of room-temperature 70% 
ethanol, and centrifuged at 10,000 g for 10 min. The supernatant was carefully decanted 
and the pellet air-dried for 5-10 min. The DNA was resuspended overnight at 4°C, in 
500 µL TE. DNA concentration was determined by spectrophotometry. 
The small scale preparation or, "mini-prep," of plasmid DNA was performed in a simi-
lar manner to that of the previously described DNA "maxi-prep". 5 mL of overnight cul-
ture was harvested by centrifugation at 5,000 g for 5 min. The Qiaprep "mini" prep kit 
from Qiagen was used for the isolation of plasmid DNA. The bacterial cells were resus-
pended in 250 [11._ of Buffer P1 containing 100 µg/mL RNase A and lysed by addition of 
250 !At Buffer P2. 350 [IL of Buffer N3 was added to the lysate, mixed gently and the 
precipitated protein and chromosomal DNA removed by centrifugation for 5 min at 
13,000 rpm. The supernatant was applied to a Qiaprep silica-gel column and centrifuged 
for 60 sec at 13,000 g. The column was washed with 750 µL Buffer PE containing 80% 
ethanol, with an additional subsequent centrifugation step to remove residual wash 
buffer. The Qiaprep column was placed in a 1.5 mL microfuge tube, and 50 1AL TE ap-
plied to the silica-gel membrane, allowed to stand for 1 minute, and eluted by centrifu-
gation at 13,000 g for 60 sec. 
Stocks of recombinant bacteria were kept frozen using glycerol: 750µL of bacterial cul-
ture in LB was mixed with 250[tL of sterile 80% glycerol-H20 in a vial, snap frozen and 
kept at -70 °C. Cells were grown from the frozen stock by taking a stab. 
iii. Extraction of DNA from agarose gels. 
Gene clean was used to isolate DNA from agarose gels (Easypure kit). Following elec-
trophoresis in a TAE agarose gel, the DNA was excised from the gel, and the volume of 
the gel slice was assessed. 3X volumes of NaI were added to the gel slice, and incubated 
at 50°C until the agarose melted. 5111_, of Glassmilk solution (an aqueous suspension of 
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silica beads) was added to the mix, and incubated on ice for 10 min, with gentle inter-
mittent shaking. The DNA/glassmilk was briefly spun at 13 000 g and the pellet washed 
three times with New wash solution (a solution of NaCI, Tris, EDTA and —50% etha-
nol). The DNA was eluted from the Glassmilk by addition of lOpt TE and centrifuga-
tion at 17 500 g for 30 sec in a bench-top centrifuge. The TE containing the DNA was 
transferred to a fresh tube. 
iv. Plasmid purification and genomic DNA extraction using PhenollChloroform or as 
crude lysates. 
Phenol/chloroform extractions were performed to remove contaminating traces of pro-
tein from plasmid DNA samples. An equal volume of TE-saturated phenol (RP3024, 
Rathum Chemicals) was added to the DNA sample, mixed by vortexing, and phases 
separated by centrifugation at 10,000g for 1 min. The aqueous phase is separated from 
the organic phase and extracted once with an equal volume of chloroform/isoamyl alco-
hol (24:1 v/v) (277106P; BDH and 1-9392; Sigma). 
After phenol/chloroform extraction or to concentrate a particular sample, DNA was pre-
cipitated by adding 2.5 volumes of 100% ethanol and 10% sodium acetate (pH 5). The 
mixture was then incubated at -20°C for 15 min and spun for 15 min at 10,000 g. The 
DNA pellet was then washed with 70% ethanol, air-dried and resuspended in an appro-
priate volume of TE. 
ES cell genomic DNA was extracted from two different culture conditions based on the 
analysis to be performed in each case, on the one hand, 96-well plate cultures yielded 
approximately 800ng and were used for PCR, on the other, 24-well plate cultures 
yielded approximately 30µg which was enough to perform Southern blots. 
To extract genomic DNA from a 96-well plate culture, cells were initially lysed by add-
ing 50µL of a 10mM Tris—HCI pH 7.5, 10mM EDTA, 10mM NaCI, 0.5% SDS 1 mg/ml 
proteinase K buffer. After an overnight incubation at 55°C in a humid environment, 
DNA was precipitated in a mixture of ice cold 100% ethanol, 75mM NaCI for 2h until 
precipitated DNA was visible. DNA will bind to the tissue culture plastic allowing us to 
eliminate the solution in each well by inverting the plate over several layers of paper 
towels. 
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Finally each sample was washed twice with 2004 70% ethanol and spun for 5 min in a 
bench top tissue culture centrifuge at 2800 g for 5 min. Ethanol was eliminated in each 
wash by inverting the plates on paper towels and air dried for 10 min after the last wash. 
Each sample was resuspended in 50µL of TE and quantified by running an aliquot 
against a quantitative marker in an agarose gel. 
From a 24-well plate, cells were resuspended in lml of THE for 30 min at 37°C. After 
incubation the cell suspension was transferred to a 2m1 eppendorf tube, 504 of 
10%SDS and 104 of 20mg/m1 of proteinase K were added and the mixture incubated 
overnight at 55°C. 
The next day DNA was phenol-chloroform extracted three times using initially 1 vol-
ume of TE saturated phenol only, then 1 volume of phenol-chloroform 1:1 and finally 1 
volume of TE saturated chloroform to eliminate traces of phenol. 
The sample was precipitated with 0.7 volumes of isopropanol (10062;Sigma), spun at 
10,000 g for 10 min, eliminating the alcoholic phase without disturbing the pellet. 
Pellets were washed twice with 5004 70% ethanol and resuspended in 2004, of TE. 
Crude lysates from mouse tail biopsies were prepares as follows: 
Approximately 5mm of tail tip biopsy was submerged in 2004 of GNTK buffer and 
digested with 0.1mg/m1 proteinase K overnight at 56°C. 
After complete digest samples were centrifuged at 10,000 g and 0.54 to 14 used for 
PCR. In each case proteinase K was inactivated by incubating the DNA template at 
95°C for 5 min before any PCR. 
v. RNA extraction for Reverse Transcriptase - PCR. 
RNA extractions from cell lysates were performed using the Absolute RNATM mini-prep 
kit . Between lx106 to 1x107 cells were lysed with 3504 of lysis buffer containing 
2-mercapto ethanol and vortexed. At this point, if necessary, samples were stored al 
-70 °C, or processed as follows. Cell-lysates were diluted with an equal volume of 70% 
ethanol (10107; BDH) in DEPC treated water and mixed by inversion. Lysates are then 
passed through a spin filter column and centrifuged at 10,000 g to eliminate cell debris, 
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filtrates are them passed through a spin binding column and centrifuged at the same 
speed. RNA binds to the column so it is kept and filtrate discarded. The column is then 
washed with 700µL of low salt buffer, centrifuged, and subsequently digested with 11.tg/ 
ml of RNAse-free DNAse I to eliminate genomic DNA. After 15 min at 37 °C, spin col-
umns are washed sequentially with 700µL of high salt buffer, 700[tL of low salt buffer 
and 300µL of low salt buffer, spinning in between, after the last wash spin columns are 
spun empty do allow drying. Spin columns are then transfered to a fresh tubes and RNA 
eluted with 60µL of elution buffer at 60 °C. 
RNA is quantified by spectrophotometry and its quality evaluated by visualization of 
ribosomal RNA (28S and 18S) on an agarose gel. Previous to the electrophoresis the 
tank was washed with 1% SDS to inactivate any contaminating RNAses. 
vi. UV spectrophotometry. 
DNA concentrations were determined by spectrophotometry spectrophotometer. A 
100µL sample was scanned at 260nm and 280nm to determine the absorbance ratio 
(A260/A280), as this ratio indicates the level of purity of the sample. 
DNA concentration was calculated considering that an OD 260nm of 1 is equivalent to a 
concentration of 50µg/m1 for dsDNA and 40µg/m1 for RNA. 
vii. Restriction enzyme digestion of plasmid and genomic DNA. 
Different amounts of DNA were digested in a reaction volume of 20-50 pL for 2-4 hrs, 
using 1-10 units of restriction enzyme per pg of DNA. Digestions were performed in 
the appropriate restriction buffer and at the optimum temperature according to manufac-
turer's specifications. 
Genomic DNA restriction digests were performed as follows. 
10X RE buffer 5µL 
Restriction enzyme 5-10U 
40mM Spermidine 1.25µL 
10mg/m1 RNAse A 0.51Th 
5mg/m1 BSA 
10-15µg of DNA +H20 up to 500_, 
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viii. Alkaline phosphatase treatment of DNA. 
Alkaline phosphatase was used to eliminate 5' phosphate groups left by restriction en-
zymes, and therefore to diminish self-religation of the vector during cloning experi-
ments. An appropriate amount of Calf intestinal alkaline phosphatase (0.01U per pmol 
of 5' ends, 1pig of a 1Kb DNA fragment equals to 3.03pmol of ends) was added to a 
sample of DNA, resuspended in Tris-HC1 pH 8, and the reaction incubated at 30°C for 
30 min. 
The phosphatase was inactivated by adding a solution of 10mM Tris-HC1, 1mM EDTA, 
200mM NaC1 and 0.5% SDS. 
After inactivation nucleic acids were isolated by phenol/chloroform extraction and 
ethanol precipitation. 
iix. Restriction overhangs modification or -end filling': 
The modification of incompatible DNA using restriction overhangs was performed by 
DNA polymerization using the bacteriophage T4 DNA polymerase, known as the Kle-
now Fragment. 
DNA -end filling- reactions comprised as follows: 
Digested DNA 	 2 pg 
DNA polymerase Klenow fragment 	 2U 
dNTP 	 2mM for each one 
10X Klenow Buffer (0.5M Tris-HC1, 0.1M MgC12) 2.5/41, 
H2O to a final volume of 	 25/41_, 
ix. DNA precipitation. 
DNA precipitation was done using the salt-ethanol method. 0.1 volume of 3Msodium 
acetate (S2889; Sigma) was added to the DNA sample, 2 volumes of 100% ethanol were 
then added and the sample incubated at 4 °C for 15 min to allow the precipitate to form. 
DNA was then pelleted by centrifugation at 10,000 g for 15 min. 
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After discarding the supernatant, DNA was washed in 70% ethanol and spun again for 5 
min before solubilization in TE. 
x. Oligonucleotide annealing. 
When an adaptor or linker is needed, either to add a restriction site or to clone an ex-
ogenous sequence into a DNA clone, chemically synthesized oligonucleotides can be 
used. In this case each complementary oligonucleotide was resuspended in 100i4L of 
sterile H2O at 4°C. An equimolar concentration of both oligos were mixed, heated at 
95°C, allowed to slowly cool to room temperature and finally kept at -20°C until ready 
to use. 
xi. Ligation of DNA fragments. 
Bacteriophage T4 ligase was used to clone DNA fragments in to plasmids. 
Ligation efficiency was determined by the ratio of vector to insert and the nature of 
templates for ligation. 
Ligation reactions comprised as follows: 
Vector 	 50-10Ong 
insert 	 50-15Ong 
10X ligase buffer 	lyL 
T4 ligase 1:4 	lyL 
H2O to a final volume of 10/IL 
xii. Transformation of E.coli. 
5-25ng of ligated DNA was added to 50/41., of competent cells, mixed gently and incu-
bated on ice for 30 min. Cells were then subjected to heat-shock for 45 sec at 42°C, fol-
lowed by quenching on ice for 2 min. 250/4L of LB broth was added and cells incubated 
for 1 hr at 37°C for 1 hr. 50-150/4L of the transformed cells was then spread onto LB-
agar plates with the correspondent antibiotic. Plates were incubated at 37°C overnight. 
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xiii. Design and synthesis of oligonucleotide primers for PCR. 
PCR primers were selected with a length between 21 to 27 bases, and with annealing 
temperatures in the range of 55 to 62°C, this temperature was determined by calculating 
the dissociation temperature as shown in (a) and the annealing temperature as in (b). 
(a) Td (°C)= 4(C+G) + 2(A+T). 
(b) Annealing temperature = Td- 5°C. 
G-C content of primers was generally 50% and, when possible, oligonucleotides had G 
or C at the end. 
xiv. Polymerase chain reaction. 
Amplification of target DNA sequences during the screening of ES cells was performed 
using the Expand Long Kit from Roche, this kit consists of a Taq polymerase mixture 
that has been optimized to efficiently amplify long PCR products from genomic DNA. 
The PCR reaction mixture consisted of 10Ong of template DNA, lOpmol of each primer, 
1.5 units of Taq, 1X PCR buffer including the optimal concentration of MgC12 and each 
dNTP at 0.1mM. 
Each reaction (50µL) was amplified following the specific conditions needed for each 
pair of primers (see table 2.1). The first stage of the reaction was an initial denaturation 
of the DNA template at 94°C for 2 min. following this, 35 cycles of amplification were 
performed in a thermocycler (PTC-100, MJResearch). 
Each cycle consisted of three steps: 94°C for 30 sec: 30 sec at the appropriate tempera-
ture to allow the annealing of the primers to the DNA template: and 3 min at 72°C for 
the extension of DNA strands. At the end of the previous cycles a 10-minute extension 
step at 72°C was allowed for the final extension of the DNA strands. 
A negative control containing no DNA template (NTC) was always included to monitor 
any exogenous DNA or cross-contamination during the reactions. 
Other PCR reactions including amplifications from cDNA were performed using Taq 
and supplied buffers from Promega. Reaction volumes (25µL) included: 10Ong of tem-
plate, primers at 0.4RM each and dNTP at a final concentration of 0.1mM for each. 
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Number of cycles of amplification were 35 except 40 for Cre genotyping). Table 2.6 
shows temperatures and extension times for each primer set and PCR reaction. 
Reverse transcription from RNA was performed using the High Capacity Archive kit 
from ABI. 400ng previously quantified by spectrophotometry and each sample standard 
amounts verified by electrophoresis, were mixed in a 1004, reaction as follows: 
2X Master mix for 50µ1.2 
10X RT Buffer 	10µL 
25X dNTP mix 	4µL 
10X Random primers 10µ1, 
Reverse transcriptase 5µ1_, (25 Units) 
RNA in DEPC-H20 to 50µ1_, 
Experiment Primers Product 
(Kb) 
Extension 
Time (sec) 
[MgC12] 
(mM) 
Annealing 
Temp (°C) 
ES cell screening 5'pF-Neo2R 7.3 7 min 20 sec Unknown 60 
ES cell screening Neo2F-GR 2.1 20 Unknown 65 
ES screening 
Genotyping 
LoxF-LoxR 0.3 WT 
0.34 Mutant 
20 3 61 
Internal probe Neol-Neo2 0.6 40 1.5 60 
5' external probe 5'pF-5'R 0.72 45 1.5 59 
Cre genotyping Crel-Cre2 0.45 45 1.6 65 
Cre-mediated 
deletion 
LoxF-PGKR 0.29 15 1.6 60.5 
Cre-mediated 
deletion 
E3EcoR1F 
E4NeoR 
0.58 WT 
0.63 Mutant 
35 1.6 60.5 
Cre-mediated 
deletion 
LoxF-E4NeoR 0.36 20 1.6 59 
CTLA-4 RT-PCR E1F-E4R 0.73, 0.65 
0.42, 0.3 
45 1.5 63 
HPRT RT-PCR HPRTF-HPRTR 0.65 30 1.5 60 
Table 2.6 Conditions for the PCR performed. 
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xv. Southern Blot, hybridization, removal of radio-labeled probes and 
autoradiography. 
Southern Blot is a technique used to detect sequences of interest from a restriction ge-
nomic DNA digest. 
In this case ES cell genomic DNA was digested as previously mentioned and then sepa-
rated by electrophoresis in a 0.8% agarose gel at 50V overnight. The gel was further 
treated 10 min with depurination buffer to hydrolyse DNA and facilitate transfer of 
large (>10Kb) fragments, followed by a 30 min incubation in denaturation buffer and a 
final 30 min incubation in neutralizing buffer. 
The denaturalized product of the separation was transferred for at least 18h by capillary 
action on to a solid support membrane (Hybond N+ RPN203B, GE Healthcare) using 
20X SSC. 
Membranes were then rinsed with SSC 20X, pre-hybridized at 50°C, for at least 30min. 
DNA fragments longer than 500bp were radio-labeled by random prime labeling using 
the T4 DNA polymerase known as Klenow fragment. A 25ng sample of probe was made 
up to 21111_, in molecular biology grade water and denatured at 95°C for 5 min. Finally, 
the probe was quenched on ice and a labeling reaction set up as follows: 
Denatured DNA 
5X Rad-prime buffer 	 204, 
5U Klenow Fragment 	 1µ1, 
1a-32P1 dCTP 	 5µL 
0.5mM of each dATP, dGTP and dTTP 
The 504, reaction was incubated at 37°C for lh and the unincorporated nucleotides 
were removed by fractionation through a TE pre-equilibrated S200 HR MicroSpin col-
umn. Each column was resuspended by vortexing and placed in a microfuge tube. The 
column was spun at 4000g for 30 sec to eliminate the storage buffer and the labeling 
reaction applied to the centre of the column. After spinning at 4000g for 30 sec the la-
beled product was collected in a tube and added to the pre-hybridization buffer before 
an overnight incubation at the same temperature as the pre-hybridization step. 
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Membranes were initially washed with a large volume of 3X SSC to eliminate traces of 
unbound probe followed by sequential washes of increasing stringency to minimize 
non-specific binding of the probe. Generally, membranes were washed once with 3X 
SSC, 0.1% SDS, 15 min in 1X SSC, 0.1%SDS and finally for 15% in 0.1X SSC, 0.1% 
SDS. All washes were performed at 65°C. 
To perform the autoradiography, the membranes were covered in cling-film and exposed 
to an Biomax X-ray film (8326886; Kodak). Exposure time varied according to signal 
intensity from 1-4 days. 
The removal of hybridized probes from membranes was done by washing the mem-
brane in 0.4M NaOH at 45°C for 30 min followed by a second 15 min wash in 0.1X 
SSC, 0.1% SDS, 0.2M Tris-HCI pH7.5 at 45°C. 
2.2.3 Techniques for protein analysis. 
i. SDS-PAGE. 
A 12% acrylamide resolving gel solution were poured into plastic cassettes 
(NC2010:Invitrogen) and allowed to set covered with a volume of 100% 2-propanol 
(10062, BDH). The alcohol was then eliminated and a solution of 5% acrylamide was 
poured on top of the resolving gel to act as stacking gel and to form the required lanes. 
Samples were mixed 1:1 with reducing loading buffer, boiled for 2 min and then loaded 
into the gel. Samples were run into the stacking gel for 20 min at 60V and then resolved 
at 120V until the dye front migrated out after approximately 90min, using a mini tank 
(X-cell, Invitrogen). The gel was then processed for electrotransfer. 
ii. Western bloting. 
After electrophoresis the gel is processed for electrotransfer. The stacking gel and lanes 
are cut away and the remaining portion of gel superimposed on a sheet of PVDF (Hy-
bond P RPN303F, GE Healthcare) membrane. Both the gel and membrane, without any 
bubbles in between, are covered with two foam sheets and placed in the corresponding 
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plastic frames inside the electrobloting apparatus (Mini-protean; Biorad). The correct 
polarity was always observed. 
Transfer was performed at 40 milli Amperes overnight in Towbin buffer and the gel 
stained with Comassie to evaluate transfer. 
Membranes after transfer were stained with the reversible dye Ponceau red (c0644, 
Sigma) and after a quick wash with PBS the blot was treated with blocking solution at 
RT for 1 hr. After that period, blots were incubated with the primary antibodies (in 
blocking buffer). After the primary antibody incubation blots were washed 3 times for 
15 min with washing solution, treated with the appropriate secondary reagents for 1 to 2 
hrs, washed again and taken for chemio-luminescence detection following manufactur-
ers indications. 
Exposure to photosensible film (03E220, Fuji) was performed at varying exposure times 
and developed in an automated developing system (Curix, Agfa). 
2.2.3 Tissue culture. 
i. Preparing single cell suspensions from peripheral, thymus, lymph nodes and 
spleen. 
Thimy, inguinal, popliteal, brachial, mesenteric and cervical lymph nodes were har-
vested immediately after the sacrifice of the animal. Single cell suspensions were pre-
pared by gentle maceration through a 70µm nylon strainer (F-2350, BD) into complete 
RPMI media. Cells were recovered by centrifugation at 530 g for 10 min and resus-
pended in 10m1 of RPMI. Cell suspensions from spleen were prepared as before but 
processed for erythrocyte lysis. After centrifugation, cells were resuspended in 5m1 of 
lysis buffer and incubated for 2 min at 4°C. After this step cells were washed once with 
complete RPMI, centrifuged at 530 g for 10 min and resuspended in the same media. 
ii. Viable cell count. 
The number of viable cells in a suspension was determined by uptake of trypan blue. 
104, of cells suspension was treated with an equal number of dye and half of this 
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volume counted in a haemocytometer. Two diagonally opposite sectors were fully 
counted and cell number determined as shown in (c). 
(c) Cells/m1= total number of trypan negative cells x 10,000 x dilution factor 
iii. Isolation of CD3 cells by paramagnetic beads. 
Negative selection was used to isolate intact CD3+ T cell populations for use in tissue 
culture. Selection was done with beads coated with antibodies specific for mouse 
(110.02, Dynal) or rat (110.07, Dynal) IgG isotypes. 
Each type of beads were used individually in sequential steps to eliminate first; cells 
expressing surface IgG (B cells) and then in combination with other (home made) anti-
bodies such as a rat anti MHC-II, to eliminate cells expressing those markers (DC). 
Cells in media were spun at 530 g and resuspended in 3m1 RPMI supplemented with 
10% FCS. 150µL of anti mouse beads were added and cells incubated at 4 °C for 15 min 
in a rotating wheel (SB1, Stuart Scientific). After this step unwanted cells, bound to 
beads, were eliminated by collection inside a strong magnet (MPC-1, Dynal). 
The supernatant from this step was then treated with lml of rat anti MHC-II, (clone 
M5114) for 15 min at 4 °C. Later cell pellets were recovered by centrifugation, resus-
pended in 3m1 of RPMI-FCS and further treated with 75µL of anti mouse IgG beads and 
75p.L anti rat IgG beads. After a third incubation, unwanted subpopulations (extra IgG 
expressing cells or MHC-II expressing cells) were removed by collection of super-
natants under the magnetic field. CD3+ T cells, up to 98.5% purity, were recovered by a 
final centrifugation step counted and analyzed phenotypically by flow cytometry. 
iv Total lymph node or primary T cells cultures. 
96 or 24 well plates (Falcon, BD) were pretreated with either 100µL/well or 
500 µL/well respectively of 1µg/ml anti mouse CD3 antibody in sterile PBS overnight 
at 4 °C. The day of experiment the PBS was aspirated and wells washed once with PBS. 
After either cell preparations from lymph nodes or negative selection, cells were diluted 
to numbers of 2x105 cells in 100µL to be added to 96 well plates or 3x106 cells per 
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500pL for cultures on 24 well plates. When necessary (i.e. on cultures of isolated T 
cells) an aliquot of anti mouse CD28 soluble antibody was added to a final concentra-
tion of 1µg/m1 in media. 
v. Measuring cell proliferation by radioactive thymidine uptake. 
Tritiated thymidine was diluted in complete media and stored at 4 °C. Assays in 96 well 
plate format were pulsed with 1µCi/well in 20µL, for the final 8 to 12 hr of culture. Af-
ter that time plates were either frozen or cells lysed on to a glass fiber matt, using a har-
vester (Mach IIIM: Tomtec). The amount of incorporated thymidine was measured us-
ing a liquid scintillation counter (1450 Microbeta, Wallace). 
2.2.4 Flow cytometry. 
i. Surface stain. 
2x105 cells were harvested, washed twice with PBS and placed in 96 "V" bottom plates 
to perform the antibody staining. 50pL of blocking solution was added to each cell 
sample and incubated on ice for 15 min. Another aliquot of 50pL of blocking solution, 
including the proper amount of each antibody (see materials) was added and incubated 
on ice for 15 min. Finally each cell sample was washed twice with washing buffer spun 
at 650 g, transferred to FACS tubes and acquired using a FACS CaliburTM cytometer 
(Beckton Dickinson). 
ii. Intracellular stain. 
4x105 cells were processed for surface stain as mentioned before. After staining, the 
cells are fixed with 50/41_, to 100pL of a 1:20 dilution of fixative (CellFix, BD) for 20 
min at RT. Subsequently, each well was filled with washing buffer to remove the fixa-
tive by centrifugation. The cells are then permeabilized for 20 min with 100pL of a 
commercial solution of saponin (Cytoperm, BD), cells washed and spun before adding 
the straining antibody diluted in fresh permeabilization solution. The stain proceeded 
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for not less that 35 min. Before transfer to tubes for acquisition, cells are washed once 
again with washing buffer. 
iii. Acquisition and analysis. 
Acquisition (a minimum of 30,000 events collected) and analysis was done using the 
software Cell QuestTM from Beckton Dickinson. 
2.2.5 Experimental animals and animal husbandry 
i. Experimental animals 
C57BL/6, 129SVPAS and mice with a mixture of both backgrounds were initially gen-
erated at GenOway (Lyon, France) and kept at Charles River animal facilities. 
Animals sent to our laboratory were housed in specific pathogen free facilities at the 
Central Biomedical Services, Imperial College London. 
Breeding tail biopsy collection and ear marking was performed under the standard regu-
lations and as determined in a personal and project Home Office license. 
Two Cre expressing transgenic strains of mice were employed in this project: 
The first strain, named [3-70 expresses Cre in a Tamoxifen-dependent, inducible fash-
ion, was kindly provided by Dr Laurence Bugeon from Imperial College. This strain 
expresses the estrogen receptor fused with Cre under the control of the ubiquitous 
Chicken [3-actin promoter. 
The second strain is a Cre transgenic that expresses the recombinase under the control 
of the early acting PGK-1 promoter (Lallemand. Y., et al 2004). This strain was kindly 
provided by Dr Tanya Tomachova at the Seabra Laboratory, Imperial College London. 
Both strains were on the C57BL/6 background. 
All animals used in experiments were of 16 weeks of age or older. 
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ii. Tamoxifen inductions. 
Adult male and females were treated with tamoxifen either orally or by intraperitoneal 
injection following these schemes: 2mg of tamoxifen administered daily for 4 days, a 
single injection of 1 mg or 2 mg, or a single oral administration of 5mg. 
2.2.6 Histological analysis. 
Histological sections were obtained and haematoxilin-eosin stains performed by the 
Histology Laboratory, Section of Leukocyte Biology Imperial College London. 
Slides were visualized and digital photography taken in an optical microscope coupled 
to an imaging system (Olympus). 
2.2.7 Statistical analysis. 
The data corresponding to the phenotypic characterization of mice bearing a targeted 
Ctla-4 allele was collected from independent experiments with groups of 1 individual 
per genotype in each experiment. Results were tested for normality using the 
Kolmogorov-Smirnov goodness of fit test and if considered normal, the mean of multi-
ple replicas of the experiments was compared between groups. When differences were 
observed, they were statistically analyzed by a one-way ANOVA with Bonferoni multi-
ple comparison post test. If the goodness of fit test could not be applied to the data 
(when only few replicas were available), the data was analyzed by a non parametric 
Kruskal-Wallis test with a Dunnett's post test comparison. Other data is only reported 
representative of several replicas. These analyses were done using the InstatTM software 
(GraphPad). 
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Chapter 3. Generation of mice bearing a targeted Ctla-4 allele. 
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3.1 Background. 
In chapter one we discussed the experiments and evidences that led to the development 
of the methodologies of gene targeting and conditional gene targeting in mice. It is 
however, important to briefly recapitulate the main aspects of this techniques before de-
scribing the results concerning the generation of mice bearing a targeted Ctla-4 allele. 
A gene targeting experiment starts by the construction of a targeting vector that com-
prises a modified mouse genomic sequence, designed to recombine with and mutate a 
specific genomic locus in pluripotent ES cells. Subsequently the ES cells that have been 
transfected with the construct are screened to detect events of homologous recombina-
tion and once a clone of ES cells is identified, chimeric animals are then generated from 
those targeted ES cells by blastocyst injection. Finally the transmission of the character-
ized mutation through the germline is assessed by crossing the chimeric animals and 
screening for targeting among the offspring of that cross. 
The vectors used in gene targeting have the following basic elements: a bacterial plas-
mid backbone, a sequence homologous to the target gene of interest and a selectable 
marker such as a neomycin resistance cassette. There are two types of targeting vectors: 
replacement and insertion vectors and both yield different recombination products. A 
description of the characteristics of both vectors can be found in chapter 1. 
The type of construct we used to generate the CTLA-4 targeted mice is a replacement 
construct. This type of vectors are commonly used to generate mice harboring null mu-
tations in a desired locus or knock outs, this is done by introducing the selectable cas-
sette into the sequence of an exon critical for the function of he corresponding polypep-
tide. Nonetheless "non disruptive" locus-specific modifications for instance; insertion of 
selectable markers or recombination sites (FRT & loxP) into non coding regions, can 
also be achieved using replacement constructs. In this case we have designed a re-
placement vector to introduce, into non-coding regions of the Ctla-4 allele two main 
elements. First a neomycin resistance cassette, essential to select ES cells that have in-
tegrated the targeting construct and second, the sequence of 3 loxP sites which will al-
low us to modify and later conditionally eliminate, by Cre-mediated recombination, 
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segments of the coding and non-coding sequences of this gene as well as the selection 
marker. The purpose of this last genetic modification is not only to eliminate the se-
quence of the neo cassette, which if retained, can result in a hypomorphic allele and a 
possible alteration in the levels of expression of Ctla-4 or other important neighbour 
genes (i.e. /cos or Cd28). More importantly this vector design will allow us to achieve 
the ultimate goal of producing an animal having both a deleted allele and the second 
allele with two loxP sites flanking exons 2 and 3, which are critical for the activity of 
CTLA-4. Mice having these modifications at the the Ctla-4 locus can subsequently be 
crossed with transgenic animals that express Cre in an inducible fashion (under the con-
trol of a inducible promoter, such as the interferon dependent Mx-1 (Kuhn., et al 1995) 
to gain temporal control of the Ctla-4 disruption. 
In summary this chapter describes: the construction of a CTLA-4 targeting vector by 
molecular cloning, the transfection and screening of targeted ES cells, the production of 
chimeric mice and finally, the generation of mice heterozygous for a targeted Ctla-4 al-
lele. These mice were produced with the ultimate aim of generating a model for condi-
tional inactivation of this key negative regulator of T cell immunity. 
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3.2. General characteristics and construction strategy of the 
targeting vector. 
The homology of a targeting construct with its target sequence is pivotal to achieve ef-
fective pairing and crossover with the homologous target gene sequence. Our construct 
was designed to share a total homology with the wild type mouse CTLA-4 locus of 6.8 
Kb (4.1 Kb on the 5' arm of homology and 2.7Kb on 3' arm of homology). These fig-
ures are much higher that the values observed to be required to obtain an acceptable fre-
quency of recombination, from 500bp-2Kb, (Moens., et al 1992). The total length of 
construct excluding the plasmid backbone is 8.65 Kb. 
Figure 3.1 shows a diagram of the targeting construct, compared with wild type Ctla-4 
allele, and the regions of homology shared by of both arms are described with respect to 
the location where events of crossover can happen. The insertion of the construct into 
the Ctla-4 allele will depend on two reciprocal crossover events. The regions of homol-
ogy of the construct are represented in figure 3.1. 
The the main elements of this targeting vector are a loxP site downstream of exon 1 
and a neomycin resistance gene flanked by two loxP sites downstream exon 3. The lo- 
cation of these elements, in relation to the coding sequences of the gene, is important to 
achieve our ultimate purpose. We are interested in generating animals by bearing an al- 
lele where exons 2 and 3 are flanked by loxP sites as well as animals having a null allele 
for experimental work (see figure 3.2, C and D). Mice having such genotypes will be 
subsequently generated from animals heterozygous for the targeted allele, by Cre re-
combination in the germ-line, using an inducible Cre transgenic mouse line already de- 
veloped in the lab. It is of interest to generate and analyze mice bearing a targeted allele 
(as in figure 3.2B) as these mice may develop a hypomorphic allele and a possible phe-
notype of interest. 
To make the construct, the Ctla-4 genomic sequence was obtained from a 129/Sv ge-
nomic DNA library. This library had previously been screened in the lab by Dr Lau-
rence Bugeon. 
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The sequence was isolated and subcloned into four plasmids with pBluescript II KS+ 
backbone and kindly provided for the construction of the targeting vector as well by Dr 
Bugeon. Two clones comprising a genomic sequence of 8.3Kb in total length, were se-
lected to proceed with the cloning strategy and a characterization by restriction digest is 
shown in figure 3.3. A diagram of the overall strategy to generate the targeting con-
struct is shown in figure 3.4 and the cloning process is describe to detail in the next two 
sections. 
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Figure 3.1 Diagram of the targeting construct compared with wild type Ctla-4 allele. 
In A, the figure shows a representation of the wild type Ctla-4 genomic region, 
homologous to the targeting vector. In B, the figure illustrates a diagram of the 
construct; solid arrows indicate the sequence of the plasmids employed to make the 
targeting vector, dashed arrows indicate the segments and size of the sequence of the 
construct homologous to Ctla-4. Restriction sites indicated as; H: Hindill, B: BamH1, 
E: EcoRl, EV: EcoRV , Xh: Xhol. 
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Figure 3.2.- Restriction map of the 129Sv Ctla-4 genomic region compared with 
the targeting vector and the modified alleles after Cre-mediated recombination. 
The figure illustrates in A, the 129Sv Ctla-4 genomic region. in B, the targeting 
vector. C and D show two different modified alleles of interest, obtained 
after Cre-mediated recombination. Restriction sites indicated as; H: HindIII, 
B: BantH I, E: EcoR I, EV: EcoRV , Xh: Xhol. 
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Figure 3.3.- Restriction digest of the plasmids, p4KHBHB and p4KBH4 containing the 
129Sv CTLA-4 genomic sequence used for the construction of the targeting vector. 
A, diagrammatic representation of the CTLA-4 region isolated from a mouse 129Sv 
DNA library and subcloned into pBluescript II KS+. B, 5ug of maxiprep DNA 
was digested with BamHI. HindIII, EcoRI, EcoRV, Not! and subjected to an agarose 
gel electrophoresis (1% agarose). Inserted picture shows the 0.26Kb fragment on 
p4KHBHB visible earlier in the electrophoresis. Uncut plasmids (last lanes) are show. 
C, Predicted sizes of restriction fragments were obtained from the sequence published 
(NCBI Ac#AF142145). 
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Figure 3.4.- Cloning strategy for the construction of the Ctla-4 targeting vector. A fragment 
of 8.36Kb, corresponding to the 129Sv mouse genomic sequence of Ctla-4, was sub-cloned 
into 2 different plasmids and used to generate an 8.65 Kb targeting construct. A, construc-
tion of pMKSB7K. B, generation of p4BH4NEO. C, final targeting vector. The cloning 
methodology is indicated for each step. 
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3.3 Molecular cloning of pMKSB7K. 
Initially, an aliquot of pBluescript without insert was modified by excising the sequence 
of 6 restriction enzyme sites from the multiple cloning site (MCS). The rationale of this 
modification was to avoid the presence the EcoRI and HindIII restriction sites, as they 
will interfere with the subsequent cloning steps. 
Approximately 10 µg of pBluescript were simultaneously digested with Smal and 
Hindi, after digestion, the sample was purified and then ligated, taking advantage of the 
two blunt ends produced by the two restriction enzymes used. 
The next step in the strategy, was to ligate a 4.14 Kb BamH1 fragment from the CTLA-
4 genomic clone (p4KHBHB) to the modified pBluescript. This fragment was isolated 
by digesting approximately 10 lig of p4KHBHB with BamHI and purifying the frag-
ment from an agarose gel. The fragment was then ligated into the modified pBluescript 
which was previously dephosphorylated. Figure 3.5 shows a restriction digest charac-
terization performed on miniprep DNA from antibiotic resistant E. coli. This cloning 
step was not directional and it was possible then to obtain plasmids with the insert in 
any orientation, The restriction digest performed shows that the insert in the selected 
clone was in the 3' to 5' orientation (see section C on figure 3.5). This was considered 
not a problem because after completing all the modifications planned, the insert will be 
excised again an ligated to complete the targeting vector. This resulting clone, desig-
nated pMKSB7K, includes introns 1,2 and 3 as well as exons 1, 2 and half the sequence 
of exon 3. It represents approximately half of the region of homology of our targeting 
vector. 
pMKSB7K was then modified by inserting, on its unique HindIII site, a 44 bp synthetic 
oligonucleotide. The sequence of this double stranded oligo included the first loxP site 
as well as a new EcoRI site introduced to change the size of the restriction fragments 
when the construct undergoes HR and the targeted allele is digested with this enzyme. 
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Enzyme Fragment size 	Enzymes 	Insert 5'-3' Insert 3'-5' 
Hind!!! Linear plasmid 7.1Kb 
BamHI 4.1Kb & 3Kb 
EcoR 1 Linear plasmid 7.1Kb EcoRI/Notl 0.4 Kb & 6.7 3.8 Kb 3.3Kb 
NotI 	Linear plasmid 7.1Kb 
Figure 3.5.- Characterization by restriction digest of clone pMKSB7K. The figure illustrates in 
A, a diagram showing the ligation of a 4.1Kb fragment into pBluescript. This vector was previ-
ously modified to eliminate six restriction sites in the MCS (sites in brackets). B, DNA from one 
representative clone was digested with 	BamHI, EcoRl, Nod and EcoRl-Notl and 
fragments resolved by a 1.5% agarose gel electrophoresis in order to assess the orientation of 
the insert after ligation. C, Expected restriction fragment sizes if the insert ligated in either of 
the two possible orientations. 
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In addition, the oligo had a base pair change in each one of its ends to change the se-
quence of the HindIII site upon ligation. This modification will avoid the regeneration 
of site, and therefore altering the pattern of restriction fragments produced after HindIII 
digest of genomic DNA from putative targeted ES cells. These alterations will be essen-
tial for the Southern blot strategy to confirm the HR of our construct in the Ctla-4 ge-
nomic locus. 
pMKSB7K was digested with HindIII, and the linear DNA purified by ethanol precipi-
tation and 5Ong of the annealed oligonucleotide containing the loxP site sequence was 
ligated to pMKSB7K. Before transformation, the ligation product was digested with 
HindIII to diminish the uptake of non recombinant pMKSB7K by bacteria. This was 
possible since the insertion of such oligo will not recreate the previous HindIII site and 
only religated vector will be digested. This step proved crucial for this cloning proce-
dure as commercial oligonucleotides lack phosphate groups and dephosphorylation of 
the recipient vector would have been detrimental for the efficiency of ligation. 
The orientation of the inserted oligo containing the loxP sequence, was tested by simul-
taneously digesting the positive clones isolated with EcoRI and BglII. According to the 
sequence of the oligo and the genomic CTLA-4 sequence published (NCBI 
Ac#AF142145), this digest would generate fragments of various sizes but the presence 
of a 0.21 Kb fragment rather than one of 0.25 Kb will discriminate between clones 
having the insert in a correct 5' to 3' orientation, irrespective of the orientation of the 
4.1Kb insert of pMKSB7K (figure 3.6). 
4 clones were found to have the correct orientation and one was selected for further mo-
lecular cloning. The presence of a complete loxP sequence as well as its orientation 
was confirmed by sequencing (data not shown). 
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5'AGCTATAACTTCGTATAATGTATGCTATACGAAGTTAT( ; .\"I I ( 3' 
3' TATTGAAGCATATTACATACGATATGCTIVAATACTTAAGTCGA 5' 
Novel EcoRI site 
A 
C 
	
LoxP site insertion into pMKSB7K 
Enzymes 	LoxP 5'-3' 	LoxP 3'-5' 
	
EcoRl/BglII 0.75 Kb 	0.75 Kb 
1.21 Kb 1.17Kb 
0.21 Kb 	0.25 Kb 
4.82 Kb 4.82 Kb 
EcoRl 	0.96 Kb & 6.2 Kb 
BglII 1.42 Kb & 5.78 Kb 
Figure 3.6.- The insertion of the first LoxP into pMKSB7K using a synthetic oligonu-
cleotide. A, shows diagram of pMKSB7K and the sequence of the LoxP site (the orien-
tation of the site is represented by an arrow). The sequence in bold correspond to the 
novel EcoR 1 site inserted, underlined are the modified HindIII overhangs and in larger 
fonts, the Cre recombinase core of the LoxP site. In B, 8 different clones collected were 
digested with EcoR l and BglII to assess the orientation of the LoxP site with respect to 
the Ctla-4 genomic sequence, single digests were also performed on DNA from one 
clone to control for the activity of the enzymes (shown to the left). Restriction frag-
ments were separated by agarose gel electrophoresis (2% agarose). The clone marked 
was used for further molecular cloning and arrows to the right show the representative 
bands indicating the correct or incorrect orientation of the double stranded oligo in 
pMKSB7K. C, The table shows the expected restriction fragment sizes according to the 
orientation of the oligo in pMKSB7K. 
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3.4 Generation of p4KBH4NEO. 
One of the most important steps towards the construction of this plasmid was the intro- 
duction of the sequence of a PGK-driven Neomycin resistance gene flanked by two 
LoxP sites into the EcoRI site downstream exon 3 of the CTLA-4 genomic clone 
p4KBH4 . This neo cassette will confer neomycin resistance to any ES cell that inte-
grates our targeting construct, therefore allowing us to select them using the neomycin 
analog, G418. Additionally, the presence of two LoxP sites flanking this gene will allow 
its excision by Cre-mediated recombination. The fact that this type of recombination 
leaves a single LoxP site behind, will allow the generation of an allele bearing exons 2 
and 3 flanked by LoxP sites (see figure 3.2 C). 
The floxed neo cassette was kindly provided by Dr Yuri Mishina, NIH,USA already 
cloned into pBluescript. Digesting the plasmid with BamHI and EcoRI to excise the 
cassette was the strategy of choice, but this produced two incompatible ends making it 
impossible to directly clone it into the EcoR1 site of p4KBH4. To overcome this prob- 
lem, p4KBH4 was modified by adding a dsDNA adaptor (EcoRlBglII). This adaptor 
included on its 5' end an EcoR1 site and on its 3' end an additional Bg111 site. Bg111 pro- 
duces compatible ends with BamHI but the resulting restriction site, after cloning, is in-
compatible with BamH1. This was necessary as introducing a new BamH1 site would 
have been inconvenient when this part of the construct is ready for subsequent ligation 
to pMKSB7K. The 3' EcoRl overhang of the adaptor has a nucleotide modification 
which upon ligation, will avoid the recreation of a novel 3' EcoRl site in this region 
(see figure 3.7). 
p4KBH4 was digested with EcoRI and dephosphorylated with CIAP. Approximately 
5Ong of double stranded adaptor (EcoRlBglII) was ligated into the plasmid (figure 3.7). 
The modification of p4KBH4 with EcoRIBglII allowed, the insertion of an EcoRI-
BamH1 digestion fragment containing the floxed neo cassette. 
The fragment containing the neo cassette was excised from pBluescript and isolated 
from an agarose gel. Modified p4KBH4 was digested with EcoRI and BgIII, the linear 
plasmid purified by the Geneclean method and both DNA segments ligated. The ligation 
mix was used to transform E coli. A BamH1/EcoRl screening of miniprep DNA sam- 
ples coming from antibiotic resistant bacteria showed a high frequency of insertion of 
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the neocassette confirming the efficiency of the adaptor strategy (data not shown). The 
selected plasmid, designated p4KBH4NEO, was characterized by restriction digest as 
shown in figure 3.8. The fragments obtained after simultaneous digestin on with Bam-
H1+EcoR1 and EcoRl+HindIII, yielded fragments with the expected sizes (see figure 
3.8 C) in accordance with the sequence published (NCBI Ac#AF142145). Single 
EcoRl, HindIII and BamH1 digest were also included as controls and to assess the pos-
sibility of insertion of novel restriction sites within the sequence of the neo cassette. 
This situation could have altered the Southern blot ES cell screening strategy. 
The integrity of both exons as well as the orientation of both loxP sites in this interme-
diate construct were assessed by sequencing and found to be as expected (data not 
shown). 
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Enzymes Fragment sizes with the 
adaptor in 5' to 3' orientation 
BglII/HindIII 
BgIII 
HindIll 
BamH 1 /EcoR 1 
BamHl 
EcoR1  
2.7 Kb & 3.3 Kb 
Linear plasmid 7 Kb 
Linear plasmid 7 Kb 
1.1 Kb & 5.9 Kb 
Linear plasmid 7 Kb 
Linear plasmid 7 Kb 
Figure 3.7.- Ligation of an adaptor (EcoRlBglII) to p4KBH4. In A, the figure shows a dia-
gram of p4KBH4 and the sequence of (EcoRlBg111). A novel BgIII site (shown in larger 
fonts) was inserted in the sequence of (EcoRlBglII). B, double and single digests were per-
formed with BgIII, HindIII and BamHI, EcoRl on DNA from a representative clone and the 
corresponding restriction fragments (C) separated in a 1% agarose gel electrophoresis. 
Arrows on the right show the sizes of restriction fragments that confirm the orientation of 
the insert 
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backbone 
(k‘N. 
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B 
Kb 
EcoR11Hinc1111 
BamH1lEcoR1 
HindIII 
BamH1 
EcoR1 
4.6 Kb &4 Kb 
1 Kb & 7.6 Kb 
Linear plasmid 8.6 Kb 
Linear plasmid 8.6 Kb 
Linear plasmid 8.6 Kb 
Figure 3.8.- Insertion of the floxed PGKneo cassette into the modified p4KBH4. 
Schematically described in A, an aliquiot of the plasmid containing the PGK neo cassette 
was digested with EcoR1 and Bg1II and the corresponding fragment ligated to p4KBH4 con-
taining the adaptor (EcoRIBglII). In B, a representative clone was digested either individu-
ally or simultaneously with EcoRl, HindIII and BamHI to confirm the ligation of the frag-
ment. The corresponding restriction fragments were separated by agarose gel electrophore-
sis (1% agarose) In C, the table shows the restriction fragment sizes expected for this digest. 
	 97 
Chapter 3. Targeting Ctla-4 
The last modification to p4KBH4NEO comprised the elimination of a 1.25 Kb segment 
downstream of exon 4. Eliminating this region will shorten the distance between the neo 
cassette and the 3' end of the construct, leaving an area with a distance suitable to be 
amplified by PCR (2.1Kb). p4KBH4NEO was digested with EcoRV and Sall and the 
fragment of interest (7Kb) was purified from an agarose gel by the. As these two en-
zymes generate incompatible ends, a restriction overhang modification was performed 
using the T4 polymerase I Klenow fragment. This enzyme was able to fill the Sall cohe-
sive restriction overhang to generate a blunt end that was compatible with EcoRV. After 
the Klenow reaction, the DNA was extracted with phenol/chloroform, ethanol-
precipitated and religated. A small aliquot of the ligation reaction was used for E.coli 
transformation. 
Figure 3.9 shows the screening characterization of successful clones obtained after this 
step. Miniprep DNA from antibiotic resistant bacteria was digested with Xhol to verify 
the elimination of the 3' area of this plasmid. Expected restriction fragment sizes be-
tween modified and unmodified plasmids is shown in figure 3.9 C. 
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B ,h 5 clones digested with Xhol 	*F- 
Xhol 	0.6Kb, 1 kb & 5.8Kb 	1Kb, 1.8Kb & 5.8Kb 
Figure 3.9.- Elimination of a 1.2 Kb region downstream exon 4. p4KBH4NE0 was digested 
with EcoRV and Sall and the corresponding 2.1Kb fragments eliminated from the plasmid. 
In A, the figure shows a diagram of the area eliminated as well as the primer location and 
product size for the screening PCR at the 3' end of the construct. B, DNA from 5 individual 
clones was digested with Xhol and the restriction fragments separated by electrophoresis 
(fragments sizes shown to the right). The unmodified plasmid digested with the same en-
zyme is also shown. In C, the figure shows the expected sized of the Xhol restriction frag-
ments corresponding to clones with or without the 2.1K region. 
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The final step to generate the targeting construct comprises the ligation of the two 
modified plasmids, the modified p4KBH4NEO and pMKSB7K containing the sequence 
of the loxP site. This last plasmid was digested with BamH1 and further purified from an 
agarose gel. The modified p4KBH4NEO was also digested with BamHI , dephosphory-
lated to avoid religation and purified by phenol chloroform extraction followed by and 
ethanol precipitation. Finally both fragments were ligated to generate a 11.6 Kb target-
ing vector and a clone selected from 25 miniprep DNA samples from antibiotic resistant 
E. coli (data not shown) was subjected to a final characterization by restriction digest. 
Figure 3.10 shows a diagram of this cloning step together with a 1% agarose gel elec-
trophoresis of a Notl, BamH1 and EcoRl single restriction digests performed on the 
selected clone. All restriction fragments were found to be of the correct size (see figure 
3.10 C), the integrity of the 4 exons and the orientation of the 3 loxP were again veri-
fied by sequencing. The location of primers used and segments of the sequence obtained 
showing both the correct 5' to 3' orientation of the 3 loxP sites together the integrity of 
each exon are shown in figures 3.11 to figure 3.14. 
Validating the 5' to 3' orientation of the 3 loxP sites is crucial if these sequences are to 
be recognize by Cre to produce the projected modifications of the Ctla-4 allele illus-
trated in figure 3.2. 
The final construct was designated pLoxCTLA-4 and a circular restriction map is shown 
in figure 3.15. 
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Figure 3.10.- Generation of pLoxCTLA-4. A 4.1Kb BamHI restriction fragment from pMKSB7K, bearing the sequence of a loxP site, was excised from the 
plasmid and ligated to p4KBH4NEO to generate the CTLA-4 targeting vector. In A, the figure shows a scheme of the cloning procedure. In B, DNA from the 
clone amplified for ES cell trasnfection, was digested with Notl, BamH1 and EcoRl for characterization and the corresponding restriction fragments separated 
by electrophoresis. C, the table reports the expected sizes for the restriction fragments. The overall homology of the construct to the Ctla-4 genomic 
sequnce is 6.84 Kb; 4.1 Kb upstream exon 3 and 2.7 Kb downstream the same exon. 
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CATACAGGTGACCCAACCTTCAGTGGTGTT 60 
pLoxCTLA-4 sense strand (top) 
Genimic CTLA-4 sense strand (bottom) 
1 CTAAGTGCCCTTTGGACTTTCCATGTCAG 
1 CTAAGTGCCCTTTGGACTTTCCATGTCAG CATACAGGTGACCCAACCTTCAGTGGTGTT 60 
GTGAGCAAAGCCATTCCACTAAGAACAAGTCTGTTGCATTATT 420 
GTGAGCAAAGCCATTCCACTAAGAACAAGTCTGTTGCATTATT 420 
361 GCAGATTTATGTCATTG 
361 GCAGATTTATGTCATTG 
pLoxCTLA-4 antisense strand (top) 
vs. 
Genimic CTLA-4 sense strand (bottom) 
Banalll 
1 GATCCTIGTTGGGITTTACTCTGCTCCCTGAGGACCTCAGCACATTTGCCCCCCAGC 
1 GATCCTGTTGGGTITTACTCTGCTCCCTGAGGACCTCAGCACATTT'GCCCCCCAGC 
T 60 
T 60 
61 GGCITGTCTTGGACTCCGGAGGTACAAAGCTCAACTGCAGCTGCCTTCTAGGACITGGCC 120 
61 GGCTTGTCTTGGACTCCGGAGGTACAAAGCTCAACTGCAGCTGCCTTCTAGGACTTGGCC 120 
121 TTTTGTAGCCCTGCTCACTCTTCTTTTCATCCCAGTCTTCTCTGAAGGTGAGTGGAGACT 180 
121 TTTTGTAGCCCTGCTCACTCTTL till CATCCCAGTCTTCTCTGAAGGTG  kGTGGAGACT 180 
61 GGCTAGCAGCCATGGTGTCGCCAGCTTTCCATGTGAATATTCACCATCACACAACACTGA 120 
61  GGCTAGCAGCCATGGTGTCGCCAGCMCCATGTGAATATTCACCATCACACAACACTGA 120 
121 TGAGGTCCGGGTGACTGTGCTGCGGCAGACAAATGACCAAATGACTGAGGTCTGTGCCAC 180 
121  TGAGGTCCGGGTGACTGTGCTGCGGCAGACAAATGACCAAATGACTGAGGTCTGTGCCAC 180 
181 GACATTCACAGAGAAGAATACAGTGGGCTTCCTAGATTACCCCTTCTGCAGTGGTACCIT 240 
181 GACATTCACAGAGAAGAATACAGTGGGCITCCTAGATTACCCCITCTGCAGTGGTACCTT 240 
241 TAATGAAAGCAGAGTGAACCTCACCATCCAAGGACTGAGAGCTGTTGACACGGGACTGTA 300 
241 TAATGAAAGCAGAGTGAACCTCACCATCCAAGGACTGAGAGCTGTTGACACGGGACTGTA 300 
301 CCTCTGCAAGGTGGAACTCATGTACCCACCGCCATACTTTGTGGGCATGGGCAACGGGAC 360 
301 CCTCTGCAAGGTGGAACTCATGTACCCACCGCCATACTTTGTGGGCATGGGCAACGGGAC 360 
421 ATTGTCTTTACACCAGAATAGTTTTGTTCCTTGGTTTGGAGTCCTTCATAGTTAGGTCTG 480 
421 ATTGTCTTTACACCAGAATAGTITTGTTCCTTGGTITGGAGTCCTTCATAGTTAGGTCTG 480 
EcoRl 
481 TGATGCATAGCTAC GAATTC CTAGTAGA 509 
481 TGATGCATAGCTA GAATICPCTAGTAGA 509 
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Figure 3.11.- Sequencing analysis of exons 1 and 2 of pLoxCTLA-4. In A, the figure shows 
a diagram of a fragment of the 5' end of the construct and the location of the primers (E1R 
& E2F) used for sequencing. A pairwise alignment between the sequences obtained using 
the primers mentioned and the CTLA-4 genomic sequence, was performed to confirm the 
integrity of exons 1 (B) and 2 (C). The coding sequences (in boxes) were determined 
according to Ling, V., et al (1999) and the sequence published (NCBIAc#AF142145). 
Relevant restriction sites shown within a grey box. 
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E4F 
pLoxCTLA-4 sequenced with E3F B 
TGAGTGTGATGTTGACGTTT 180 
TGAGTGTGATGTTGACGTTT 179 
C pLoxCTLA-4 sequenced with E4F 
AAGGCCGTTTATGAAGAAGAAGGAGCAT 180 121 AATTTCAGCCTTATITTATTCCCATCAACTGA 
AAGGCCGTrTATGAAGAAGAAGGAGCAT 180 121 AATTTCAGCCTTATTTTATTCCCATCAACTGA 
E3F E3 
pBluescript 
backbone 
11011 pGKneo 
121 TACAGTTTCCTGGTCACTGCTGTTTCTTTGAGCAAGAT 
120 TACAGTTTCCTGGTCACTGCTGTTTCTTTGAGCAAGAT 
pLoxCTLA-4 sense strand (top) 
Genimic CTLA-4 sense strand (bottom) 
1 ACAATTGGAAACTCTCTCAGGAGGTTGATGCTTCGTCTTCTGTTGCA ATCCAGAACCA 59 
1 ACAATTGGAAACTCTCTCAGGAGGTTGATGCITCGTCTTCTGTTGCA ATCCAGAACCA 59 
BamHI  
60 TGCCCGGATTCTGAC1TCCTCC 	fill dATC - GTCGCAGTTAGCTTGGGGTTG 1 1 1 1 1 	T 120 
60 TGCCCGGATTCTGACTTCCTCCTTT 	TTGTCGCAGTTAGCTTGGGGTTGT 1 1 	1 1 1 119 
TAAAGAAAAGAA 60 
TAAAGAAAAGAA 60 
1 TCTATATTCTTFGATAATAATTGCC i 1 AAAAAATG 1 1 1 1 1TGCA 
1TCTATATTCTTTGATAATAATTGCCTTTTAAAAAATG1IllITGCA 
61 GTCCTCTTACAACAGGGGTCTATGTGAAAATGCCCCCAACAGAGCCAGAATGTGAAAAGC 120 
61 GTCCTCTTACAACAGGGGTCTATGTGAAAATGCCCCCAACAGAGCCAGAATGTGAAAAGC 120 
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pLoxCTLA-4 3' end 
Figure 3.12.- Sequencing analysis of exons 3 and 4 of pLoxCTLA-4. In (A) the figure 
shows a diagram of the 3' end of the construct and the location of the primers (E3F & E4F) 
used for sequencing. A pairwise alignment between the sequences obtained using the prim-
ers mentioned and the CTLA-4 genomic sequence was performed to confirm the integrity of 
exons 3 (B) and 4 (C). The coding sequences (in boxes) were determined according to Ling, 
V., et al (1999) and NCBI Ac#AF142145. Relevant restriction sites shown within a grey 
box. 
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pLoxCTLA-4 5' end 
00, 
A 
pBluescript 
backbone 
5' CTGCFCCFGGTTGACAGAGGTACGCTTATAAATAAGTAGGTAGGAAAATTT 
Hindlll 	 Novel Lae sile 9 b3' o 
	Hindfll 
ver ng Ero12.1 site 	OVelfiang 
TGAAGCT ATAACTTCGTATAATGTATGCTATACGAAGTTA AATTCAGCT 
TAC1 	I 1 GAGAGATGAGGCAAGGITCTGCACCTCAAGCTCCAGGAATGTCTCG 3' 
LoxP oligonucleotide sequence 
Hind111 end 	 EcoR1 site 
5•AGCTATAACTTCGTATAATGTATGCTATACGAAGTFATG A A' ruc 3' 
3' TATTGAAGCATATTACATACGATATGCTTCAATACTTAAGTCGA  5' 
HindIll end 
B 
Figure 3.13.- Sequence analysis of the LoxP immediately downstream exon 1. In A, the fig-
ure shows a diagram of the 5' end of the construct and the location of the primer (Lox1F) 
used for sequencing. The the oligonucleotide used to introduce the sequence of this LoxP 
site is also shown. A segment of the sequences corresponding to the sense strand of 
pLoxCTLA-4 is shown in B. The sequence of the LoxP site is shown within a box HindIII 
overhangs and the new EcoRl sites are also indicated. 
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3 	pGKneo 
pLoxCTLA-4 3' end 
pBluescript 
5 TGCA 
EcoRl 
GAATTdICTGCAGCCCAATTCCGATCATATTCAATAACCCTTAAT 
LatP.sitc 5' to 3' 
ATAACTTCGTATAATGTATGCTATACGAAGTTA AGGTCTGAAGAGGAG 
TTTACGTCCAGCCAAGC 3' 
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E3EcoR1F 
LoxP oligonucleotide sequence 
5'ATAACTTCGTATAATGTATGCTATACGAAGITAT 3' 
3'TATTGAAGCATATTACATACGATATGCTTCAATA5' 
pLoxCTLA-4 sequenced with E3EcoR1F 
pLoxCTLA-4 sequenced with BpAF 
LosP site 5' to 3' 
5' AACCCTTAAT ATAACTTCGTATAATGTATGCTATACGAAGTTAT 
Xhol 
TAGGTCTIMA-GpGGATCTAATTCAGCTTCAAAGCAGGTTATCA 
GAGCCACCITCAAATATTTCAGGTGC1 	1 1 GATTACCACAGACA 3' 
Figure 3.14.- Sequence analysis of the LoxP sites flanking the neo cassette. In A, the figure 
shows a diagram of the 3' end of the construct and the location of the primers (E3EcoR1F & 
BpAF) used for sequencing. The sequence of the LoxP site in 5' to 3' orientation is also 
shown. Two segments of the sequences corresponding to the sense strand of pLoxCTLA-4, 
as sequenced with the above primers, are shown in (B) and (C). Relevant restriction sites 
are indicated in grey boxes. 
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	 pLoxCTLA-4 	 ORI 
loxP 2 	11.65 kb 
pBluescript Ks+ 
Exon 3 
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Exon 2 Bg 
loxP 1 
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Figure 3.15.-. Circular restriction map of the targeting construct pLoxCTLA-4. 
A; ApaI, B; BamHI, Bg; BglII E; EcoRI, Ev; EcoRV K; KpnI, N; Not I, Sp; SpeI, Xm; 
XmnI, Xh; Xho I, P; Pstl, Ev-S; EcoRV-Sall AMPR; ampicillin resistance gene, neo; neo-
mycin transferase gene, ORI; origin of replication. 
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3.5. Screening for homologous recombination among 
neomycin-resistant ES cell clones by PCR. 
A volume of pLoxCTLA-4 was re-transformed and a maxi-prep performed from a sin-
gle colony of antibiotic resistant E.coli. Restriction digest verified the authenticity of 
this clone. Concentration and purity of the preparation was assessed by UV spectropho-
tometry, and approximately 200 lig of DNA were linearised by digestion with the 
unique Notl site present in the pBluescript backbone. 
An aliquot was analyzed by agarose gel electrophoresis to ensure complete digestion of 
the DNA, following by extraction, ethanol precipitation and re-suspension ( to an esti-
mated concentration of 1 µg/µL). 40 Rg of this preparation was used to electroporate 
5x106 129SvPAS ES cells in serum-free media under the following parameters: a volt-
age of 260 V, a capacitance of 500 1.1F in a 4mm cuvette. Cells were immediately plated 
in a 10 cm tissue culture Petri dish containing a monolayer of fibroblast feeder cells and 
allowed to recover for 48 hours prior to supplementation of the ES medium with 200 
µg/ml of G418. 
The plating of the transfected ES cells at low density permitted the clonal expansion of 
individual cells and after a period of positive selection, G418 resistant ES cell colonies 
were of sufficient size to be individually picked and cultured in wells of 96 multi—well 
plates coated with 2% porcine skin gelatin. 
These ES colonies were subsequently split into two plates, and one multi—well plate was 
frozen at —80°C in freezing media to preserve ES cell colonies alive. From this plate, ES 
cell cultures where homologous recombination is detected by PCR, will be amplified for 
Southern blot analysis and also for blastocyst injection. 
The plasmid DNA maxi-prep, ES cell transfection and cell culture was performed at 
genOway LTD in Lyon France (www.genoway.com) and 96-well plates containing dry 
frozen ES cells were sent to our lab for PCR screening. 
A PCR screening strategy was designed to select a small number of ES cells cultures, 
from the 221 initially received from genOway, for subsequent amplification and South-
ern blot analysis. This strategy is summarized in figure 3.16 and comprises 2 PCRs one 
across each 5' and 3' ends of Ctla-4. 
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Figure 3.16.- PCR strategy to detect homologous recombination (HR) between the targeting vector (in solid line) and the 
wild type Ctla-4 locus (in dashed lines) in ES cells. In A, the figure illustrates the wild type Ctla-4 locus. In B, the same 
locus after homologous recombination with the targeting vector. 2 different PCR were designed to confirm HR after 
electroporation and selection of ES cells. The location of the primers and the sizes of the expected PCR products across the 
regions amplified are shown. 
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3.5.1 Screening for homologous recombination at the 3' end of 
Ctla-4. 
221 ES cell cultures in 96-well plates were sent in the first instance by genOway to our 
laboratory. ES cells were lysed, in situ, with 200 N.L. of 50mM Tris, 10% SDS, 20 pg/ml 
proteinase K and the genomic DNA extracted from each well by ethanol/NaC1 precipita-
tion followed by re-suspension in TE. The DNA yield of the extractions from each plate 
was relatively homogeneous (see example in figure 3.17) and between 1 µ1... to 5 !IL 
were used as template for the PCR. 
The 221 ES cell cultures were first screened using primers Neo2F and GR. The condi-
tions of amplification of this PCR are reported in chapter two. The expected 2.1Kb 
product was obtained in 14 individual ES cell cultures out of 221. Figure 3.17 shows an 
agarose gel electrophoresis of a sample of ES cell cultures representative of the total 
lysates processed. The first ES cell lysate that produced the specific 2.1Kb product, was 
included as positive control in all subsequent reactions. Non template controls were also 
always included to rule out false positive amplification due to DNA contamination or 
carry-over of a positive sample. Finally, in order to verify if this PCR will amplify a 
fragment that is not specific, the reaction was performed using wt mouse DNA and no 
product was detected (data not shown). 
3.5.2 Screening for homologous recombination at the 5' end of 
Ctla-4. 
The appearance of the 2.1 Kb PCR product in the previous experiment indicates that, at 
least, the region of the construct amplified by the PCR has undergone homologous re-
combination. This PCR, however, does no show wether the entire construct or a seg-
ment of its sequence longer than the 3' arm of homology replaced the target Ctla-4 al- 
lele after 2 reciprocal events of crossover (see figure 3.16). 
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Figure 3.17.- Assessment of homologous recombination of the targeting vector in the Ctla-4 
locus by a PCR on the 3' end. The figure shows in A, the location of the primers used to 
amplify the 2.1 Kb segment. In B, it illustrates a representative PCR amplification of 12 
individual ES cell cultures grown in a 96 well plate format. In the top panel, 1µ1 of freshly 
extracted genomic DNA of each ES cell culture was subjected to 1% agarose gel electro-
phoresis to determine the integrity of the template. The bottom panel shows an electropho-
resis of the PCR performed with the primers indicated. This PCR will only amplify a prod-
uct if the construct undergoes homologous recombination with the Ctla-4 allele as this event 
will provide a suitable template for the PCR to proceed. Lanes 13 and 14 show: the non-
template control (NTC) and a positive control for the PCR (sample previously identified as 
positive). 
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Recombination through a single crossover event, could introduce all the construct com-
ponents and duplicate the size of the allele. This situation could still produce the suit-
able 2.1 Kb template for the PCR, despite being an undesirable targeting mutation. 
The screening strategy included a PCR across the 5' arm area of the locus, produced 
after amplification with primers 5'pF and Neo2R. The product size expected for this 
reaction was 7.3 Kb (see figure 3.16) but if the construct integrated by a single cross-
over, the template of the PCR will increase in size and it is unlikely that a product will 
be amplified. After the screening of only ten ES cell samples, out the fourteen found to 
be positive for the initial PCR, five ES cell DNA samples produced the expected 7.3Kb 
fragment. The four outstanding samples could not be properly analyzed at this stage due 
to a shortage of genomic DNA template. 
Figure 3.18 shows a set of amplified products of ten ES cell DNA samples. The condi-
tions of this PCR are reported in chapter 2 and no positive control was included due to 
the lack of a DNA known, a priori, to be positive for this required sequence. 
No product was observed when using WT mouse genomic DNA as template (data not 
shown). 
A second round of PCR amplification was carried using primers 5'pF and Neo2R and 
the product digested with EcoRl and HindIII. The rationale behind this was to confirm 
that recombination through two crossover events introduced the entire area of homology 
of the vector. If the crossover on the 5' arm of homology is proximal to exons 2 and 3 
and distal from exon 1, the replacement of Ctla-4 by the construct may be incomplete 
and therefore a critical element of the whole strategy; the first loxP site will not be inte-
grated, (see figure 3.19). 
To do this, the PCR products, from all 10 ES cell cultures previously identified, were 
ethanol-precipitated and resuspended in TE. The DNA obtained was divided into 2 frac-
tions and one each subjected to a restriction digest with the two enzymes mentioned. 
Figure 3.20 shows a diagram of the different restriction fragments produced after di-
gesting a PCR product corresponding to an ES cell sample where the entire construct 
replaced the WT Ctla-4 region, or a product where only the area of homology down-
stream the loxP site recombined. A representative agarose gel electrophoresis of 10 PCR 
products digested is shown in the bottom panel of the figure. 
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Figure 3.18.- PCR amplification of a 7.3 Kb region across the 5' region of the Ctla-4 
locus. The figure shows in A, the location of the primers used and in B, it shows a 0.8% 
agarose gel electrophoresis of the PCR amplification corresponding to 10 individual ES cell 
cultures grown in a 96 well plate format. Non-template controls were always included to 
exclude any amplification on contaminant or carried-over DNA template (sample not shown 
in the picture). EcoRl: E, HindIII: H, BanzHl: B. 
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The results of the PCR screening indicated the following: 2 ES cell samples out of 221 
(designated according to their location in the culture multi-well plate) as 1A1, 5B11, 
showed amplification at both ends of the Ctla-4 locus as well as a pattern of restriction 
digest suggesting the presence of the loxP site downstream exon 1. Consistent with the 
entire vector having undergone the desired homologous recombination event. 
In addition, the amplification of the 7.3 Kb 5' area by PCR in these ES cell colonies, 
strongly suggests that no insertions in 3' duplicate have occurred. There were four re-
maining samples (1Al2 and 1B11, 4A 1 1 and 3B5) that could not be fully analyzed at 
this stage and were only selected on the basis of a positive PCR evidence at the 3' end 
of the locus. The complete set of six samples were considered for further PCR and 
Southern blot analysis. 
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Figure 3.20.- Assessment of a complete or partial insertion of pLoxCTLA-4 into the 
Ctla-4 allele. A second round of PCR amplification using primers 5'pF and Neo2R, was 
performed on ES cell samples previously identified for homologous recombination and 
the corresponding 7.3 Kb product obtained was subjected to EcoRl and HindIII restric-
tion digest. The presence of the LoxP can be assessed in this restriction digest, because 
of the new EcoRl site engineered downstream the sequence of this loxP site and the ab-
sence of the HindIII site, originally located in that region of the locus, therefore the re-
striction pattern of a PCR product with or without such loxP site will be different. In A, 
a diagram shows the Ctla-4 locus after an incomplete insertion of the construct. In B, 
the figure shows the insertion the entire construct and therefore the presence of the first 
loxP site. The location of the PCR product and the sizes of the expected restriction 
fragments are represented by horizontal. In C, the figure illustrated an agarose gel elec-
trophoresis (1%) of 10 ES cell DNA samples amplified. The presence of a 0.9 Kb 
EcoRl fragment and a 6.7Kb HindIII fragment (panel on the left) represent the expected 
pattern following complete insertion of the construct. A 4.6Kb EcoRl fragment and a 
3.6 Kb HindIII fragment were obtained when only a segment of the construct has un-
dergone homologous recombination (panel on the right). EcoRl: E, HindIII: H. 
pUC digested with the correspondent enzymes was used to control the digest conditions 
and viability of the enzyme. 
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3.6. Screening for a single gene replacement by Southern blot 
analysis, Chimera production and germ-line transmission 
analysis. 
3.6.1 Screening for a single gene replacement by Southern blot analysis 
The final selection of the ES cells exhibiting a single Ctla-4 gene replacement by ho-
mologous recombination required the development of a strategy able to confirm that the 
complete sequence of the targeting vector has undergone homologous recombination 
and that such cells have no random pLoxCTLA-4 integrations. The technique imple-
mented to select such ES cells was Southern blotting and it aims at identifying restric-
tion fragments that will be specifically altered by the gene targeting. A scheme of the 
strategy is shown in figure 3.21, the length of the restriction fragments produced after 
digestion of genomic DNA with EcoRl and HindIII were calculated and mapped with 
reference of the CTLA-4 sequence published (NCBI Ac#AF142145). 
2 probes located within the Ctla-4 genomic region but external or non-homologous to 
the construct, one on each end of the locus were used. Such a probes will detect 
changes in restriction fragment lengths generated by a homologous recombination 
event, but will not hybridize to the targeting vector itself and thus will not illuminate 
random integration events. The main modifications that can be detected upon homolo-
gous recombination of pLoxCTLA-4 are an increase in the length of the targeted allele, 
as compared with the wt allele, due to the presence of the neo-cassette. The other modi-
fications correspond to changes in size of restriction fragments due to modifications in-
troduced with the sequence of the loxP site downstream exon 1. A third probe, was spe-
cific for a part of the sequence of the neo-cassette. This probe is internal to the construct 
and therefore can also to detect events of random integration. 
The 5' external probe and the internal neo-specific probe were the result of PCR ampli-
fications (see materials and methods). Suitable primers were designed to amplify, in the 
case of the 5' probe, a fragment of 750 bp homologous to an area adjacent to the Hin-
dill site upstream exon 1 but outside the area of homology of pLoxCTLA-4. For the 
internal probe another PCR was designed and a 630 bp product specific for the sequence 
of the neomycin transferase amplified. The third probe (external 3') was a 1 Kb product 
of the EcoRV/HindIII digest of the genomic CTLA-4 construct p4KBH4 (see figure 3.3 
and 3.21 for the location of the probes). 
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The diagram shows the area of homology between the 3 probes selected (black boxes). 
The 5' and 3' external probes are homologous to the genomic Ctla-4 sequence, outside the area 
of homology of the construct, (dashed lines) and the internal probe is homologous to the sequence of the PGK-neo 
in the construct. The expected EcoR1 and HindIII restriction fragments are shown as horizontal arrows. 
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ES cell samples 1A1, 5B11, 1Al2, 1B11 were cultured in 24 multi-well tissue culture 
plates for a greater scale genomic DNA extraction at genOway. These ES cell samples 
were sent to out laboratory and DNA extraction was performed. The genomic DNA ob-
tained was then subjected to the above-mentioned Southern blotting method. 
Figure 3.22 and 3.23 show the hybridization of the 5' and 3' external probes, to ES cell 
genomic DNA that was respectively digested with either EcoRl or HindlII. 
WT mouse DNA was used as a control to reveal the location of the WT allele. 
Figure 3.22 revealed for samples 5B11 and 1A1, a pattern of hybridization indicating 
the integration of at least the 5' end of the construct by HR to one of the Ctla-4 alleles. 
Samples 1B11 and 1Al2 show no modifications in their EcoR1 restriction digest pattern 
indicating the absence of recombination. 
The previous PCR evidence obtained for samples 1Al2 and 1B11 on the 3' end (posi-
tive for the 2.1 Kb PCR product), suggested that at least the end of construct had inte-
grated by HR, however, as shown by the Southern blot analysis (figure 3.22), incom-
plete insertion of the 5' end may have happened in this samples. No insertions in 5' du-
plicate or concatamers were observed for these samples as no bands of unexpected sizes 
appeared. 
In figure 3.23 a hybridization of genomic DNA digested with Hindu was performed 
using the 3' external probe, for the same set of samples. Only sample 1A1 showed the 
correct restriction digest pattern and all the evidence gathered so far indicates that in 
this sample, the construct integrated its entire homologous sequence by HR. 
Samples 1B11 and 5B11 showed hybridization of a genomic fragment grater than 10Kb, 
suggesting the integration of the construct in a 3' duplicate. Interestingly, this type of 
insertion was permissive to the amplification and correct restriction digest of the 7.3 Kb 
PCR, possibly indicating concomitant homologous recombination of the entire sequence 
of the construct and an insertion in 3' duplicate for this sample. 
Sample 1Al2 shows hybridization to a 7 Kb fragment indicating incomplete insertion 
of the construct by homologous recombination and therefore the lack of the loxP site 
downstream exon 1. 
Figure 3.24 shows two independent hybridizations of the internal probe to DNA from 
the 4 ES cells samples, one after the digest with EcoRl, and the other after HindIII. For 
samples 1Al2 and 1B11 multiple events of random integration were detected in both 
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Southern hybridizations. Sample 5B 11 showed once more a single band greater than 
10Kb indicating the possibility of an integration in 3' duplicate. This is consistent with 
what it was observed in previous Southern blots. 
In conclusion after the screening by PCR and Southern blot analysis only sample sam-
ple 1A1 was chosen for amplification and blastocyst injection as it displays a single 
gene replacement at 1 allele of the Ctla-4 locus and no random integration events. 
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Figure 3.22.- Southern blot analysis using the 5' external probe hybridized to ES cell ge-
nomic DNA digested with EcoRl. The figure shows in A, a diagram of the location of the 
probe and the expected restriction fragments illuminated by the probe. In B, a autoradio-
graph of the genomic DNA on a nylon support membrane, showing the hybridization pat-
terns of samples (5B11, 1A1, 1B11, 1Al2). Corresponding WT and targeted restriction 
fragment size is indicated by the arrows. 
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the probe and the expected restriction fragments illuminated. In B, a autoradiograph of the 
genomic DNA on a nylon support membrane, showing the hybridization pattern of the sam-
ples (5B11, 1A1, 1B11, 1Al2). WT and targeted restriction fragment size is indicated by the 
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the genomic DNA on a nylon support membrane, showing the hybridization pattern of 
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3.6.2 Chimera production from ES cell sample 1A1 and analysis of 
germ line transmission. 
The ES cells from sample 1A1 were further amplified and injected to recipient blasto-
cysts isolated from C57BL/6 females (with specific pathogen free health status) and re-
implanted into OF1 pseudopregnant females (specific and opportunistic pathogen health 
status). Table 3.1 summarizes the results of the blastocyst injections performed for ES 
cell sample 1A1. 
Injection 
sessions 
Blastocysts Foster 
mothers 
implanted 
Pregnant 
foster 
mothers 
Number of 
pups 
Chimeras 
obtained 
and % 
1st 75 5 4 18 2 , 5% 
&20% 
2nd 28 2 nil nil nil 
3rd 52 4 nil nil nil 
Table 3.1 Blastocyst injection sessions performed with ES cell sample 1A1 
and chimeras produced. 
The likelihood that ES cells from sample 1A1 had contributed to the germline of the 
mouse was estimated to be small in this experiment. This is because only a 5% and a 
20% chimeric animals were produced. To test such contribution and their ability to 
transmit, the Ctla-4 targeted mutation, the chimera possessing a 20% agouti coat colour, 
was bred with 3 C57BL/6 females and only black pups were born. This indicated that 
the ES cells from sample 1A1 did not contribute to the germline of the chimera and no 
further crosses were performed. In light of this results we asked genOway to amplify ES 
cell samples 4A11 and 3B5 as well as to re-amplify sample 1A1 for further confirma-
tory analysis. 
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3.6.3 Screening for a single gene replacement by Southern blot analysis 
of ES cell samples 4A11 and 3B5. 
A second batch containing ES cell samples 4A11 and 3B5, as well as a new lysate from 
sample 1A1 was received in our lab for analysis. PCR across the 5' region of the locus 
together with restriction digests, were initially performed, to rapidly determine if ES 
cell samples 4A11 and 3B5 had a single Ctla-4 gene replacement. In this experiment, 
DNA from sample 1A1, previously identified positive for this PCR was included and no 
product was detected. This observation may indicate the loss of the cells containing the 
targeted mutation. 
Figure 3.25 shows a diagram of the PCR, its expected restriction fragments and two 
agarose gel electrophoresis showing the amplification of the 7.3Kb PCR product for 
each sample including 1A1 (Figure 3.25 C) and the restriction digest analysis performed 
on samples 4A11 and 3B5 (Figure 3.25 D). The pattern corresponding to an insertion of 
the entire construct into the Ctla-4 allele by homologous recombination was observed in 
both samples. 
Southern blot analysis was carried out on ES samples 4A I 1 and 3B5 to confirm the evi-
dence observed by PCR. Sample 1A1 was also included in this analysis to further de-
termine if the cells bearing the targeted mutation were truly lost. Figure 3.26 shows a 
hybridization of the 5' external probe on DNA digested with EcoRl. Both ES samples 
(4A 1 1 and 3B5) produced the expected restriction fragment pattern, corresponding to 
the insertion of the 5' arm of homology into the Ctla-4 locus. No other types of insertion 
were observed. In this experiment, the restriction fragment corresponding to the targeted 
allele was not detected in sample 1A1. 
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Figure 3.25.- Assessment of complete or partial insertion of pLoxCTLA-4 into Ctla-4. 
A PCR amplification using primers 5'pF and Neo2R, was performed on ES cell samples 
4A11, 3B5 and 1A1. The 7.3 Kb product obtained was subjected to and EcoRl and a 
HindIII restriction digest to detect the presence of the LoxP. In A, a diagram shows the 
Ctla-4 locus after incomplete insertion of the construct. In B, the figure shows the in-
sertion the entire construct including the first loxP site. The location of the PCR product, 
the sizes of the expected restriction fragments that differentiate an event of HR of the 
entire vector versus the insertion of only the 3' end, are represented by horizontal lines. 
An agarose gel electrophoresis (1%) of the PCR before digest is shown in C, and the 
electrophoresis of the resulting restriction fragments in D. Sample 1A1 was included in 
this analysis (C). Further ethanol/salt precipitation of that PCR reaction is also per-
formed (D) to confirm that no product was produced at levels under the detection limit 
of the electrophoresis. EcoRl: E, HindIII: H. 
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Figure 3.26.- Southern blot analysis using the 5' external probe hybridized to ES cell ge-
nomic DNA digested with EcoRl. The figure illustrates in A, a diagram of the location of 
the probe and the expected restriction fragments illuminated. In B, an autoradiograph of the 
genomic DNA on a nylon support membrane, showing the hybridization patterns of samples 
4A11 and 3B5. DNA from sample 1A1 was also included to confirm what was observed by 
PCR (see figure 3.25). An aliquot of DNA from sample 5B11 was included in this blot as a 
control to show the location of the targeted allele. WT DNA was also included as in previ-
ous analyses. 
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Southern blot analysis using the 3' and internal probes were also performed on samples 
4A11 and 3B5. The two samples displayed the restriction fragments corresponding to 
both a targeted and a WT allele with neither, undesired integrations in duplicate, nor 
random integrations (see figures 3.26, 3.27 and 3.28). Sample 1A1 was included in 
these analyses and no signal corresponding to the targeted allele was detected. This 
strongly indicates that the cells bearing the targeted mutation in this sample were lost, 
possibly during the culturing of the ES cells from 96 well plates to 24 well plates before 
Southern analysis or blastocyst injection. 
In a Southern blot analysis, the bands corresponding to the WT and targeted allele 
should appear with similar intensity. Homologous recombination rarely occurs in both 
of the alleles of diploid ES cells and if each ES cell clone identified, is collected and 
further cultured under appropriate conditions, it should remain as a clonal population 
during amplification. It can be observed in figures 3.26 and 3.27, that this was certainly 
not the case, and for both samples 4A11 and 3B5, there are differences in intensity be-
tween the WT and targeted alleles, being the WT the brightest band. 
The grater abundance of genomic DNA fragments corresponding to the WT allele, 
compared with the targeted allele can be explained if the correct concentration of G418 
was not constantly used in the culture of ES cells after transfection, or if the initial pe-
riod of selection was not long enough (generally not less than 15 days). 
These two circumstances may have affected the selection of the ES cells giving rise to a 
mixed population of neo-resistant ES cells as well as neo-sensitive cells. The problem in 
this scenario is that the first group of cells will proliferate and out-compete cells bearing 
targeted mutations. This could have been the cause for the complete loss of clone 1A1. 
Samples 4A 1 1 and 3B5 showed the expected hybridization pattern corresponding to ES 
cells samples bearing a targeted Ctla-4 allele with no random integrations of the con-
struct. However both show a considerable degree of contamination with WT ES cells 
and this situation will become an obstacle to produce reliable chimeric animals where 
targeted ES cells can contribute to the germline and further transmit our targeted muta-
tion. In order to minimize the chances of such phenomena, both ES cell samples (4A 1 1 
and 3B5) were amplified for blastocyst injection, in the presence of G418. 
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An aliquot of genomic DNA was sent to our laboratory before the injection sessions and 
a final Southern blot was performed. In order to minimize the loss of recombinant ES 
cells in the mixed samples (4A11 and 3B5) the amplification of cells before blastocyst 
injection was performed in the presence of G418. 
An aliquot of genomic DNA was sent to our laboratory before the injection sessions and 
a final Southern blot was performed . 
The results of this analysis is shown in figure 3.29. No significant improvement on the 
differences in intensity between alleles was observed for both ES cell samples. 
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Figure 3.27.- Southern blot analysis using the 3' external probe hybridized onto ES cell ge-
nomic DNA digested with Hind'''. The figure shows in A, a diagram of the location of the 
probe and the expected restriction fragments illuminated. In B, a autoradiograph of the di-
gested genomic DNA on a nylon support membrane, showing the hybridization pattern for 
samples 4A11 and 3B5. Sample 1A1 was also included in this analysis. WT genomic DNA 
was included in lane one to indicate the size of this allele. 
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Figure 3.28.- Southern blot analysis using the internal probe hybridized onto ES cell ge-
nomic DNA digested with HindlIl . The figure illustrates in A, a diagram of the location of 
the probe and the expected restriction fragments illuminated. In (B) an autoradiograph of 
the digested genomic DNA on a nylon support membrane, showing the hybridization pat-
tern for both samples 1A1, 4A11 and 3B5. 
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Figure 3.29.- Southern blot analysis using the 3' external probe, performed on genomic 
DNA digested with EcoR1 from ES cells after amplification and before blastocyst injection. 
The figure illustrates in A, a diagram of the location of the probe and the expected restric-
tion fragments which it hybridizes to. In B, an autoradiograph of the genomic DNA of 
samples 4A1 1 and 3B5. Sizes for both the targeted and WT alleles are shown and WT 
genomic DNA was used as control. 
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3.6.4 Chimera production from ES cell samples 4A11 and 3B5 and 
analysis of germ line transmission. 
The ES cells from both 4A11 and 3B5 ES cell samples were injected to recipient blasto-
cysts isolated form C57BL/6 females. Table 3.2 summarizes the results of the blasto-
cyst injections performed for ES cell sample 4A11. 
Total 
injection 
sessions 
Blastocysts Foster 
mothers 
implanted 
Pregnant 
foster 
mothers 
Number of 
pups 
Male 
Chimeras 
obtained 
3 137 9 5 24 4 (80% 
30%60% 
50%) 
Table 3.2.- The results of the blastocyst injections performed with ES cells from 
sample 4A11. 
Chimeras with 80%, 50% and 60% were mated with 3 C57BL/6 females and they pro-
duced only 19 pups. From these animals 9 were agouti (two from the 50% chimera and 
seven form the 60%). Non of the agouti offspring produced from these chimeras pos-
sessed a targeted allele (figure 3.30). This demonstrates that the targeted ES cells did not 
contributed to the germline and/or the ES cells that contributed to the germline were of 
a WT CTLA-4 genotype, possibly coming from the "contaminant" fraction of wt ES 
cells described before. 
Table 3.3 shows the results obtained from the blastocyst injections with ES cells from 
sample 3B5. 
Total 
injection 
sessions 
Blastocysts Foster 
mothers 
implanted 
Pregnant 
foster 
mothers 
Number of 
pups 
Male 
chimeras 
obtained 
5 255 20 8 24 3 (5%,30% 
and 90% 
Table 3.3.- The results of the blastocyst injections performed with ES cells from 
sample 3B5. 
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Figure 3.30.- Southern blot analysis of tail genomic DNA of agouti offspring from chimeric 
animals generated by blastocyst injections of ES cell sample 4A11. In (A) the figure illus-
trates a diagram showing the EcoR1 restriction digest performed and the expected restric-
tion fragments. The probe used in this analysis was the 5' external probe. 
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From the blastocyst injections of sample 3B5, two of the chimeras (90% and 30%) were 
mated with 2 C57BL/6 females and 42 pups were produced. 26 of those were agouti (14 
from the 30% chimera and 12 from the 90%), and after Southern blot analysis of tail 
genomic DNA from these animals, only 5 agouti pups showed a targeted allele, all com-
ing form the 90% chimera. This indicates that the targeted ES cells contributed to the 
germline of this animal. The transmission of the targeted mutation was subsequently 
assessed by Southern blot (figure 3.31). After evaluating the germline transmission of 
the targeted mutation, the number of agouti pups obtained from this 90% chimera was 
close to the statistical frequency of targeted offspring expected (50%). ES cells have 
only one targeted allele therefore, 1 out of every 2 pups should bear a targeted allele. 
In this 90% chimera there was no apparent effect of the WT ES cells present in the 
original sample injected, on the transmission of the targeted mutation. 
The lack of targeted agouti pups from the breeding of the 30% chimera is still an indica-
tion that WT ES cells in the original "mixed" sample injected have contributed to the 
germline of this animal. 
Figure 3.31 shows the Southern blot analysis performed on tail DNA, from the agouti 
offspring born from the cross of a C57BL/6 female and the 90% agouti chimera. The 
analysis was performed to confirm the presence of a targeted allele using the external 5' 
probe. In addition, to further determine that no random integrations are present in the 
genome of these animals, a Southern analysis was carried out using the internal probe. 
The animals having a targeted Ctla-4 targeted allele showed no random integrations. 
This analisys established the founders of a targeted Ctla-4 line. 
The genotype of these animals will be further modified, particularly by Cre-mediated 
recombination in the germline. Those genetic modifications and the analysis of their 
phenotypes are reported in the subsequent chapters of this thesis. 
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Figure 3.31.- Southern blot analysis of agouti animals heterozygous for the Ctla-4 tar-
geted allele. In A, a scheme shows the EcoRl restriction digests performed and the sizes 
of the expected restriction fragments. The location of the 5' external probe as well as the 
internal probe are indicated. In B, a photograph of the 90% chimera that transmitted the 
targeted mutation. The figure shows in C, (Top panel) hybridization using the 5' probe 
on DNA digested with EcoRl. The bottom panel corresponds to hybridization using the 
internal probe to analyze random integrations in these mice. 
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3.7 Concluding remarks. 
3.7.1 Estimation of the frequency of homologous recombination at the 
Ctla-4 locus. 
Values of the frequency of recombination are not often reported in gene targeting ex-
periments. Previous knowledge of expected frequencies are useful to design future tar-
geting experiments on previously mutated alleles as they can provide valuable informa-
tion to decide, for instance; how many ES cell clones will be screened for homologous 
recombination and how such screening step should be performed. 
Ctla-4 has been targeted three times in the past (see chapter 1) but so far the frequencies 
observed have not been reported. 
Here we found that three out of 221 individual ES cell samples were identified, initially 
by PCR and then confirmed by Southern blot, to have a single gene replacement of the 
entire targeting vector at the Ctla-4 locus. This suggests an estimated 1.3% frequency of 
homologous recombination at this locus. 
Further estimations, like the absolute frequency of recombination, are difficult to deter-
mine in this targeting experiment, as none of our ES cell samples were true clones, 
therefore the genotypes observed by PCR or Southern may not be a faithful reflection of 
the genotypes of all the individual ES cells in the sample. 
3.7.1 Towards a model for conditional inactivation of Ctla-4. 
We have successfully generated and characterized by Southern blot, mice heterozygous 
for a Ctla-4 targeted allele. This targeted mutation includes 3 Cre-recombinase sites, 
located in specific intronic regions of the Ctla-4 locus, to allow further deletion by in-
ducible recombination in vivo. The design of this targeting experiment, responds to the 
overall aim of generating mice possessing an allele in which exons 2, 3 and the neo cas-
sette have been deleted, together with a further modification in the remaining allele, 
comprising the sole deletion of the neo cassette. This will leave exons two and three 
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(that code for the extracellular ligand binding and the transmembrane domains respec-
tively) flanked by loxP sites (see figure 3.2). Mice with this genetic modification can be 
further crossed with a inducible Cre transgenic, such as Mx-Cre, (Khun. et al 1995) to 
generate a model for conditional inactivation of this regulatory gene. 
3.7.3 Phenotypic analysis of mice bearing a targeted Ctla-4 allele prior 
to any modification. 
Ctla-4 has polymorphic variants that have shown to be significantly relevant for the 
function of this molecule. Sequence changes in either coding and non-coding segments 
of the gene have been implicated in alterations in the normal splicing and expression 
levels of the molecule. In fact there is ever-growing evidence that correlate such se-
quence variations to autoimmune disease in humans and mice (reviewed in Gough., et 
al 2005). For this reason we decided not to eliminate the selection cassette from targeted 
ES cells, for instance using transient transfection of Cre . 
The genetic modification performed in this targeting experiment may generate an inter-
esting phenotype in homozygous animals which can help to elucidate how Ctla-4 is 
regulated. 
In the next chapter we describe the data corresponding to a phenotypic characterization 
of heterozygous and homozygous Ctla-4 targeted mice. 
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4.1 Background. 
Antibiotic selection cassettes such as the neomycin resistance gene driven by the PGK-1 
promoter (PGK-neo), are invaluable tools as markers for homologous recombination in 
embryonic stem cells and transfected cell lines. As previously discussed, their se-
quences also serve as elements to disrupt the open reading frame of functionally impor-
tant coding regions, when knock out mice are generated. This last methodology requires 
the retention of the selection marker, but that can often yield unexpected phenotypes. 
A striking example was illustrated by the myogenic basic helix-loop-helix gene (MRF4) 
knock outs. In this case, a range of targeting vectors was designed to produce knock 
outs. Homozygous animals generated form these mice showed a dramatic range of phe-
notypes; from complete viability to lethality. Further analysis demonstrated that the se-
lection markers used altered the expression of downstream MRF genes in the cluster 
(Olson., et al 1996), generating a hypomorphic allele. 
Other examples have also been reported in which the expression of neighbouring genes 
is affected by the insertion of selection cassettes, and they underscore the unpredictabil-
ity of the phenotypes that can be caused by the retention of selectable markers. 
The mechanisms that determine these effects are poorly understood, nonetheless the in-
duction of neighbour effects have sometimes been useful to bypass the lethality pro-
duced when the gene of interest is involved in a vital biological process. Hypomorhic 
alleles have been recently used to study mice bearing a disruption in transport factor 
genes. These genes are crucial for development and embryos die early. To overcome 
the problem, a series of mouse mutants have been generated with varied levels of ex-
pression of this genes allow some mice to survive and therefore be studied (Dawlaty., et 
al 2006). 
It would be of interest to generate mice bearing a hypomorphic allele of CTLA-4 for 
two reasons. First, two important and related molecules share a locus with Ctla-4. Cd28 
and in particular Icos are not only functionally related but also, they located closely up-
stream and downstream of Ctla-4 respectively, possibly within range for a neighbor-
hood effect. 
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Second, is the very well documented phenomena that discrete sequence variations, such 
as, single basepair changes in the coding and non-coding regions of this gene, can have 
important implications for its function, as well as being correlated with autoimmune 
disease (reviewed in Gough., et al 2005). 
It has been reported that the existence of a polymorphism in exon 2 of the mouse Ctla-4 
correlates with diabetes in NOD mice (Vijayakrishnan., et al 2004). This sequence 
modification is believed to alter the splicing of CTLA-4 altering the production of an 
isoform highly expressed in diabetes resistant mice. 
Taking into consideration all these aspects, we decided to generate homozygous and 
heterozygous mice bearing all the elements of the targeting vector (see chapter 3), with 
the aim of evaluating if the insertion of the loxP sites and particularly the PGK-neo cas-
sette can alter the expression of Ctla-4 or its neighbours and if that leads to a detectable 
phenotype. 
The aims of this chapter are: 
• Generate homozygous and heterozygous mice bearing targeted Ctla-4 alleles. 
• Characterize any possible phenotype developed by these mice by histologic analysis 
of the vital organs including secondary lymphoid tissue. 
• To study the phenotype of their thymocytes and peripheral T cells either ex vivo or in 
culture, this in terms of surface markers and the expression of CTLA-4. 
• Analyze the expression of the main CTLA-4 splice variants. 
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4.2 Generation of heterozygous and homozygous mice bearing 
a targeted Ctla-4 allele. 
Gene targeting in ES cells was used to create mice having a targeted CTLA-4 allele 
(Chapter 3). This genetic alteration comprised the insertion of a foxed neomycin cas-
sette in intron number 4 and a loxP site in intron 2 downstream exon 1. A germ-line 
transmitting chimera was bred to C57BL/6 females and progeny heterozygous for the 
CTLA-4 mutation produced. We then performed an intercross of two heterozygotes and 
the genotyping of the progeny resulted in the expected three allele combinations (figure 
4.1). 
Homozygous mice develop normally, show no obvious signs of disease and have a 
normal life span. 
A PCR across the loxP site located downstream exon 1 was used throughout for geno-
typing. This reaction is able to selectively amplify a product from both alleles, thus al-
lowing the detection of the presence and absence of the loxP site as a marker of the tar-
geted allele see figure 4.1. 
For all subsequent experiments animals of at least 16 weeks of age were used. All the 
experimental groups were selected using only littermates. 
4.3 Histological analysis of CTLA-4 targeted mice. 
CTLA-4 knock out mice develop a lethal phenotype characterized by a severe intersti-
tial infiltration of macrophages, neutrophils and lymphocytes. These mice show signifi-
cant tissue damage in most organs (except kidney) but most lesions are dramatically 
observed in the pancreas and the heart. In the previous; destruction of both the islets and 
the glandular tissue is observed, and in the later, a mononuclear infiltrate and myocardi-
tisis observed. 
The lymphoproliferation that characterizes this phenotype is evident in splenic histo-
logical sections of these mice. Normal spleen morphology is lost with only remnants of 
red pulp within an extended white pulp (Tivol., et al 1995). 
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Figure 4.1.- Intercross of heterozygous animals bearing a targeted Ctla-4 allele to 
produce homozygote mutants. Agouti littermates from the cross of the chimeric male 
and C57BL/6 females, were intercrossed as it is schematically shown in A, 
The genotype of the resulting offspring was determined by amplifying a 0.3Kb region 
downstream exon 2 of Ctla-4, using primers flanking the LoxP site in the region (B). 
PCR products were resolved on 2% agarose gels to discriminate between a product 
produced after amplification of an allele bearing a loxP site (targeted; 0.34Kb), and 
the corresponding WT allelle lacking this sequence. Non template control (NTC) (C). 
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In contrast, microscopic analysis of Haematoxilin-Eosin (H&E) histologic sections re-
vealed no malformation, infiltration or tissue damage when the organs of heterozygote 
and homozygote CTLA-4 targeted mice are compared with wild type littermates (figure 
4.2). In addition, no signs of myocarditis and infiltration was observed in the heart or 
the pancreas, the organ that shows perhaps the most damage in the CTLA-4 knock outs 
and indeed in our mice where a full deletion of the gene has been produced ( Chapter 5). 
A normal morphology in the spleen was also observed with white and red pulps clearly 
defined. No signs of infiltration or altered morphology was detected in the kidney and 
thymus, that could suggest pathology. CTLA-4 knock outs show no infiltration or dam-
age in the kidney (Waterhouse., et al 1995). 
During the dissection of mice, homozygous individuals were observed to possess en-
larged lymph nodes and Peyer's patches when compared with wt littermates (see figure 
4.3 A). Lymph node tissue from homozygotes showed enlarged follicles and clear ger-
minal centres. The Peyer's patches in this mice showed a grater cell density in the fol-
licular area (figure 4.2 arrowed). Both observations may indicate an accumulation of B 
cells. Despite this accumulation in the Peyer's patches, no infiltration or damage was 
observed in the neighbouring bowel. 
Throughout the analysis heterozygous individuals showed no differences when com-
pared with wild type. 
4.4 Homozygous Ctla-4 targeted mice develop lymphoadeno-
pathy. 
The increase in size of the lymph nodes from homozygous animals (figure 4.3 A) was 
reflected in an increase in the number of total lymphocytes that could be isolated. 
Lymph node cells collected after dissections were counted and viable cell numbers di-
rectly compared between animals. The increased cellularity observed in lymph nodes of 
homozygous animals, as compared with wild type and heterozygous littermates, was 
statistically significant p<0.05 (figure 4.3). 
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Figure 4.2.- Hystologic analysis of organs from Ctla-4 targeted mice. 
Tissue sections from parafin embedded organs were stained with H&E 
and visualized under optical microscopy. All photographs are mignified 
10X. Areas of greater cell density are shown with arrows. 
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Figure 4.3.- The lymphoadenopathy observed in homozygous mice is reflected in increased 
cell numbers. In A, the comparative sizes of three lymph nodes (brachial, mecenteric and 
inguinal) extracted from wild type, homozygous and heterozygous mice. In B, Total viable 
lymph node cells were counted after gentle masceration of nodes. The mean cell count of 7 
independent observations (horizontal lines) are compared between genotypes (*p<0.05). 
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Cellularity of the spleens of these mice was also evaluated and no significant differ-
ences were observed between genotypes. There was a considerable variability in the 
data from different animals perhaps due to the extraction methods employed for this tis-
sue. The data shown in figure 4.4 corresponds to counts from 4 different mice. 
The possibility that the increased cellularity seen in the lymph nodes of homozygous 
mice could be the result of an altered proportion of different lymphocyte populations, 
was suggested by the observation that greater cell density was evidenced in areas re-
stricted to B cells. Flow cytometry was used to assess the proportions of T cells and B 
in the lymph nodes of these mice. This analysis demonstrated a greater percentage of B 
cells, reflected in a greater absolute number of CD19+ positive cells in homozygous 
when compared to wt and heterozygous-targeted littermates. Those differences were 
statistically significant (p<0.05). (see figure 4.5). 
The expected proportion of T cells in the mouse lymph node is about 60% to 70% and 
for B cells the normal percentage is lower being; between 15% to 20%, as observed 
here in WT mice, Mice homozygous for the targeted Ctla-4 allele, besides having a 
slight but not significantly lower percentage of T cells, show no significant differences 
in the absolute numbers of these cells when compared WT littermates. Further pheno-
typic analysis of the T cell compartment is necessary to determine if these cells are in-
volved in the increased B cells activation seen in homozygous mice. 
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Figure 4.4.- Total cell counts in the spleen of wild type, heterozygous and homozygotes 
animals. The mean of 4 independent observations (horizontal lines) are compared 
between genotypes. 
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Figure 4.5.- Increased lymph node cellularity observed in homozygous Ctla-4 targeted mice 
results from an incresed proportion of B cells. 
In A, CD19 vs CD3 scatter plots gated on live cells on the basis of SSC and FSC. 
In B, the plots sown are representative of 4 independent experiments (*p<0.05), differences 
for the absolute numbers of CD19+ cells were analyzed by a one-way ANOVA with 
Dunnet's post test. 
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4.5 Homozygous mice have an increased proportion of CD4 
single positive thymocytes and lower numbers of double posi-
tive thymocytes. 
Thymi were harvested and analyzed to test for alterations in the development of T cells 
as this could alter the proportion of T cells populating the periphery. 
The thymocytes of homozygous mice when compared to wild type and heterozygous 
individuals showed a moderate but consistent trend of an increased percentage of single 
CD4 positive thymocytes, together with an overall reduced proportion of CD4, CD8 
double positive cells. Variations in CD8 single positives and double negative thymo-
cytes were not consistent between independent experiments. 
Figure 4.5 shows a comparative set of representative CD4 vs CD8 scatter plots of mice 
with the three genotypes of interest. 
It is important to consider that this data is preliminary and the variations observed may 
no be greater that what expected by chance. Further analyses of these subpopulations 
on a larger sample are required to determine if this differences are real. 
The same analysis was performed on lymph node cells of the experimental animals, but 
there was no indication of an alteration in the T cell compartment of this organ. Figure 
4.7 shows this as a dispersion plot of data cumulative of 4 independent experiments. 
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Figure 4.6.- Homozygous animals have a distinct CD4-CD8 profile in thymus 
when compared to WT or heterozygous individuals. 
The figure shows CD4 vs CD8 scatter plots gated on live thymocytes on the basis 
of SSC and FSC. The data is representative of 3 independent experiments and the 
percentage of cells in each quadrant correspond to gated events. 
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Figure 4.7.- Percentage of CD4+ and CD8÷ T cells in lymph nodes from CTLA-4 targeted 
mice. The data is cumulative of 4 independent experiments and represents a percentage 
of either CD4 or CDS positive cells from a gate of live cells determined by their 
parameters of FSC and SSC. 
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4.6 Ex vivo analysis of the activation state of T cells from ex-
perimental animals. 
The activation status of T cells from experimental animals immediately ex vivo was 
then examined. CD69 is an early marker of activation not present constitutively in the 
surface of peripheral blood T cells but expressed upon activation. This marker is useful 
for our analysis as its expression may indicate the presence of a "recent" or maybe con- 
tinuous activation signal in the lymph nodes of this mice This may seem unlikely from 
the data already described but important in view of the increased proportion of B cells 
observed in the lymph nodes of homozygous animals. CD25 is upregulated later after 
activation when compared with CD69 and if present differentially on the T cells of ho-
mozygous mice, may serve as evidence to suggest an increased T cell activation state in 
this mice. 
As shown in figure 4.8 the percentage of cells expressing either CD69 or CD25 in cells 
extracted from lymph nodes from homozygote animals, are similar to the values ob- 
served for wild type and heterozygous T cells. This observation suggest that T cell acti-
vation in homozygotes remains normal, and this is consistent with the observations that 
the percentages of T cells in the enlarged lymph nodes of homozygous animals are 
within normal levels or even lower (figure 4.5) 
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Figure 4.8;- Percentage of lymph node cells expressing the activation markers CD69 
and CD25 is similar between experimental animals. Freshly isolated cells from lymph 
nodes were double stained with antibodies specific for CD3, CD69 and CD25. The 
percentages of CD3+ CD69+ cells (top three panels) and CD3+ CD25+ cells (bottom 
panels) are reported and correspond to gated events These data are representative of 5 
independent experiments. 
	 155 
	  Chapter 4. The phenotype of Ctla-4 targeted mice 
4.7 T cells from homozygous mice over-express CTLA-4 upon 
polyclonal activation. 
As described in section 4.1 there are reasons to think the modifications we have per-
formed to the genomic CTLA-4 sequence in the targeting process can alter the genetic 
regulation of this important gene. It has been reported that naturally occurring single 
nucleotide modifications can modify the expression of splice variants of this molcules 
and in general, ever-growing evidence point that these sequence variations can associate 
with autoimmunity (reviewed in Gough., et al 2005). Our observations in homozygous 
animals indicate a mildly abnormal phenotype. 
With this in mind, the levels of expression of CTLA-4 in the different genotypes of the 
targeted CTLA-4 mice were therefore assessed. CTLA-4 is only expressed in T cells 
following activation and direct surface staining has proved difficult due to the dynamic 
regulation and internalization that controls the levels of membrane expression of this 
molecule. Intracellular staining, using fixed and saponin-permeabilized cells, was there-
fore performed. 
At resting, freshly extracted total lymphocytes from lymph nodes of the mice, did not 
express CTLA-4 ( figure 4.9), data consistent with the reported kinetics of expression of 
this molecule, but at day 3 and day 5 of culture (11.1g/m1 anti CD3) very significant over 
expression in cells from homozygotes as compared with wt littermates was observed. 
Heterozygous mice showed an intermediate level of expression when compared with 
homozygous and wt littermates, and this trend was observed more clearly at day 3 
(p<0.01) than at day 5 (p<0.05). Data cumulative of at least 4 independent observations 
is shown in figure 4.10. The same phenomena was observed on CD3 purified T cells 
(figure 4.11) when costimulation was not provided by APC but by using CD28 anti-
body (figure 4.12). 
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Figure 4.9.- Resting total lymph node cells do not express CTLA-4 intracellularly. 
The figure compares the expression of intracellular CTLA-4 of freshly extracted 
lymph node cells from wild type, heterozygous and homozygous mice. The mean 
flourescence intensity reported corresponds to the value of all gated live cells. 
Intracellular isotype control stain is overlayed. The data is representative of 5 
independent observations 
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Figure 4.10.- Lymphocytes of homozygous mice over-express intracellular CTLA-4 
upon activation.The graphs show the CTLA-4 intracellular expression on activated 
total lymphocytes (lug/ml anti CD3) in culture at day 3 (A) or day 5 (B). The expression 
is reported as the mean fluorescence intensity of the total gated live cells. **(p<0.01) 
* (p<0.05) as determined by a Kruskal Wallis test with Dunn's post test. 
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Figure 4.11 Purity assesment after CD3+ T cell negative isolation with paramagnetic beads. 
The hystograms show the intensity of fluorescence of either total LN cells (pre) or isolated 
CD3+ T cells (post). Purity is expressed as % of cells gated for viavility and either positive 
for CD3 (T, NK cells), or negative for CD19 (B cells) (see MO. The overlay correspond 
to the isotype control. All experiments were performed with purities not lower that 98%. 
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Figure 4.12.- Intracellular expression of CTLA-4 increased in homozygotes as 
compared with littermates. Side scatter vs forward scatter plots and hystograms show 
the intracellular expression of CD3÷ T cells in culture over a period of 5 days. Plots 
report the MR of the gated live cell population and overlayed with the corresponding 
isotype control. The data are representative of 4 independent experiments. 
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4.8 CTLA-4 over-expression is not associated with heterogene-
ity in background. 
The CTLA-4 targeted mouse line originally established, which we have used for the 
vast majority of the phenotypic characterization reported here, posses a heterogeneous 
genetic background being descendants of the Fl from the 129Sv-B6 chimera 
(Chapter 3) and C57BL/6 females. The mix of genetic information of the strains 
129SvPAS (ES cells) and C57BL/6 in the mice analyzed, is not desirable as it can influ-
ence the phenotypes observed. In order to determine if the phenotypic characteristics 
previously observed in the Ctla-4 targeted mice were influenced by the genetic hetero-
geneity, we generated a new line of targeted mice possessing the same genetic modifica-
tion but on a pure 129 background. 
These mice were produced by crossing the 129 chimera with WT 129SvPAS females 
and by subsequently establishing the germline transmission of the targeted mutation by 
Southern blot analysis of all the progeny of this cross (figure 4.13). 
The F1 offspring from heterozygous targeted mice, on the 129SvPAS pure background, 
were genotyped using a PCR across the loxP site downstream of exon 1. 
Once homozygous and heterozygous targeted mice were obtained, we performed dissec-
tions and as before, enlarged lymph nodes were observed. CTLA-4 expression on total 
lymph node cells of these animals was evaluated and as shown in figure 4.15, the lymph 
node cells from these mice show the CTLA-4 over-expression previously observed in 
mice on a mixed background. This rules out the possibility that the effect observed 
could be influenced by genetic heterogeneity. It is nevertheless important to mention 
that so far only one observation has been recorded, and further analysis of this new ge-
netically modified line is required. 
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A / 
Figure 4.13.- Generation of a line of CTLA-4 targeted mice on a 129SvPAS (of agouti coat col-
our) pure background. (A). The 129-B6 chimera (see chapter 3) was crossed with 129Sv PAS 
wild type females to transmit the targeted CTLA-4 mutation through the germline of a pure 
129Sv background. Southern analysis from tail DNA of the all the offspring (B) was performed 
to establish germline transmission. CTLA-4 targeted founders were inter-crossed (D) to obtain 
mice bearing the CTLA-4 targeted allele in homozygosity (E). 
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Figure 4.14.- Intercross of heterozygous animals bearing a targeted Ctla-4 allele to 
on a 129SvPAS background to produce homozygote mutants (A). 
The genotype of the resulting offspring (B) was determined by amplifying a 0.3Kb 
region downstream exon 2 of Ctla-4, using primers flanking the LoxP site in the region 
(C). PCR products were resolved on 2% agarose gels to discriminate between a product 
produced after amplification of an allele bearing a loxP site (targeted; 0.34Kb), and 
the corresponding WT allelle lacking this sequence. Non template control (NTC) (D). 
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Figure 4.15.- Intracellular expression of CTLA-4 is also increased in 129SvPAS 
homozygotes as compared with littermates. Side scatter vs forward scatter plots and 
hystograms show the intracellular expression of LN cells in culture over a period of 
5 days. Plots report the MFI of the gated live cell population and overlayed with the 
corresponding isotype control. The data corresponds to a single observation. 
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4.9 Activated lymph node cells from homozygous mice express 
higher levels of CD25 but do not proliferate differentially. 
Upon activation, homozygous mice express higher levels of intracellular CTLA-4 com-
pared to wild type or heterozygous littermates. In order to evaluate if this had a func-
tional outcome, we compared the ability of lymph node cells to proliferate in vitro under 
the standard conditions of polyclonal stimulation use throughout this analysis. We first 
observed that after a period of 72h of polyclonal stimulation with antibodies (anti CD3 
and anti CD28 both at 1 µg/ml), CD34- cells of homozygous mice expressed greater lev-
els of CD25 as compared to wild type littermates. Heterozygous animals showing an 
intermediate level of expression. This observation suggested that cells from homozy-
gotes are able to reach a higher level of activation, however this was not reflected in 
proliferation as measured by tritiated thymidine incorporation. 
Figure 4.15 shows a comparative analysis of the expression of CD25 by CD3+ cells 
from lymph nodes in culture. Homozygous mice showed increased CD25 expression, 
measured as percentage of positive cells and intensity of fluorescence, although there 
are no clear differences in the proliferation of CD3+ cells, as assessed by 3H-Thymidine 
incorporation, from this mice when compared with the littermates. 
Altogether these observations suggest that the CTLA-4 over expression seen in homo-
zygous mice, may have a potential functional implication inhibiting T cell proliferation. 
This evidence is consistent with the lack of irregular T cell proportions in the lymph 
node of these mice. 
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Figure 4.16.- Homozygous CD3+ cells express higher levels of CD25 but does not prolif-
erate differentially. Top panels show a comparative flow cytometry analysis of the CD25 
expression of viable CD3+ cells from lymph nodes. The expression is reported in percentage 
of positive cells or intensity of fluorescence and the data is representative of 5 independent 
observations. The graph at the bottom shows the comparative proliferative responses of to-
tal lymph node cells stimulated with 1pg/m1 of anti CD3 and anti CD28. The data is repre-
sentative of 2 experiments. Percentiles show the SEM calculated from the triplicates in the 
assay. 
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4.10 Analysis of the expression of known Ctla-4 splice 
variants. 
It has been recently postulated that changes in the expression patterns of functional 
CTLA-4 splice variants may contribute to the control of autoimmunity (Ueda., et al 
2003 & Vijayakrishnan., et al 2004). One of the functional splice variants in mice is Li-
CTA-4, an isoform produced after skipping exon 2, its open reading frame therefore 
lacking the B7 binding domain. The expression of this isoform on lymph node cells 
from of our mice was therefore evaluated by Western blot using a polyclonal antibody 
specific for intracellular domain of CTLA-4 (C19). 
The analysis was restricted to resting lymphocytes because, in contrast to full length 
CTLA-4, LiCTLA-4 shows maximal expression on resting T cells (Vijayakrishnan., et 
al 2004). No differences in the expression of LiCTLA-4 were observed between homo-
zygous and heterozygous or wt littermates, suggesting normal levels of expression of 
this isoform at least at resting (figure 4.17). 
The expression kinetics of all known CTLA-4 splice variants was then explored by RT-
PCR. Using primers published in (Vijayakrishnan., et al 2004) (figure 4.18) all the 
known CTLA-4 splice variants were amplified from cDNA produced from either resting 
or activated purified CD3+ T cells from the lymph nodes of targeted mice. 
Striking differences were observed between the homozygotes and wild type or hetero-
zygote in terms of the relative levels of expression of Fl-CTLA-4, sCTLA-4 and 
LiCTLA-4 mRNA. 
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Figure 4.17.- Li-CTLA-4 expression is similar in homozygous 
targeted mice as compared to littermates. lOug of total protein from 
lysed resting lymphocytes was separated by SDS-PAGE and tranfered to 
PVDF membrane for bloting with a an anti CTLA-4 antibody, specific 
for the intracellular domain (C19). Positive (BALBc total lymph node 
cells) and negative controls (CTLA-4-/- cells) were also analyzed. 
Equivalent amounts of protein were loaded to the gel as shown by the actin 
expression levels. Data representative of one single observation. 
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Figure 4.18.- Ctla-4 and its splice variants. Ctla-4 has four exons encoding 
different polypetide chains (top). Four different splice variants have been identified 
at the level of mRNA and RT-PCR products product can be amplified using primers 
homologous for exon one and four. 
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Figure 4.19.- The kinetics of expression of all splice variants are altered in 
homozygous targeted mice as compare with littermates. 
The figure shows PCR amplifications from cDNA of either resting or activated 
CD3+ T cells from targeted mice. Polyclonaly activation was performed with 
CD3, anti CD28 mAb both at lug/ml in culture for a period of 3 days. 
Top panel shows the amplification of all Ctla-4 splice variants in one reaction. 
The bottom panel shows an amplification of HPRT as a qualitative control for the 
amount of RNA used to reverse transcribe to cDNA. Samples with no template 
were used as negative controls The products are resolved in a 1.8% agarose. 
Data representative of two independent experiments. 
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Using a non-quantitative RT-PCR performed on cDNA from either resting or activated 
CD3+ T cells differences in the abundance of three of the four splice variants of CTLA-
4 were observed. Resting T cells from homozygous mice showed apparently lower lev-
els of F1CTLA-4 as compared to WT or Heterozygotes after 3 days of activation. These 
T cells produced increased levels of this variant as compared with its littermates. This is 
consistent with the differences obtained by flow cytometry. In contrast PCR indicates 
lower transcript levels corresponding to sCTLA-4 and LiCTLA-4 in homozygotes than 
those produced by the littermates at resting. After activation, homozygous mice appear 
to produce slightly higher levels of both variants as compared with the littermates at that 
time point (see figure 4.19). 
No absolute comparisons can be drawn from this analysis as this RT-PCR used is not 
quantitative. Nonetheless, it is possible to suggest that homozygous individuals have a 
differential ratio of expression between splice variants. Confirmation of this results by 
quantitative RT-PCR is essential. 
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4.11 Discussion. 
The insertion of a PGK-neomycin cassette located in an intronic region downstream the 
coding region for the transmembrane domain of CTLA-4 may interfere with the net-
works of gene regulation and alter not only the gene that contains the sequences but also 
neighbouring genes as far as 100Kb. (Pham., et al 1996). A second smaller modifica-
tion in the form of the loxP containing sequence of 50 bp was introduced downstream 
exon 1 and despite its size, this could also alter the normal mechanisms of CTLA-4 
gene regulation since even single nucleotide variations can alter the function of this 
gene (Gough., et al 2005). For these reasons, mice retaining the neo cassette were there-
fore produced. Producing an altered CTLA-4 allele may provide insights on how these 
gene is regulated. 
Homozygous mice bearing a targeted CTLA-4 allele were generated (figure 4.1), de-
veloped and lived normally throughout an average life span. Direct inspection through 
necropsy, however, demonstrated that homozygotes developed enlarged lymph nodes 
with no signs of tissue damage or inflammatory disease. Histologic sections showed no 
organ deterioration yet, the lymph nodes and Peyer's patches developed areas with 
greater cell density, localized in compartments corresponding mainly to B lymphocytes 
(lymph node cortex and follicular areas). 
Total cellularity in the lymph nodes was significantly increased, but B and not T cell 
absolute numbers were increased. The same was not observed in the spleen. The data 
for the spleen is variable and additional experiments are required to analyze any possi-
ble differences. 
It would be very valuable to analyze the activation state of B cells in the lymph nodes of 
homozygous mice, and this can be done using flow cytometry and double staining of 
lymph node cells for CD19 vs CD80 and CD86, as the expression of these markers in-
dicates that B cells are activated and able to provide costimulation. Another readout to 
assess B cell effector activity could be the measurement of immunoglobulin in serum 
obtained by extraction of blood through cardiac puncture. 
CTLA-4 knock out mice show increased levels of B7 receptors in the surface of B cells 
and also higher levels of basal Ig in sera. These mice also develop B cell infiltrates (Wa-
terhouse., et al 1995) and it has been postulated that B cell activation, and in general 
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the whole pathology in homozygous knockouts, is mediated by dysregulated CD4+ 
helper T cells. A similar crosstalk between lymphocyte subsets may be happening in 
homozygous mice bearing CTLA-4 targeted allele, but more experiments are required 
to confirm this. The slight skew observed towards an increased CD4 single positive 
cells in the thymus suggests that this must be worth pursuing, although no major altera-
tions in the percentage of CD4 and CD8 T cells were observed in the lymph node. A 
greater sample of animals should to be analyzed to determine if there are subtle differ-
ences in this lymphoid organ. Regardless of the altered B cell numbers and enlarged 
lymph nodes, there is no apparent tissue damage or inflammation. 
T cells in these mice are not in a pre activated state as observed in CTLA-4 knock outs. 
However, upon in vitro activation, either with APC or anti CD3, anti CD28 mediated 
costimulation, T cells of homozygous mice express up to ten fold more intracellular 
CTLA-4 than wild type littermates. 
Masteller, E.L., et al, reported that a CTLA-4 transgenic strain lacking the intracellular 
domain, when crossed with CTLA-4 deficient mice, showed a long life span but a very 
similar phenotype, associated with a moderate lymphoadenopathy (Mateller., et al 
2000). They concluded that the cytoplasmic signaling domain was important for CTLA-
4 to exert its inhibitory function and in the present studies, it is possible that the avail-
ability of an specific splice variant is altered, resulting in a similar effect. 
An important finding is that the CTLA-4 over expression seen here in homozygous in-
dividuals is not influenced by the genetic background as targeted animals in a 129 pure 
background show the same increased CTLA-4 expression upon activation as seen in 
mice on a mixed background (figure 4.15). 
The CTLA-4 over expression observed in homozygous mice, may have functional im-
plications. In vitro activated CD3+ cells express higher levels of CD25 indicating a 
greater level of activation, nevertheless these cells do not proliferate at a greater extent 
than cells from wt or heterozygous littermates. This suggests that the over expression of 
CTLA-4 in this cells is keeping them regulated probably by inhibiting IL-2 production 
or by inducing apoptosis. It would be very interesting to assess apoptosis in these T 
cells, and this can be performed relatively to their proliferation, by flow cytometry using 
the dye CFSC and simultaneously staining for phosphatidyl serine with Anexin V. 
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A possible explanation for the differences in CTLA-4 expression observed in homozy-
gotes is the altered pattern of expression of 3 of the 4 splice variants of CTLA-4. Ge-
netic as well as functional studies by others support the idea that genetic variation that 
results in changes in the expression of the isoforms of CTLA-4 (sCTLA-4, LiCTLA-4 
and FLCTLA-4), contributes to the genetic control of autoimmunity (Ueda., et al 2003). 
It is unlikely however that LiCTLA-4, previously associated with T cell signalling and 
protection against diabetes (Vijayakrishnan., et al 2004), could play an important role in 
our model, as its expression in the homozygotes is similar to that seen in wt littermates 
(figure 4.17). 
The ratio between FLCTLA-4 and, for instance, soluble CTLA-4 was different in rest-
ing T cells from homozygous mice when compared with its littermates (figure 4.19). 
Lower levels of soluble CTLA-4, when compared with FLCTLA-4, have been corre-
lated with homozygous individuals, susceptible to auto immunity, and that the possible 
mechanism of action of this secreted form of CTLA-4 could be the regulation of T cell 
activity by inducing IDO production (reviewed in Gough., et al 2005). Further data on 
these mice is required, particularly through quantitative PCR, but if we are able to con-
firm this variations, our model is consistent with the observations in humans. 
After 3 days of activation cells from homozygous individuals still express detectable 
levels of LiCTLA-4, despite the reported early kinetics of expression (Vijayakrishnan., 
et al 2004)). This leaves us with the question as to wether the expression of this splice 
variant may be linked to the over expression of FL-CTLA-4 also observed at that time 
point. Finally another CTLA-4 isoform was also detected in our assays which corre-
sponds to transcript lacking exons 2 and 3 and to which no function has been assigned. 
This splice variant is expressed in resting T cells but disappears upon activation in wt 
mice, but not in homozygous animals after activation. 
Taking together all these data, it is tempting to speculate that a possible trigger of the 
phenotype observed in homozygous mice could be a dysregulation in the expression of 
a CTLA-4 splice variant (for instance FLCTLA-4) at the resting state altering the re-
quired availability of this molecule to maintain T cell homeostasis. Furthermore more 
experiments are required to confirm this hypothesis. 
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Finally it can be postulated that an alteration in the levels of expression of Cd28 or Icos, 
(located in close proximity to Ctla-4) caused perhaps by the insertion of a neo-cassette, 
may be driving the phenotype observed in mice homozygous for the targeted mutation. 
It has been recently reported that CTLA-4 knock out mice over express ICOS (van 
Berkel., et al 2005) and in these knock out model homozygous mutants retained the neo 
cassette in a similar position as the mice here reported. In addition, costimulation by 
ICOS seams to be critical for an efficient T cell-mediated B cell response (Coyle., et al 
2000), in which case an alteration in its levels of expression in this mice could, be re-
sponsible for the increased proportion of CD19+ cells observed in the lymphnodes of 
homozygous Ctla-4 targeted mice. Analysis of the surface ICOS and CD28 expression 
of T cells in these mice by flow cytometry is essential to test this hypothesis. 
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Chapter 5. Cre-mediated recombination and Ctla-4 
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	 Cre-mediated recombination and Ctla-4. 
5.1. Background. 
The value of generating a mouse model that can provide us the possibility to gain tem-
poral control of the Ctla-4 inactivation has been described. The lethal phenotype devel-
oped by CTLA-4-1- mice, generates important limitations to study the peripheral immune 
system in the absence of this molecule at stages later than 1 month after birth. In addi-
tion, it would also be very desirable to have access to particular T cells subsets, such as 
regulatory T cells or CD45RB+ memory T cells, in which the deletion of this gene can 
be induced in vivo or ex vivo, to then use them in culture assays or in adoptive transfer 
experiments. 
Mice bearing 3 Cre recombinase (loxP) sites and a neo cassette have been generated. 
The location of these sites within the CTLA-4 intronic sequences, allows selective 
modifications of this locus and not only the elimination of the neo cassette, but also the 
generation of mice having two loxP sites flanking the sequences that encode for two 
domains critical for the function of this molecule. Further modification of this locus 
allows the elimination of the sequences corresponding to the ligand binding and trans-
membrane domains of CTLA-4 (exons 2 and 3), thus generating an animal deficient for 
this molecule, similar to those previously reported where CTLA-4 has been disrupted 
(Tivol., et al 1995 and Waterhouse., et al 1995), ( Figure 5.1) 
All the modifications to the Ctla-4 locus can be achieved using transgenic mice able to 
deliver active Cre in germ cells. After recombination, the resulting modified forms of 
the gene can be inherited. 
The aims of this chapter are: 
• Generate mice bearing 2 loxP sites, flanking exons 2 and 3 by inducible Cre-mediated 
recombination in germ cells. 
• Generate mice homozygous and heterozygous for a modified Ctla-4 allele lacking 
exons 2 and 3 as a new model of null expression of this molecule. 
• Analyze the phenotype of mice lacking exons 2 and 3. 
	 177 
.E3 
LoxP2/3 LoxPl 
E4 
D 
E 
LoxP 1/3 
C 
pGKneo 
LoxP1/2 	LoxP3 
1 110  
LoxP1 LoxP2 	 LoxP3 
E2 
4 
	 Cre-mediated recombination and Ctla-4. 
A 
El 	 E2 E3: 	E4 
B 
Figure 5.1.- Outcomes of Cre-mediated recombination on the Ctla-4 targeted allele. 
Cre recombinase is is able to excise a sequence of DNA that is flanked by 2 of its re-
combination sites (loxP). The position of the 3 loxP sites in the intronic sequence of 
Ctla-4 can therefore produce 3 different alleles two of which are of interest in this chap-
ter (C, D). In A, the figure illustrates the intron-exon configuration of Ctla-4, in B the 
targeted allele. The 3 possible deletion products are shown in C, D and E. 
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5.2. The generation of mice bearing two loxP sites flanking 
exons 2 and 3 of Ctla-4. 
In order to generate mice with a modifications of Ctla-4, as shown in figure 5.1 C, a Cre 
transgenic mouse that expresses a fusion protein of Cre with mutated estrogen receptor 
domains was used. In these mice (strain (3-70) , the expression of the Cre fusion is 
driven by the chicken (3-actin promoter providing potentialy ubiquitous expression al- 
though in practice the expression and the activity of the recombinase varies between 
tissues (Dr Laurence Bugeon personal communication). It has been reported, however, 
that in these mice, Cre is expressed and functional in germ cells (Tolmachova., et al 
2006), thus making them a useful germ-line deleter strain. 
To produce the mice with the Ctla-4 genotypes of interest, we crossed a (3-70 mouse 
with an animal heterozygous for a targeted allele. The resulting offspring (heterozygous 
for the Ctla-4 targeted allele and either possessing the Cre transgene or not) were as-
sayed for both genotypes by PCR. Figure 5.2 summarizes the breeding and tamoxifen 
induction strategy and figure 5.3 shows representative PCR data corresponding to the 
genotyping. 
As shown in figure 5.3, mice heterozygous for the Ctla-4 targeted allele and positive for 
the Cre were identified. A series of tamoxifen inductions were performed (see materials 
and methods) to induce deletion of Ctla-4 in the germline of these mice followed by 
crossing induced animals with WT C57BL/6 mice. The offspring was genotyped for the 
various deletion products that could have occurred after Cre mediated recombination in 
the germ cells of their progenitors. To discriminate between the 3 different CTLA-4 
alleles produced by recombination, a set of PCR reactions was designed which ampli-
fied junctional regions specific for each deletion product. Together with this analysis the 
previously described PCR that amplifies an area downstream exon 1, around the 5'-most 
loxP site in the targeted allele was used. Figure 5.4 shows a scheme of this PCR strat- 
egy, the characteristics of the PCR specific for the area downstream exon 1 has been 
described before (chapters 3 and 4), a "close up" of the location for this PCR is how- 
ever shown when appropriate. 
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After several attempts and variations of in the scheme of tamoxifen administration mice 
bearing a Ctla-4 locus where exons 2 and 3 are flanked by loxP sites or also called 
"floxed" was generated. Another genotype obtained corresponded to an allele in which 
exons 2, 3 and the neo cassette were deleted ("deleted allele"). Figure 5.5 shows a rep-
resentation of the PCR analysis performed to identify the above mentioned genotypes. 
So far we have not identified the third possible modified allele ("neo allele") but we do 
not require mice with such genotype. 
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Figure 5.2.- Generation of mice bearing loxP sites flanking exons 2 and 3 for use in 
experiments for conditional inactivation of CTLA-4 (in box). Heterozygous Ctla-4 
targeted mice were crossed with a Cre transgenic, able to express an inducible form of 
Cre in the germ cells (A). Cre positive offspring bearing the targeted Ctla-4 allele was 
induced with tamoxifen (B) and crossed with WT C57BL/6 mice (C). 
Heterozygous offspring bearing a Ctla-4 allele with various deletions were analysed (D) 
and animals with loxP sites flanking exons 2 and 3 were identified. 
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Figure 5.3.- Generation of mice heterozygous for a targeted Ctla-4 allele and positive 
for a transgene encoding an inducible form of Cre (MerCreMer). 
Heterozygous Ctla-4 targeted mice were crossed with a Cre transgenic, able to express an 
inducible form of Cre in the germ cells (A). Cre positive offspring (B) were analysed 
by PCR to select Ctla-4 targeted, Cre positive individuals (C). This animals can be 
induced with tamoxifen to perform the desired Ctla-4 deletion. 
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Figure 5.4.- Schematic representation of the PCR strategy to detect Cre-
mediated deletion of Ctla-4. A, shows a representation of the targeted allele and 
the location of the 4 primers used. If recombination happens between loxP sites 
2 and 3 (B), the deletion product will allow primers E3EcoR1F and E4NeoR to 
amplify a product on the allele, an additional product on a wt allele is also 
expected.If recombination proceeds between loxP sites 1 and 3 (C) or 1 and 2 
(D), the corresponding PCR products should also be amplified. 
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Figure 5.5.- In vivo inducible Cre mediated deletion of Ctla-4. 
Heterozygous Ctla-4 targeted mice, positive for a tamoxifen-inducible form of Cre 
(A), were induced by intraperitoneal injection or orally (1mg-5mg of tamoxifen, 
see materials and methods) and subsequently crossed with wt C57BL/6 animals (B). 
The offspring (C) was genotyped using PCR as described in figure 5.4. D shows two 
representative PCRs to detect; a "foxed allele" (left) and a "deleted allele" (right). 
The rest of the offspring was tested and found not positive for the third type of deletion 
"neo allele". 
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5.3. Generation of mice with a Ctla-4 allele lacking exons two 
and three. 
In parallel to the experiments reported in section 5.2, a second system to modify Ctla-4 
was employed to rapidly generate mice having a deletion in exons 2 and 3. The ration-
ale of this modification was the generation of a novel CTLA-4 knock out line, one lack-
ing a neo cassette and perhaps showing a variable phenotype to the models published 
(Tivol., et al 1995 and Waterhouse., et al 1995). 
The transgenic system used this time was a mouse that also delivers Cre-mediated re-
combination. PGK-Cre transgenics express Cre under the PGK-1 promoter and under 
dominant maternal control. This means that Cre in these mice is expressed early in oo-
genesis, so when male mice having a gene flanked by loxP sites are crossed with PGK-
Cre females, even animals that do not inherit the Cre gene, show efficient deletion. This 
happens because of the high and early expression of Cre due to the strong PGK-1 pro-
moter, therefore active concentrations of the enzyme, present in the cytoplasm and pro-
nucleus of the oocyte can act on any "foxed" target DNA in the male pronucleus (Lal-
lemand, Y., et al 1988). This transgenic strain (kindly provided by Dr Tomalchova at the 
Seabra Lab, Imperial College) was mated with homozygous Ctla-4 targeted mice and as 
expected, all the offspring of this cross were heterozygous for a "deleted allele" thus 
Cre mediated recombination proceeded between loxP 1 and 3 (figure 5.1), this probably 
is due to the high concentrations of Cre expressed in the embryos at early stages as a 
result of the strength of the PGK-1 promoter. 
Further intercrosses between offspring with such genotype were set up and littermates 
wild type, heterozygous and homozygous for the mutation were generated, figure 5.6 
summarizes this strategy. To genotype the mice produced after the intercross the PCR 
previously selected to detect a "deleted allele" was used in conjunction with the PCR 
specific for Cre, so only pups that had not inherited Cre were intercrossed Figure 5.7 
shows representative genotyping data. As expected 100% of the progeny form the cross 
described in figure 5.7 possessed the deleted Ctla-4 genotype. 
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For simplicity in nomenclature, from now and during the characterization of the pheno-
type of mice bearing a deletion at the Ctla-4 locus, wild type littermates will be referred 
as wt/wt heterozygous mutants, wt/del and homozygous del/del. 
Previously generated mice with a disrruption in exons 2 and 3 due to the insertion of a 
neo cassette (Tivol., et al 1995 and Waterhouse., et al 1995) will be referred to as 
CTLA-4 knockouts. 
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Figure 5.6.- Generation of Ctla-4 del/del mice by Cre mediated deletion. 
Mice homozygous for the Ctla-4 targeted allele were crossed with a transgenic 
strain that expresses Cre under the PGK-1 promoter (A). High expression of active 
Cre early in oocytes exerts complete deletion of the Ctla-4 targeted in embryos, 
resulting in mice with a heterozygous deleted genotype at the Ctla-4 locus (B). 
An intercross of Cre negative offspring allows the production of mice homozygous 
for Ctla-4 deleted allele therefore theoretically defficient for this molecule. 
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Figure 5.7.- Generation of mice bearing a deleted Ctla-4 allele by Cre mediated 
recombination. Mice homozygous for the Ctla-4 targeted allele were crossed with a 
transgenic strain that expresses Cre under the PGK-1 promoter (A). This cross resulted 
in mice with a heterozygous deleted genotype at the Ctla-4 locus (B). This was 
confirmed by performing a PCR using primers LoxF and E4NeoR. 
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5.4. Analysis of the phenotype of del/del mice. 
Del/del mice were generated as mentioned in section 5.3, genotyping of this line was 
performed using an PCR specific for the sequence downstream exon 1 where loxP site 
number 1 is located, together with the PCR designed to identify a "deleted allele". 
With this PCR combination, it was readily possible to discriminate between genotypes, 
as DNA from wt/wt mice should not produce a product when amplifying for the deleted 
allele and, in contrast, DNA from del/del mice should do so. Wt/del mice are expected 
to produce a product in both reactions. Figure 5.8 shows representative PCR data. All 
individuals used in experiments were genotyped accordingly, del/del mice were always 
screened again post mortem. 
del/del mice developed normally and were born healthy at a normal Mendelian fre-
quency. However significant lag in growth when compared with the littermates and 
signs of disease developed with in the first two weeks of life. After about 3 weeks they 
become moribund. Following some initial qualitative observations survival data was 
collected and figure 5.9 shows a curve from 13 individuals. Wt/del individuals survived 
as wt littermates and showed no signs of disease. 
The survival of del/del mice is a first indication that these mice developed a phenotype 
similar to the reported CTLA-4 knock outs generated by a disruption of exons 2 and 3 
by the insertion of a neo cassette (Tivol., et al 1995 and Waterhouse., et al 1995). But 
before pursuing characterization, the levels of expression of CTLA-4 by lymphocytes 
using intracellular antibody staining and flow cytometry, together with a western blot 
from total resting lymph node cells were performed. 
No expression of CTLA-4 was observed in del/del mice when compared with the litter-
mates, this result confirms that the mutation generated in these mice substantially abro-
gates CTLA-4 expression (figure 5.10). CTLA-4 expression of wt/del animals is com-
parative to that of wt/wt littermates. 
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Figure 5.8.- Genotyping of Ctla-4deudel mice. 
Mice heterozygous for a deleted Ctla-4 allele and negative for Cre, were intercrossed (A). 
The result of this intercross (B) were mice homozygous for Ctla-4 deleted allele therefore 
theoretically defficient for this molecule. wt/wt and wt/del littermates were also 
produced for comparisons. These genotypes were confirmed by a PCR amplification 
of a region arround the loxP site downstream exon 1 (C top) and the PCR designed 
to detect a "deleted allele" (C bottom) (see figure 5.2). 
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Figure 5.9.- del/del mice show a lethal phenotype and die 4 weeks after birth. 
The curve shows the percentage survival of del/del mice (n=13) from a single 
breeding pair. Mean survival and range are indicated. 
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Figure 5.10. CTLA-4 expression analysis by flow cytometry and Western blot of cells from 
del/del mice compared with wt/wt and/or wt/del littermates. Approximately 3x106 cells 
from lymph nodes were cultured for 3 days under polyclonal stimulation (1µg/m1 anti CD3) 
and harvested for surface CD3 and intracellular CTLA-4 antibody stains. Comparative 
CTLA-4 expression in the mice is reported as intensity of fluorescence (filled hystograms), 
isotype control stains are overlayed (in green). In B, the figure illustrates a Western blot of 
total resting lymph node cells comparing the expression of CTLA-4 between animals. 10 mg 
of protein separated by SDS-page transfered and blotted with an antibody (C19) specific 
for the intracellular portion of CTLA-4. Two bands, corresponding to 2 isoforms of the 
molecule can be detected (LiCTLA-8 at 8kDa and FLCTLA-4 between (30-35kDa). 
Two bands are detected for FLCTLA-4 due to differences in glycosilation. 
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During the dissection it was possible to observe dramatic differences in the sizes of 
lymph nodes from del/del individuals when compared with their littermates and this was 
reflected to the cellularity of these organs as del/del mice showed at least 20 fold more 
total cells than wt/wt or wt/del littermates (see table below). 
wt/wt wt/del del/del 
13x106 14x106 286x106 
19x106 18x106 625x106 
Table 5.1.- Viable cell count from lymph nodes of wt/wt, wt/del and del/del mice. Data corre-
sponds to 2 independent observations. 
Comparative histologic analysis of del/del mice showed a dramatic infiltrate and tissue 
destruction particularly in the pancreas where morphology was completely compro-
mised. Organs on wt/wt and wt/del appeared normal. In contrast with the published 
CTLA-4 knock out histologic data, moderate infiltrate was observed for del/del indi-
viduals in organs in which greater damage is reported for such knock outs. For instance, 
in the heart a moderate infiltrate with no apparent signs of myocarditis was detected (see 
figure 5.11). Myocarditis was reported for the CTLA-4 knock out mice. Another inter-
esting difference was that the spleen of del/del mice does not show a morphology of ex-
tended white pulp and and compromised red pulp as observed in CTLA-4 knock outs 
and indicative of lymphoproliferation in this organ. Consistent with the literature for the 
CTLA-4 knock outs, del/del mice show no damage or infiltration in the kidney. wt/del 
mice showed no histologic signs of damage or infiltration. 
The proportion of CD4 and CD8 cells in lymph nodes and in thymus were also analyzed 
in experimental animals by flow cytometry (figure 5.12 and 5.13). Interestingly the 
CD4/CD8 ratio in del/del mice was altered as compared with wt litternates, favouring a 
greater number of CD4 positive cells in the former group. Early reports suggested that 
this was not the case for CTLA-4 knock outs and their wt littermates (Waterhouse., et al 
1995). However later it was demonstrated that there was indeed a change in the ratio of 
these subsets due to a preferential activation of CD4+ T cells, as antibody depletion of 
these cells rescuing CTLA-4 knock outs from their phenotype (Chambers., et al 1997). 
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No clear changes in the numbers of CD4 and CD8 cells were observed in wt/del animals 
when compared to wt/wt littermates. 
In the thymus of del/del mice, a gross variation was observed in CD4 to CD8 profile 
when compared with littermates (figure 5.12). An increased proportion of CD4 single 
positives and a decrease in double positives is consistent with previous reports indicat-
ing that this does not correspond to a dysregulated thymocyte development but a techni-
cal issue (Chambers., et al 1997). During the harvesting of thymi, the discrimination 
between this organ and the parathymic lymph nodes is not always straight forward and 
it seams likely we had harvested both organs and our single cell suspensions are mixed 
with lymphocytes other than from thymus. More careful dissections are required to de-
termine a precise thymus CD4-CD8 profile. 
As expected, CD3 positive cells in del/del mice showed a phenotype of early and consti-
tutive activation as determined by the surface expression of CD69 and CD25 by flow 
cytometry. Lymph node cells from these mice showed a higher percent of cells positive 
for the two markers as compared with wt/w and wt/del littermates. 
The proportion of T cells in the lymph node of del/del animals was not increased as 
compared to littermates, however due to the dramatic differences in cellularity in the 
lymph nodes, total numbers of T cells are indeed increased. In contrast CD19+ cells 
showed and increased percentage when compared with wt/wt and wt/del. These data 
was determined by staining freshly extracted lymph node cells for CD3 and CD19. The 
expression of activation markers is consistent with the previous CTLA-4 knock out re-
ports (see figure 5.13). 
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wt/wt 	 wt/del 	 del/del 
Figure 5.11- Histologic analysis of organs from del/del mice as compared 
the littermates. Sections from parafin embedded tissues were stained with H&E 
and observed by optical microscopy. All photographs shown are magnified as 
indicated. 
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5.5. Discussion. 
i. Generation of a model for conditional inactivation of CTLA-4 
Animals with two main modifications at the Ctla-4 locus after Cre mediated recombina-
tion were generated. These mice were obtained by Cre recombination in germ cells us-
ing either a transgenic line that expresses Cre in an inducible fashion, 13-70 MerCreMer 
(Produced in the Dallman Laboratory Imperial College London and used by Tolma-
chova., et al 2006 and unpublished data), or another transgenic mouse that is able to de-
liver high levels of Cre early in fertilization due to the PGK-1 promoter (Lallemand., et 
al 1988). 
For the overall relevance of this project the most important Ctla-4 genotype obtained is 
an animal bearing an allele with only two loxP sites, one upstream of exon 2 and the 
second downstream of exon 3, and lacking the sequence of the neo cassette. This animal 
is the precursor of mice in which conditional inactivation of Ctla-4 can be induced. The 
simple crosses required to produce which mice are shown in figure 5.14. 
A model for conditional inactivation through the Cre-loxP system, requires a transgenic 
animal able to express Cre in an inducible fashion and in the cell type of interest, in our 
case we can use animals that express Cre under the control of the Mx-1 promoter in 
which interferon alfa induces Cre expression (Khun, R. et al 1995). These mice are 
available in our lab and the advantages and disadvantages together with other mice that 
can be employed will be discussed in the next chapter. Overall and as confirmed in pre-
vious sections of in this chapter, all the animals required to inactivate CTLA-4 condi-
tionally are now generated and this is the main future branch of the work reported in 
this thesis. 
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Figure 5.14.- Breeding strategy to generate mice suitable to conditionally inactivate 
CTLA-4. A first cross (A) between wt/del and an animal with the CTLA-4 exons 2 and 3 
flanked by loxP sites, is required to generate mice with only one Ctla-4 allele "fl oxed". 
In parallel wt/del mice need to be crossed with animals that express inducible Cre (B), 
to finally bring the two genotypes together (C) to generate an individual in which condi-
tional inactivation can be achieved. Animals in boxes are genotypes of overall interest 
during the strategy. 
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ii. The phenotype of mice lacking exons 2 and 3 of CTLA-4. 
Heterozygous and homozygous mice bearing a deletion of exons two and three of Ctla-
4 have also been created first by PGK-Cre mediated deletion and subsequently by inter-
crossing. These mice develop a phenotype very similar to the CTLA-4 knock outs made 
though conventional gene targeting (Tivol, E.A., et al 1995 and Waterhouse, P., et al 
1995) as far as the phenotype of lymphocytes and thymocytes is concerned. However-
mice generated here show a more moderate phenotype in terms of damage, lymphopro-
liferation and infiltration as analyzed by histology. 
Consistent with the previous reports of CTLA-4 knock out mice the pancreas in del/del 
mice showed dramatic damage with a completely compromised morphology, neverthe-
less no signs of myocarditis or destructive lymphoproliferation was observed in the 
heart and the spleen respectively. No major damage was also observed in other tissues 
like Kidney, liver or gut (data not shown). Immunohistochemical analysis of tissue sec-
tions is required to confirm the absence or a lower level of cell specific infiltrate ( by T 
cells, B cells, or other leukocytes) in the heart and other tissues to establish if these mice 
have or not a milder phenotype. 
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Chapter 6. Concluding discussion 
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6.1. The rationale of generating a model for conditional inac-
tivation of CTLA-4. 
The overall aim of this project was to generate mice in which the inactivation of Ctla-4 
could be achieved under temporal control using the Cre-loxP system. The reasons why it 
would be very useful to have of such a model come, paradoxically, from the characteris-
tics of perhaps the most important tool we have so far to understand the function of this 
molecule. CTLA-4 knock out mice have been essential to confirm the negative role of 
this T cell surface negative costimulator, yet the lethal phenotype these mice develop at 
early stages (Waterhouse., et al 1995, Tivol., et al 1995). This limits the study of the 
immune system in the absence of this molecule, and either the use of CTLA-4 deficient 
animals or only T cells from these mice for functional experiments, is limited to the first 
month of life of these animals. 
The Cre-loxP system comprises two elements. One of them is a mouse having Cre rec-
ognition sites (loxP) flanking the sequences of the gene of interest that are critical for 
the function of the polypeptide. In the case of Ctla-4 such animals were not available 
until now. 
The strategy utilized to produce these genetically modified mice was the insertion, in 
intronic sequences of the gene, of a single loxP sequence downstream of exon 1 and a 
foxed neo cassette downstream of exon 3. These modifications to Ctla-4 were intro-
duced to the mouse genome via gene targeting in ES cells. Mice bearing these exoge-
nous elements in a Ctla-4 allele are not themselves useful to perform conditional inacti-
vation experiments, as various outcomes of deletion can be obtained simultaneously af-
ter Cre recombination. Nonetheless these mice were generated in order to study animals 
bearing modifications at the Ctla-4 locus that will not generate an allele with null ex-
pression, but that can alter the mechanisms of genetic control, for instance, by produc-
ing a hypomorphic allele. Effects on the expression of targeted genes or its neighbours 
have been reported in the past (Pham., et al 1996 and Olson., et al 1996), and the main 
candidate to cause this type of alterations is the neomycin cassette driven by strong 
promoters such as the phosphoglycerate-kinase promoter PGK-1. 
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In the case of Ctla-4 even small modifications in the genomic sequence can result in an 
alteration of its expression and examples are comprehensively reported in the literature 
(reviewed in Gough., et al 2006). Sequence polymorphisms have been correlated with 
various autoimmune disorders and some specific single nucelotide polymorphisms 
(SNP) have even been associated with changes in the expression of functional splice 
variants of this gene (Vijayakrishnan., et al 2004). 
Making a mouse having the mentioned modifications in the Ctla-4 locus provided us 
also with the possibility of generating, through Cre-mediated deletion in germ cells, 
mice in which two of the most important coding sequences are flanked by loxP sites; 
the relevance of these two exons for the function of CTLA-4 has been revealed by the 
phenotype of the three knock out models already reported (Waterhouse., et al 1995; Ti-
vol., et al 1995 and Chambers., et al 1997). 
Mice having loxP sites flanking exons 2 and 3 also lack the neo cassette and in light of 
what we observed of the phenotype of mice possessing such antibiotic resistance se-
quence, retaining the cassette may complicate the analysis of any phenotype that can be 
obtained following conditional inactivation. Animals with this genotype have been gen-
erated and can now considered for use in experiments for conditional inactivation. 
A final genotype, also obtained after Cre-mediated recombination in germ cells, com-
prised the deletion of exons 2 and 3 and the neo cassette. Homozygous mice with this 
genotype were of interest because they are a novel knock out model that lacks a neo 
cassette, and it was of value to evaluate if these animals develop the lethal lymphopro-
liferation observed in mice generated by gene targeting and whether or not the pheno-
type observed varies form the published characterizations. 
One recent and intriguing observation is that CTLA-4 deficient mice over express ICOS 
(van Berkel., et al 2005). This gene is a neighbor of CTLA-4 and the mice used by the 
authors retained the neo cassette disrupting exons 2 and 3. Therefore it seems likely that 
the overexpression could be the result of an effect of the neo cassette and this can be 
analyzed in the mice we have generated, in fact those experiments are now ongoing. 
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6.2. Key findings. 
Mice having 3 loxP sites and a neo cassette developed lymphoadenopathy as confirmed 
by visible enlarged lymph nodes and increased cellularity in homozygous mice as com-
pared with heterozygootes or wt littermates. In addition the proportion of B cells, as de-
fined by the expression for the surface marker CD19, was comparatively increased in 
homozygous. Furthermore histological analysis showed greater cell accumulation in 
areas of secondary lymphoid organs were B cells are the main cell type. In order to 
confirm an accumulation of B cells in situ, a B cell specific immunohistochemical 
analysis on such tissue sections should be performed. 
The T cell compartment in the lymph node seemed not to be altered in the resting state. 
There were no significant differences in the absolute numbers of T cells, and those cells 
did not show a phenotype of activation as seen in CTLA-4 knock out mice (Tivol., et al 
1995). Upon activation, total lymphocytes and more clearly CD3 enriched T cells cells 
from homozygous mice, over expressed CTLA-4 as defined by intensity of fluorescence 
(figures 4.12 and 4.15). The over expression of CTLA-4 was concomitant with greater 
expression of the activation marker CD25 (figure 4.16), suggesting at least a proportion 
of the T cells from homozygotes have been previously primed, this can be confirmed in 
future experiments by staining for Mel-14, a marker present in naive T cells. The over 
expression observed of both CD25 and CTLA-4 is line with previous reports showing a 
relationship between these two molecules. Blockade of the IL-2R prevented CTLA-4 
expression in T cells following activation (Alegre., et al 1996) and indirectly, the rela-
tionship between CTLA-4 and the IL-2 pathway is also demonstrated by the functional 
implications of a decreased CTLA-4 expression seen in IL-2 deficient mice and how 
transgenic over expression of CTLA-4 prevents autoimmune hemolytic anemia and in-
flammatory bowel disease (Schorle., et al 1991 and Hwang., et al 2004) . 
Interestingly, T cells form homozygous mice did not show proliferative responses 
greater than heterozygous of homozygous indicating the possibility that the CTLA-4 
over expression seen in these mice can have a functional implication. It is of relevance 
to measure the ability of these T cells to produce IL-2 as another readout of this result. 
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The activation and quiescence of T cells is a tightly controlled phenomenon important 
for maintaining T cell homeostasis, in which CTLA-4 indeed plays a major role, and 
recently splice variants of this molecule have been implicated in this process. 
The splice variant which has been characterized the most, is that which lacks the B7 
ligand-binding domain. LiCTLA-4, but not FICTLA-4, has been shown to have greater 
expression on regulatory and memory T cells from diabetic resistant congenic strains 
(Vijayakrishnan., et al 2004). We analyzed the expression of this splice variant in rest-
ing and activated lymphocytes and although qualitative differences were observed in the 
mRNA levels of this splice variant of homozygotes when compared with the littermates 
at resting, no differences were observed at the protein level as detected by Western blot-
ting. Another interesting splice variant, that has been poorly studied in mice, is sCTLA-
4 and lower expression of this variant has been associated with autoimmunity (Thyroid 
disease) in humans (Oaks., et al 2000). In our mice we have found qualitatively lower 
levels in the expression (as measured by non quantitative RT-PCR see figure 4.19) of 
this splice variant as well as FL-CTLA-4 in homozygotes when compared to litter-
mates, all at resting. Altogether these data may indicate that a dysregulated expression 
of CTLA-4 splice variants may be the cause of the phenotype observed but these differ-
ences have to be confirmed using, for instance, quantitative RT-PCR. 
Mice bearing a Ctla-4 allele in which exons 2, 3 and the neo cassette have been excised 
by Cre-mediated recombination (figure 5.1), showed phenotype remarkably similar to 
the published CTLA-4 knock out mice. Del/del mice die 1 month after birth and de-
velop a fatal tissue-destructive lymphoproliferation, particularly evidenced in the pan-
creas. While differences in the severity of the tissue damage were observed in these 
mice when compared with the published knock outs, it would be necessary to perform 
immunohistochemical analysis in order to firmly establish this. 
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6.3 Inducible Cre transgenics suitable to inactivate Ctla-4. 
In order to conditionally inactivate Ctla-4, animals must be crossed with a transgenic 
animal that expresses Cre in the lymphoid tissue and under temporal control. 
A relatively small number of inducible Cre transgenics have been generated that show 
expression and activity of Cre in lymphoid tissue. For instance we have used an induci-
ble Cre transgenic line (13-70) to delete the Ctla-4 floxed allele in germ cells. This strain 
expresses the tamoxifen inducible form of Cre under the control of an ubiquitous pro-
moter (Chicken I3-actin), but no expression of Cre has been observed in the T cells of 
this mice (Dr Laurence Bugeon personal communication). 
Another now widely used strain is the Mx-Cre line. These mice express the recombi-
nase under the control of the Mx-1 interferon inducible promoter, which requires the use 
of double stranded RNA or poly(I)-poly(C) for inducibility (Kuhn., et al 1995). Mx-Cre 
mice have been used to provide temporal control of gene inactivation in T cells. In an 
article by Huan Han at the Honjo Lab in Japan this interferon controlled Cre transgenic 
was used to eliminate the expression of the Notch pathway transcription factor, RBP-J. 
They measured the efficiency of recombination under their induction conditions (30011g 
of inducer daily and weekly) by Southern blot in various tissues. The spleen showed a 
relatively high percentage of recombination (80%) as compared with other non lym-
phoid tissues (around 40% in kidney) however recombination in the thymus was not as 
high (60%) (Han., et al 2002). This suggests that because in adult mice T cell numbers 
in the periphery depend on a constant and input from the thymus, experiments of condi-
tional inactivation of CTLA-4 may require the use of thymectomized animals. 
In another report Zhenyue, H., et al reported successful deletion of Fas using Mx-Cre 
mice and similar concentrations of poly(I)-poly(C). In this case they did not quantify 
the efficiency of deletion in their system, but they report a functional outcome of the 
deletion of Fas. Mice induced developed a Fas ligand-mediated T cell depletion 
(Zhenyue., et al 2004). 
The efficiency of deletion using these mice is expected to be allele dependent. Pilot 
studies must therefore be performed to determine the efficiency of the system for Ctla-4. 
As reported for RBP-J, this can be done by Southern blot analysis and a strategy in 
place. 
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In Mx-Cre mice the molecule used for the induction of Cre activity, dsRNA or poly(I)-
poly(C), is also a potent activator of antigen presenting cells through the Toll-like re-
ceptor 3 pathway. Stimulation of cells with dsRNA triggers the production of cytokines, 
like IFN-a, that can induce the response of cytotoxic cells, obscuring perhaps important 
features of a potential phenotype associated with the absence of CTLA-4. In this case 
littermates bearing a floxed Ctla-4 allele but negative for the Mx-Cre transgene and in-
duced with poly(I)-poly(C) transgene, will be required as critical controls. 
6.4. The uses and the value of a Ctla-4 conditional knock out. 
Overall, the main advantage of gaining temporal control of the inactivation of CTLA-4 
is the possibility of analyzing the peripheral immunity of mice at stages later than 1 
month. Being able to trigger the excision of this gene at different stages in the lifetime 
of the mice would allow evaluation of whether the dramatic lymphoproliferation seen in 
Ctla-4 deficient mice is reproduced later in life. If a similar phenotype is observed, 
studying the differences in the mechanisms underlying autoimmunity would be of out-
standing relevance. In practice, upon induction of Cre mediated recombination of Ctla-
4, the first set of experiments would most likely follow the lines of what was done to 
characterize the phenotype of conventional Ctla-4 knock outs. These would include for 
instance: the analysis of potential tissue destruction by histology and immunohisto-
chemistry and a comparative analysis of phenotype of T cells in the lymphoid organs of 
these mice by flow cytometry. These basic assays are very useful to determine poten-
tially interesting characteristics that can be further pursued. 
An enormous amount of data has now been accumulated to demonstrate the role of 
CTLA-4 in maintaining T cell homeostasis, although other inhibitory costimulatory 
molecules have been identified (PD-1 and BTLA), and they have been proven to have 
an independent inhibitory potential, as shown by the development of specific lymphop-
roliferative disorders in mice deficient for them (Nishimura., et al 2001 and Watanabe., 
et al 2003). Analyzing the expression and perhaps their functions in the context of an 
induced CTLA-4 inactivation, using blocking antibodies for cells in culture or as treat 
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ment for CTLA-4 conditional knock animals in vivo, could help to determine if these 
receptors have a potential to compensate for the lack of CTLA-4. 
An additional advantage of controlling the CTLA-4 deficiency is the possibility to iso-
late and employ functionally distinct subsets of T cell in order to dissect the function of 
this molecule in such cells. In chapter 1 the limitations of using blocking antibody 
strategies have to address this questions was discussed. A very recent paper has come 
out to address this issue and to report that blocking CTLA-4 on CD4+ CD25+ regulatory 
T cells in vivo, abrogates its function by inhibiting T regs rather than effector CD25- T 
cells (Read, S., et al 2006). This together with more evidence available (reviewed in 
Sansom., et al 2006) establishes a critical role of CTLA-4 in T reg biology. 
An interesting approach to further study this idea, would be to isolate CD25± T regs 
from CTLA-4 conditional knock outs to induce the deletion of the gene in vitro, by de-
livering Cre through retroviral transduction, or to isolate them from mice already in-
duced and then use them in assays to determine their suppressive capacities. 
Another approach would be to use them in vivo as a cell treatment for experimental 
mouse models of autoimmunity, like the diabetic susceptible strain NOD or autoim-
mune colitis, in which the effects of the treatment can be monitored in terms of progres-
sion of disease. 
Conventional CTLA-4 knock outs have been used in conjunction with Ragl Do11.10 
transgenic mice designed to examine the mechanisms of tolerance of CD4+ T cells, ei-
ther to tissue restricted or systemic autoantigens (Lohr., et al 2005). As in any functional 
system that employs these knockouts, the power of the analysis that can be obtained, is 
affected by the age limitations imposed by the phenotype of CTLA-4 deficient mice. 
Using instead mice in which the inactivation of CTLA-4 can be controlled, could 
now allow to use these powerful transgenic models at stages beyond the ages at which 
CTLA-4 knock outs develop their fatal disorder in order to study the role of this mole-
cule in establishing peripheral T cells tolerance to tissue restricted or systemic antigens. 
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